Amsurg (AMSG) 10-K 25 Feb 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Feb. 24, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Registrant Name	AMSURG CORP
Entity Central Index Key	895,930
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		54,720,648
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Public Float			$ 3,318,935,487

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Assets
Cash and cash equivalents	$ 106,660	$ 208,079
Restricted cash and marketable securities	13,506	10,219
Accounts receivable, net of allowance of $167,411 and $113,357, respectively	337,330	233,053
Supplies inventory	21,406	19,974
Prepaid and other current assets	75,771	92,900
Total current assets	554,673	564,225
Property and equipment, net	189,168	180,448
Investments in unconsolidated affiliates	169,170	75,475
Goodwill	3,970,210	3,381,149
Intangible assets, net	1,641,811	1,273,879
Other assets	21,450	25,886
Total assets	6,546,482	5,501,062
Liabilities and Equity
Current portion of long-term debt	20,377	18,826
Accounts payable	32,561	29,585
Accrued salaries and benefits	202,537	140,044
Accrued interest	30,480	29,644
Other accrued liabilities	119,237	67,986
Total current liabilities	405,192	286,085
Long-term debt	2,405,130	2,232,186
Deferred income taxes	699,498	611,018
Other long-term liabilities	$ 96,183	$ 89,443
Commitments and contingencies
Noncontrolling interests – redeemable	$ 175,732	$ 184,099
Equity:
Preferred stock, no par value, 5,000 shares authorized, 1,725 shares issued and outstanding	166,632	166,632
Common stock, no par value, 120,000 and 70,000 shares authorized, respectively, 54,294 and 48,113 shares issued and outstanding, respectively	1,345,418	885,393
Retained earnings	781,413	627,522
Total AmSurg Corp. equity	2,293,463	1,679,547
Noncontrolling interests – non-redeemable	471,284	418,684
Total equity	2,764,747	2,098,231
Total liabilities and equity	$ 6,546,482	$ 5,501,062

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 167,411	$ 113,357
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	1,725,000	1,725,000
Preferred stock, shares outstanding	1,725,000	1,725,000
Common stock, shares authorized	120,000,000	70,000,000
Common Stock, Shares, Issued	54,294,000	48,113,000
Common stock, shares outstanding	54,294,000	48,113,000

Consolidated Statements Of Earn

Consolidated Statements Of Earnings - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues	$ 2,832,958	$ 1,738,950	$ 1,057,196
Provision for uncollectibles	(287,427)	(139,274)	(21,947)
Net revenue	2,566,884	1,621,949	1,057,196
Operating expenses:
Salaries and benefits	1,314,392	694,576	327,585
Supply cost	184,222	164,296	153,126
Other operating expenses	397,794	284,928	216,501
Transaction costs	8,324	33,890	300
Depreciation and amortization	97,493	60,344	32,400
Total operating expenses	2,002,225	1,238,034	729,912
Net gain on deconsolidations	36,694	3,411	2,237
Equity in earnings of unconsolidated affiliates	16,152	7,038	3,151
Operating income	617,505	394,364	332,672
Interest expense, net	121,586	83,285	29,525
Debt extinguishment costs	0	16,887	0
Earnings from continuing operations before income taxes	495,919	294,192	303,147
Income tax expense	113,790	48,103	48,654
Net earnings from continuing operations	382,129	246,089	254,493
Net earnings (loss) from discontinued operations	(1,013)	(1,296)	7,051
Net earnings	381,116	244,793	261,544
Less net earnings attributable to noncontrolling interests	218,169	191,092	188,841
Net earnings attributable to AmSurg Corp. shareholders	162,947	53,701	72,703
Preferred stock dividends	(9,056)	(4,503)	0
Net earnings attributable to AmSurg Corp. common shareholders	153,891	49,198	72,703
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	154,892	50,777	71,009
Earnings (loss) from discontinued operations, net of income tax	(1,001)	(1,579)	1,694
Net earnings attributable to AmSurg Corp. common shareholders	$ 153,891	$ 49,198	$ 72,703
Basic earnings per share attributable to AmSurg Corp. common shareholders:
Net earnings from continuing operations (usd per share)	$ 3.22	$ 1.29	$ 2.27
Net earnings from discontinued operations (usd per share)	(0.02)	(0.04)	0.05
Net earnings (usd per share)	3.20	1.25	2.32
Diluted earnings per share attributable to AmSurg Corp. common shareholders:
Net earnings from continuing operations (usd per share)	3.18	1.28	2.22
Net earnings from discontinued operations (usd per share)	(0.02)	(0.04)	0.05
Net earnings (usd per share)	$ 3.16	$ 1.24	$ 2.28
Weighted average number of shares and share equivalents outstanding:
Basic (in shares)	48,058	39,311	31,338
Diluted (in shares)	51,612	39,625	31,954
Physician Services [Member]
Provision for uncollectibles	$ (266,074)	$ (117,001)	$ 0
Net revenue	$ 1,336,834	$ 512,014	$ 0

Consolidated Statements Of Chan

Consolidated Statements Of Changes In Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Mandatory Convertible Preferred Stock [Member]	Retained Earnings [Member]	Non-Controlling Interests - Non-Redeemable [Member]	Total Equity (Permanent) [Member]	Non-controlling Interests - Redeemable (Temporary Equity) [Member]
Balance at Dec. 31, 2012		$ 183,867	$ 0	$ 505,621	$ 310,978	$ 1,000,466	$ 175,382
Balance (in shares) at Dec. 31, 2012		31,941,000	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	$ 261,544			72,703	49,789	122,492	139,052
Issuance of restricted stock (in shares)		292,000
Cancellation of restricted stock (in shares)		(16,000)
Stock options exercised		$ 33,349				33,349
Stock options exercised (in shares)	1,392,366	1,393,000
Stock repurchased		$ (45,964)				(45,964)
Stock repurchased (in shares)		(1,257,000)
Share-based compensation		$ 8,321				8,321
Tax benefit related to exercise of share-based awards		7,247				7,247
Acquisitions and other transactions impacting noncontrolling interests		679			48,115	48,794	(319)
Distributions to noncontrolling interests, net of capital contributions					(49,533)	(49,533)	(134,298)
Disposals and other transactions impacting noncontrolling interests		(1,626)			2,010	384	(2,120)
Balance at Dec. 31, 2013		$ 185,873	$ 0	578,324	361,359	1,125,556	177,697
Balance (in shares) at Dec. 31, 2013		32,353,000	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	$ 244,793			53,701	56,048	109,749	135,044
Issuance of stock		$ 693,289	$ 166,632			859,921
Issuance of stock (in shares)		15,490,000	1,725,000
Issuance of restricted stock (in shares)		272,000
Cancellation of restricted stock (in shares)		(12,000)
Stock options exercised		$ 2,630				2,630
Stock options exercised (in shares)	111,743	111,000
Stock repurchased		$ (4,615)				(4,615)
Stock repurchased (in shares)		(101,000)
Share-based compensation		$ 10,104				10,104
Tax benefit related to exercise of share-based awards		3,177				3,177
Dividends paid on preferred stock				(4,503)		(4,503)
Acquisitions and other transactions impacting noncontrolling interests		744			54,725	55,469	6,482
Distributions to noncontrolling interests, net of capital contributions					(56,439)	(56,439)	(133,594)
Disposals and other transactions impacting noncontrolling interests		(5,809)			2,991	(2,818)	(1,530)
Balance at Dec. 31, 2014	$ 2,098,231	$ 885,393	$ 166,632	627,522	418,684	2,098,231	184,099
Balance (in shares) at Dec. 31, 2014		48,113,000	1,725,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	$ 381,116			162,947	67,568	230,515	150,601
Issuance of stock		$ 447,720				447,720
Issuance of stock (in shares)		5,835,000
Issuance of restricted stock (in shares)		314,000
Cancellation of restricted stock (in shares)		(14,000)
Stock options exercised		$ 2,584				2,584
Stock options exercised (in shares)	113,220	113,000
Stock repurchased		$ (3,684)				(3,684)
Stock repurchased (in shares)		(67,000)
Share-based compensation		$ 15,009				15,009
Tax benefit related to exercise of share-based awards		4,001				4,001
Dividends paid on preferred stock				(9,056)		(9,056)
Acquisitions and other transactions impacting noncontrolling interests		1,019			81,863	82,882	(725)
Distributions to noncontrolling interests, net of capital contributions					(66,294)	(66,294)	(147,182)
Disposals and other transactions impacting noncontrolling interests		(6,624)			(30,537)	(37,161)	(11,061)
Balance at Dec. 31, 2015	$ 2,764,747	$ 1,345,418	$ 166,632	$ 781,413	$ 471,284	$ 2,764,747	$ 175,732
Balance (in shares) at Dec. 31, 2015		54,294,000	1,725,000

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net earnings	$ 381,116	$ 244,793	$ 261,544
Adjustments to reconcile net earnings to net cash flows provided by operating activities:
Depreciation and amortization	97,493	60,344	32,400
Amortization of deferred loan costs	8,362	17,715	1,977
Provision for uncollectibles	287,427	139,274	21,947
Net (gain) loss on sale of long-lived assets	(12)	2,843	(1,468)
Net gain on deconsolidations	(36,694)	(3,411)	(2,237)
Share-based compensation	15,009	10,104	8,321
Excess tax benefit from share-based compensation	(4,001)	(3,177)	(7,247)
Deferred income taxes	19,037	30,780	38,363
Equity in earnings of unconsolidated affiliates	(16,152)	(7,038)	(3,151)
Debt extinguishment costs	0	4,536	0
Net change in fair value of contingent consideration	8,804	0	0
Increases (decreases) in cash and cash equivalents, net of acquisitions and dispositions:
Accounts receivable	(326,234)	(137,663)	(23,244)
Supplies inventory	(342)	(206)	132
Prepaid and other current assets	25,880	(9,091)	(5,308)
Accounts payable	3,131	(8,440)	441
Accrued expenses and other liabilities	66,600	66,175	6,693
Other, net	8,535	4,833	3,661
Net cash flows provided by operating activities	537,959	412,371	332,824
Cash flows from investing activities:
Acquisitions and related expenses	(962,689)	(2,184,058)	(73,594)
Acquisition of property and equipment	(60,305)	(40,217)	(28,856)
Proceeds from sale of interests in surgery centers	7,114	7,069	3,553
Purchases of marketable securities	(3,984)	(6,474)	0
Maturities of marketable securities	4,233	3,486	0
Other	(1,194)	(4,941)	159
Net cash flows used in investing activities	(1,016,825)	(2,225,135)	(98,738)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	560,133	2,048,958	162,204
Repayment on long-term borrowings and revolving credit facility	(392,586)	(408,475)	(202,083)
Distributions to noncontrolling interests	(214,899)	(190,097)	(184,149)
Proceeds from preferred stock offering	0	172,500	0
Proceeds from common stock offering	466,777	439,875	0
Proceeds from issuance of common stock upon exercise of stock options	2,584	2,630	33,349
Repurchase of common stock	(3,684)	(4,615)	(45,964)
Payments of equity issuance costs	(19,058)	(24,494)	0
Financing costs incurred	(1,111)	(65,811)	(1,322)
Other	(20,709)	(468)	8,321
Net cash flows provided by (used in) financing activities	377,447	1,970,003	(229,644)
Net increase (decrease) in cash and cash equivalents	(101,419)	157,239	4,442
Cash and cash equivalents, beginning of period	208,079	50,840	46,398
Cash and cash equivalents, end of period	106,660	208,079	50,840
Supplemental cash flow information:
Interest payments	112,678	38,129	28,378
Income tax payments, net of refunds	$ 74,602	$ 19,224	$ 7,756

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Accounting Policies Below are a summary of the Company's policies that are not otherwise found within other notes. a. Principles of Consolidation Ambulatory Services AmSurg Corp. (the “Company”), through its wholly-owned subsidiaries, owns interests, primarily 51%, in limited liability companies (LLCs) and limited partnerships (LPs) which own and operate ASCs primarily in the following specialties: gastroenterology; multi-specialty; ophthalmology; and orthopaedics. All LLCs and LPs and noncontrolling partners are referred to herein as “partnerships” and “partners”, respectively. The Company does not have an ownership interest in a partnership greater than 51% which it does not consolidate. The Company has ownership interests of less than 51% in 23 partnerships, 2 of which it consolidates as the Company has substantive participation rights and 21 of which it does not consolidate as the Company’s rights are limited to protective rights only. Consolidation of certain less than wholly owned partnerships is necessary as the Company’s wholly-owned subsidiaries have primarily 51% or more of the financial interest of the partnership, are the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the partnership, and have control of the entities. The responsibilities of the Company’s noncontrolling partners (LPs and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests. Intercompany profits, transactions and balances have been eliminated. Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company’s equity. However, for instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the noncontrolling interests are identified and presented on the consolidated statements of earnings; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary are measured at fair value. Certain transactions with noncontrolling interests are also classified within financing activities in the statements of cash flows. As further described in note 19, upon the occurrence of various fundamental regulatory changes, the Company would be obligated, under the terms of certain partnership and operating agreements, to purchase the noncontrolling interests related to a substantial majority of the Company’s partnerships. While the Company believes that the likelihood of a change in current law that would trigger such purchases was remote as of December 31, 2015 , the occurrence of such regulatory changes is outside the control of the Company. As a result, these noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets. Center profits and losses of consolidated entities are allocated to the Company’s partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests. The partners of the Company’s center partnerships typically are organized as general partnerships, LLCs or LPs that are not subject to federal income tax. Each partner shares in the pre-tax earnings of the center in which it is a partner. Accordingly, the earnings attributable to noncontrolling interests in each of the Company’s consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings. However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its income tax expense. In addition, distributions from the partnerships are made to both the Company’s wholly-owned subsidiaries and the partners on a pre-tax basis. Physician Services On July 16, 2014, the Company completed its acquisition of Sheridan Healthcare (Sheridan). Sheridan is a national provider of multi-specialty physician and administrative services to hospitals, ambulatory surgery centers and other healthcare facilities. Sheridan focuses on delivering comprehensive physician services, primarily in the areas of anesthesiology, radiology, children's services and emergency medicine to healthcare facilities. Through its contracts with healthcare facilities, Sheridan is authorized to bill and collect charges for fee for service medical services rendered by its healthcare professionals and employees in exchange for the provision of services to the patients of these facilities. Contract revenue is earned directly from hospital customers through a variety of payment arrangements that are established to supplement payments from third-party payors. Sheridan also provides physician services and manages office-based practices in the areas of gynecology, obstetrics and perinatology. The consolidated financial statements include the accounts of Sheridan and its wholly-owned subsidiaries along with the accounts of affiliated professional corporations (PCs) with which Sheridan has certain management arrangements. Sheridan's agreements with these PCs provide that the term of the arrangements is permanent, subject only to termination by the Company, except in the case of gross negligence, fraud or bankruptcy of the Company. The PC structure is primarily used in states which prohibit the corporate practice of medicine. The arrangements are captive in nature as a majority of the outstanding voting equity instruments of the PCs are owned by nominee shareholders appointed at the sole discretion of the Company. The nominee shareholder is generally a medical doctor who is generally a senior corporate employee of the Company. The Company has a contractual right to transfer the ownership of the PCs at any time to any person it designates as the nominee shareholder. The Company has the right to all assets and to receive income, both as ongoing fees and as proceeds from the sale of any interest in the PCs, in an amount that fluctuates based on the performance of the PCs and the change in the fair value of the interest in the PCs. The Company has exclusive responsibility for the provision of all non-medical services required for the day-to-day operation and management of the PCs and establishes the guidelines for the employment and compensation of the physicians and other employees of the PCs which is consistent with the operation of the Company's wholly-owned affiliates. Based on the provisions of these agreements, the Company has determined that the PCs are variable interest entities and that the Company is the primary beneficiary as defined in ASC 810 “ Consolidations. ” b. Cash and Cash Equivalents Cash and cash equivalents are comprised principally of demand deposits at banks and other highly liquid short-term investments with maturities of less than three months when purchased. Cash and cash equivalents are reflected in the financial statements at cost, which approximates fair value. c. Restricted Cash and Marketable Securities As of December 31, 2015 and 2014 , the Company had $27.4 million and $30.3 million , respectively, of restricted cash and marketable securities in the accompanying consolidated balance sheets which is restricted for the purpose of satisfying the obligations of the Company's wholly-owned captive insurance company. The Company has reflected $13.9 million and $20.1 million as of December 31, 2015 and 2014 , respectively, of its restricted cash and marketable securities as a component of other assets in the accompanying consolidated balance sheets. Restricted cash and marketable securities reflected as a component of total current assets in the accompanying consolidated balance sheets represent amounts available to satisfy the claims payments estimated to occur in the next 12 months. As of December 31, 2015 and 2014 , the Company had $2.7 million and $3.0 million , respectively, included in restricted cash and marketable securities at cost, consisting of certificates of deposit with maturities less than 180 days, which approximates fair value. d. Supplies Inventory Supplies inventory consists of medical and drug supplies and is recorded at cost on a first-in, first-out basis. e. Fair Value Measurements The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The inputs used by the Company to measure fair value are classified into the following hierarchy: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date. Level 3: Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. In determining the fair value of assets and liabilities that are measured on a recurring basis at December 31, 2015 and 2014 , with the exception of contingent purchase price payables and the retained interests of investments in unconsolidated affiliates (further discussed in note 4 and note 5, respectively), the Company utilized Level 1 and 2 inputs to perform such measurements methods, which were commensurate with the market approach. There were no transfers to or from Levels 1 and 2 during the year ended December 31, 2015 . The Company's non-patient receivables and accounts payable are reflected in the financial statements at cost, which approximates fair value. f. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. g. Reclassifications Certain amounts in the consolidated financial statements and these notes have been reclassified for the retrospective adoption of the Financial Accounting Standards Board's (FASB) Accounting Standards Update (ASU) 2015-17 “ Balance Sheet Classification of Deferred Taxes ” . See below for further explanation. h. Recent Accounting Pronouncements In April 2014, the FASB issued ASU 2014-08 “Presentation of Financial Statements and Property, Plant and Equipment,” which raised the threshold for a disposal to qualify as a discontinued operation and requires certain new disclosures for individually material disposals that do not meet the new definition of a discontinued operation. The ASU’s intent is to reduce the number of disposals reported as discontinued operations by focusing on strategic shifts that have or will have a major effect on the Company’s operations and financial results rather than routine disposals that are not a change in the Company’s strategy. The guidance is effective for interim and annual periods beginning after December 15, 2014, with earlier adoption permitted. From time to time, the Company will dispose of certain of its entities due to management’s assessment of the Company’s strategy in the market and due to limited growth opportunities at those entities. Historically, these dispositions were classified as discontinued operations and recorded separately from continuing operations. The Company adopted this ASU effective January 1, 2015. In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers,” which will eliminate the transaction and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach using the following steps: identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. In August 2015, the FASB issued ASU 2015-14 “ Revenue from Contracts with Customers (Topic 606), Deferral of the Effective Date” which granted a one-year deferral of this ASU. The guidance in ASU 2014-09 will now be effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. Early adoption will be permitted for annual reporting periods beginning after December 15, 2016, including interim periods therein. The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows. In February 2015, the FASB issued ASU No. 2015-02, “ Consolidations (Topic 810) - Amendments to the Consolidation Analysis”. The new guidance makes amendments to the current consolidation guidance, including introducing a separate consolidation analysis specific to limited partnerships and other similar entities. Under this analysis, limited partnerships and other similar entities will be considered a variable-interest entity unless the limited partners hold substantive kick-out rights or participating rights. The standard is effective for annual periods beginning after December 15, 2015, including interim periods therein. The Company does not believe this ASU will impact the Company's consolidated financial position, results of operations or cash flows. However, the Company continues to evaluate the disclosures required under this ASU and has not yet determined the impact, if any. In April 2015, the FASB issued ASU No. 2015-03, “ Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. ASU 2015-03 amends current presentation guidance by requiring that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU 2015-15 “Interest - Imputation of Interest (Subtopic 835-50), Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements - Amendments to Securities and Exchange Commission (SEC) Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (SEC Update)” which incorporates into the Accounting Standards Codification an SEC staff announcement that the SEC staff will not object to an entity presenting the cost of securing a revolving line of credit as an asset, regardless of whether a balance is outstanding. The standards are effective for annual periods beginning after December 15, 2015, and interim periods within those fiscal years. Upon adoption, the Company will reclassify debt issuance costs which are currently presented as a component of intangible assets in the accompanying consolidated balance sheets to long-term debt, except those debt issuance costs associated with the Company's revolving credit facility. The Company expects the adoption of this standard will not have a significant impact on the Company's consolidated financial position and will have no impact on the results of operations or cash flows. In September 2015, the FASB issued ASU 2015-16 “Business Combinations (Topic 805), Simplifying the Accounting for Measurement-Period Adjustments” which eliminates the requirement that an acquirer in a business combination account for measurement-period adjustments retrospectively. Instead, an acquirer will recognize a measurement-period adjustment during the period in which it determines the amount of the adjustment, including the effect on earnings of any amounts it would have recorded in previous periods if the accounting had been completed at the acquisition date. The guidance is effective for fiscal years, including interim periods within those fiscal years, beginning after December 31, 2015 with early adoption permitted. The Company adopted this standard as of September 2015. The adoption of this ASU did not have a material effect on the Company's consolidated financial position, results of operations or cash flows as of December 31, 2015. In November 2015, the FASB issued ASU 2015-17 “Balance Sheet Classification of Deferred Taxes” which requires companies to classify all deferred tax assets and liabilities as noncurrent on the balance sheet instead of separating deferred taxes into current and non-current. The guidance is effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. Early adoption is permitted and companies may adopt the guidance prospectively or retrospectively. The Company adopted this standard retrospectively as of December 31, 2015 and as a result, reclassified $22.5 million from prepaid and other current assets to noncurrent deferred income taxes at December 31, 2014 in the accompanying consolidated balance sheets.

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2015
Revenue Recognition [Abstract]
Revenue Recognition	Revenue Recognition Ambulatory Services Ambulatory services revenues consist of billing for the use of the centers’ facilities directly to the patient or third-party payor and, at certain of the Company’s centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by the Company’s centers. Such revenues are recognized when the related surgical procedures are performed. Revenues exclude any amounts billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor. Revenues from ambulatory services are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid. During the years ended December 31, 2015 , 2014 and 2013 , the Company derived approximately 26% , 25% and 25% , respectively, of its ambulatory services revenues from governmental healthcare programs, primarily Medicare and managed Medicare programs. Physician Services Physician services revenues primarily consist of fee for service revenue and contract revenue and is derived principally from the provision of physician services to patients of the healthcare facilities the Company serves. Contract revenue represents income earned from the Company's hospital customers to supplement payments from third-party payors. The Company records revenue at the time services are provided, net of a contractual allowance and a provision for uncollectibles. Revenue less the contractual allowance represents the net revenue expected to be collected from third-party payors (including managed care, commercial and governmental payors such as Medicare and Medicaid) and patients insured by these payors. The Company also recognizes revenue for services provided during the period but are not yet billed. Expected collections are estimated based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient's healthcare plan, mandated payment rates under the Medicare and Medicaid programs, and historical cash collections. The Company's provision for uncollectibles includes its estimate of uncollectible balances due from uninsured patients, uncollectible co-pay and deductible balances due from insured patients and special charges, if any, for uncollectible balances due from managed care, commercial and governmental payors. The Company records net revenue from uninsured patients at its estimated realizable value, which includes a provision for uncollectible balances, based on historical cash collections (net of recoveries). Net revenue for the physician services segment consists of the following major payors (in thousands): Year Ended December 31, 2015 Period from July 16, 2014 - December 31, 2014 (1) Medicare $ 172,783 12.9 % $ 61,378 12.0 % Medicaid 69,607 5.2 28,224 5.5 Commercial and managed care 1,007,902 75.4 382,343 74.7 Self-pay 222,830 16.7 102,727 20.1 Net fee for service revenue 1,473,122 110.2 574,672 112.3 Contract and other revenue 129,786 9.7 54,343 10.6 Provision for uncollectibles (266,074 ) (19.9 ) (117,001 ) (22.9 ) Net revenue for physician services $ 1,336,834 100.0 % $ 512,014 100.0 % (1) On July 16, 2014, the Company completed the acquisition of Sheridan. Accordingly, historical amounts for periods prior to that date are not included.

Accounts Receivable

Accounts Receivable	12 Months Ended
	Dec. 31, 2015
Receivables [Abstract]
Accounts Receivable	Accounts Receivable The Company manages accounts receivable by regularly reviewing its accounts and contracts and by providing appropriate allowances for contractual adjustments and uncollectible amounts. Some of the factors considered by management in determining the amount of such allowances are the historical trends of cash collections, contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors, changes in payor mix and procedure statistics. Assessment of actual collections of accounts receivable in subsequent periods may require changes in the estimated contractual allowance and provision for uncollectibles. The Company routinely tests its analysis by comparing cash collections to net patient revenues and monitoring self-pay utilization. In addition, when actual collection percentages differ from expected results, for each facility or contract, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by the Company to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectability of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. The Company may also supplement its allowance for doubtful accounts policy for its physician services using a hindsight calculation that utilizes write-off data for all payor classes during the previous periods to estimate the allowance for doubtful accounts at a point in time. Material changes in estimates may result from unforeseen write-offs of patient or third party accounts receivable, unsuccessful disputes with managed care payors, adverse macro-economic conditions which limit patients’ ability to meet their financial obligations for the care provided by physicians, or broad changes to government regulations that adversely impact reimbursement rates for services provided by the Company. Significant changes in payor mix, specialty mix, acuity, business office operations, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on the Company’s estimates and significantly affect its results of operations and cash flows. Due to the nature of the Company's operations, it is required to separate the presentation of its bad debt expense on the consolidated statement of earnings. The Company records the portion of its bad debts associated with its physician services segment as a component of net revenue in the accompanying consolidated statement of earnings, and the remaining portion, which is associated with its ambulatory services segment, is recorded as a component of other operating expenses in the accompanying consolidated statement of earnings. The bifurcation is a result of the Company's ability to assess the ultimate collection of the patient service revenue associated with its ambulatory services segment before services are provided. The Company's ambulatory services segment is generally able to verify a patient's insurance coverage and ability to pay before services are provided as those services are pre-scheduled and non-emergent. Bad debt expense for the ambulatory services segment is included in other operating expenses and was approximately $21.4 million , $21.9 million and $21.7 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. Bad debt expense related to physician services was $266.1 million for the year ended December 31, 2015 and $117.0 million during the period from July 16, 2014 through December 31, 2014. At December 31, 2015 and 2014 allowances for doubtful accounts were $167.4 million and $113.4 million , respectively. The increase in the allowance for doubtful accounts is primarily a result of operations from acquisitions completed during the year ended December 31, 2015 . At December 31, 2015 and 2014 , approximately 80% and 73% , respectively, of the Company’s allowance for doubtful accounts was related to fee for service patient receivables associated with the Company's physician services segment. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance. Concentration of credit risk is limited by the diversity and number of facilities, patients, payors and by the geographic dispersion of the Company’s operations.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Acquisitions	Acquisitions The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method. Ambulatory Services Acquisitions During 2015 and 2014 , the Company, through a wholly-owned subsidiary, acquired a controlling interest in seven and eight surgery centers, respectively. Of the centers acquired during 2014 , three were acquired as part of the Sheridan transaction and five were individually acquired in separate transactions. The aggregate amount paid for the centers and for settlement of purchase price payable obligations during December 31, 2015 and 2014 was approximately $131.3 million and $50.9 million , respectively, and was paid in cash and funded by a combination of operating cash flow and borrowings under the Company’s revolving credit facility. The acquisitions completed during the year ended December 31, 2015 consist of the following: Acquired Operations Location Date Acquired Specialty River Drive Surgery & Laser Center, LLC Elmwood Park, NJ February 2015 Ophthalmology Campus Surgery Center, LLC Daly City, CA June 2015 Multi-Specialty Waverly Surgery Center, LLC Palo Alto, CA June 2015 Multi-Specialty Surgical Center at Millburn, LLC Millburn-East Willow, NJ July 2015 Multi-Specialty Eye Surgery Center of Western Ohio, LLC Lima, OH August 2015 Ophthalmology Surgical Specialty Center of Northeastern PA, LLC Forty Fort, PA October 2015 Multi-Specialty South Portland Surgical Center, LLC Tualatin, OR November 2015 Multi-Specialty Physician Services Acquisitions The Company completed the acquisition of nine physician practices in 2015 and two physician practices in 2014 following the acquisition of Sheridan. During 2015 and 2014 , the total consideration consisted of cash of $831.4 million and $19.0 million , respectively, which was funded at closing through available cash, current year operating cash flow and borrowings through the Company's credit facility. The acquisitions completed during the year ended December 31, 2015 consist of the following: Acquired Operations Location Date Acquired Specialty Ambulatory Anesthesia Care, PC Mountainside, NJ January 2015 Anesthesia Sheridan Radiology Management Services, Inc. Beachwood, OH January 2015 Radiology Radiology Associates of Hollywood, P.A. Pembroke Pines, FL March 2015 Radiology Halifax Anesthesiology Associates, P.A. Daytona Beach, FL April 2015 Anesthesia Coastal Anesthesiology Consultants, P.A. St. Augustine, FL July 2015 Anesthesia Bay Area Anesthesia, LLC Tampa, FL August 2015 Anesthesia Valley Anesthesia Consultants, Ltd. Phoenix, AZ November 2015 Anesthesia Chandler Emergency Medical Group, LLC Phoenix, AZ December 2015 Emergency Northside Anesthesiology Consultants, LLC Atlanta, GA December 2015 Anesthesia As a result of certain acquisitions completed during the year ended December 31, 2014, the Company has agreed to pay as additional consideration, amounts which are contingent on the acquired entities achieving future performance metrics. As of December 31, 2015 and December 31, 2014, the Company had accrued $5.5 million and $20.7 million , respectively, as a component of accrued liabilities and other long-term liabilities in the accompanying consolidated balance sheets which represents management's estimate of the fair values of the contingent consideration. During the year ended December 31, 2015 , the Company made a payment of $28.7 million , of which $15.7 million was to settle the amount recorded at the acquisition date and represents a financing outflow in the consolidated statement of cash flows. As of December 31, 2015 , the Company estimates it may have to pay between $5.0 million and $6.0 million in future contingent payments for acquisitions made prior to December 31, 2014 based upon the current projected financial performance or anticipated achievement of other targets of the acquired operations. The current estimate of future contingent payments could increase or decrease depending upon the actual performance of the acquisitions over each respective measurement period. During the year ended December 31, 2015 , the Company recorded a net increase of $10.0 million based on results of operations of the associated acquisitions, of which $8.8 million is included in other operating expenses in the accompanying consolidated statements of earnings. Additionally, the Company recorded an increase in the contingent liability of $3.5 million during the year ended December 31, 2015 as a result of the acquisition accounting associated with the purchase of Sheridan. The acquisitions completed during the year ended December 31, 2015 did not contain provisions for contingent consideration. The Company utilizes Level 3 inputs, which include unobservable data, to measure the fair value of the contingent consideration. The fair value was determined utilizing future forecasts of both earnings and other performance metrics which are expected to be achieved during the performance period, in accordance with each respective purchase agreement. In estimating the fair value, management developed various scenarios and weighted the probable outcome of each scenario using a range of expected probability specific to each agreement. Management utilized a market rate to discount the results of such analysis in order to record the present value of the expected future payout. The timing of the payments of the additional consideration varies by agreement but is expected to occur within one to three years from the respective date of acquisition. Sheridan Acquisition On July 16, 2014 (the “acquisition date”), the Company completed the acquisition of Sheridan in a cash and stock transaction. At closing, the Company paid approximately $2.1 billion in cash and issued 5,713,909 shares of its common stock to the former owners of Sheridan in exchange for all of the outstanding equity interests of Sheridan. The shares issued to Sheridan were valued at approximately $272.0 million based on the closing price of the Company's common stock on July 16, 2014. The acquisition of Sheridan enhances the growth profile and diversity of the Company focusing on complementary specialties across the healthcare continuum. To fund the transaction, the Company completed offerings of common stock and mandatory convertible preferred stock resulting in the issuance of 9,775,000 shares of common stock and 1,725,000 shares of mandatory convertible preferred stock. Proceeds from the common stock offering and mandatory preferred stock offering, net of transaction fees, were approximately $421.3 million and $166.6 million , respectively. In addition, on July 16, 2014, the Company entered into a new senior secured credit facility, which includes an $870.0 million term loan and a $300.0 million revolving credit facility, and completed a private offering of $1.1 billion aggregate principal amount of 5.625% senior unsecured notes due 2022. Fees and expenses associated with the Sheridan transaction, which includes fees incurred related to the Company's equity issuances and debt financings, was approximately $139.1 million during the year ended December 31, 2014 . Approximately $53.0 million was capitalized as deferred financing costs, $24.5 million was related to the equity offerings and recorded as a reduction to equity, $31.9 million was expensed as transaction costs, $12.8 million was amortized through interest expense and $16.9 million was recorded as debt extinguishment costs during the year ended December 31, 2014 . Purchase Price Allocations The acquisition date fair value of the total consideration transferred and acquisition date fair value of each major class of consideration for the acquisitions completed during 2015 and 2014 , including post acquisition date adjustments recorded to purchase price allocations, are as follows (in thousands): 2015 2014 Individual Individual Acquisitions (1) Acquisitions Sheridan Accounts receivable $ 62,216 $ 1,816 $ 130,260 Other current assets 21,477 1,075 105,757 Property and equipment 15,484 3,294 20,185 Goodwill 682,458 101,865 1,534,656 Intangible assets 420,414 14,207 1,200,028 Other long-term assets 342 — 50,304 Accounts payable (3,641 ) (2,519 ) (5,862 ) Other accrued liabilities (45,386 ) (626 ) (118,548 ) Deferred income taxes (88,728 ) — (432,792 ) Other long-term liabilities (4,958 ) (8,588 ) (69,456 ) Long-term debt (6,046 ) (717 ) (4,594 ) Total fair value 1,053,632 109,807 2,409,938 Less: Fair value attributable to noncontrolling interests 85,443 39,371 24,365 Acquisition date fair value of total consideration transferred $ 968,189 $ 70,436 $ 2,385,573 (1) Represents the preliminary allocation of fair value of acquired assets and liabilities associated with these acquisitions at December 31, 2015 . During 2015 , no significant changes were made to the purchase price allocation of assets and liabilities, existing at the date of acquisition, related to individual acquisitions completed in 2014 . During 2015 , factors became known to the Company that resulted in changes to the purchase price allocation of assets and liabilities, existing at the date of acquisition, related to Sheridan and resulted in a net decrease to goodwill of $8.3 million , an increase to other accrued expenses, a decrease to other current assets and a decrease to deferred income taxes. The total fair value of acquisitions completed by the Company include amounts allocated to goodwill, which result from the acquisitions' favorable reputations in their markets, their market positions and their ability to deliver quality care with high patient satisfaction consistent with the Company’s business model. Fair value attributable to noncontrolling interests is based on significant inputs that are not observable in the market. Key inputs used to determine the fair value include financial multiples used in the purchase of noncontrolling interests primarily from acquisitions of centers. Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability. The fair value of noncontrolling interests for acquisitions where the purchase price allocation is not finalized may be subject to adjustment as the Company completes its initial accounting for acquired intangible assets. Additionally, the Company continues to obtain information relative to the fair values of assets acquired, liabilities assumed and any noncontrolling interests associated with acquisitions completed in the last twelve months. Acquired assets and assumed liabilities include, but are not limited to, fixed assets, licenses, intangible assets and professional liabilities. The valuations are based on appraisal reports, discounted cash flow analyses, actuarial analyses or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed. A majority of the deferred income taxes recognized as a component of the Company's purchase price allocation is a result of the difference between the book and tax basis of the amortizable intangible assets recognized. The amount allocated to the deferred income tax liability is subject to change as a result of the final allocation of purchase price to amortizable intangibles. The Company expects to finalize the purchase price allocation for its most recent acquisitions as soon as practical. During the year ended December 31, 2015 , the Company incurred approximately $8.3 million of transaction costs associated with its acquisition of surgery centers and physician practices. During the year ended December 31, 2014 , the Company incurred approximately $33.9 million of transaction costs primarily associated with the acquisition of Sheridan. Such costs excluded those amounts that were either capitalized or expensed as part of the financing transactions associated with acquisitions. Revenues and net earnings included in the years ended December 31, 2015 and 2014 associated with completed acquisitions are as follows (in thousands): 2015 2014 Individual Individual Acquisitions Acquisitions Sheridan Net revenue $ 179,113 $ 20,844 517,213 Net earnings 26,901 5,155 26,776 Less: Net earnings attributable to noncontrolling interests 7,448 2,859 459 Net earnings attributable to AmSurg Corp. common shareholders $ 19,453 $ 2,296 $ 26,317 The unaudited consolidated pro forma results for the years ended December 31, 2015 and 2014 , assuming all 2015 acquisitions had been consummated on January 1, 2014 , all 2014 acquisitions had been consummated on January 1, 2013 are as follows (in thousands): 2015 2014 Net revenue $ 2,858,544 $ 2,680,273 Net earnings 401,950 322,653 Amounts attributable to AmSurg Corp. common shareholders: Net earnings 170,453 104,548 Net earnings per common share: Basic $ 3.55 $ 2.21 Diluted $ 3.48 $ 2.20

Investments in Unconsolidated A

Investments in Unconsolidated Affiliates	12 Months Ended
	Dec. 31, 2015
Equity Method Investments and Joint Ventures [Abstract]
Investments in Unconsolidated Affiliates	Investments in Unconsolidated Affiliates Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest. Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value. The fair value measurement utilizes Level 3 inputs, which include unobservable data, to measure the fair value of the retained noncontrolling interest. The fair value determination are generally based on a combination of multiple valuation methods which can include discounted cash flow, income approach, or market value approach which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. These investments are included as investments in unconsolidated affiliates in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments is reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statements of earnings. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary. As of December 31, 2015 and 2014 , the Company has recorded in the accompanying consolidated balance sheets its investments in unconsolidated affiliates of $169.2 million and $75.5 million , respectively. The Company's net earnings from these investments during the years ended December 31, 2015 , 2014 and 2013 were approximately $16.2 million , $7.0 million and $3.2 million , respectively. During the year ended December 31, 2015 , the Company's ambulatory services segment entered into five separate equity method investments. As a result of these investment transactions, the Company contributed its controlling interest in nine centers and received net cash of $8.5 million in exchange for noncontrolling interests in the new investments. Each of these investments is jointly owned by a health system and the Company. The newly formed investments (including the contributed centers) are controlled by the health systems. Also, as part of these transactions, the Company obtained a non-controlling interest in three additional centers and one surgical hospital which were contributed by the health systems. During the year ended December 31, 2015 , the Company's physician services segment contributed three contracts into an entity jointly owned by the Company and a health system. During the year ended December 31, 2014 , the Company's ambulatory services segment entered into four separate equity method investments. As a result of these investment transactions, the Company contributed its controlling interest in four of its centers and received net cash of $1.2 million in exchange for noncontrolling interests in the new investments. Each of these investments is jointly owned by a health system and the Company. The newly formed investments (including the contributed centers) are controlled by the health systems. Also, as part of these transactions, the Company obtained a non-controlling interest in one additional centers which was contributed by a health system. During the year ended December 31, 2013, the Company's ambulatory services segment entered into one equity method investment. As a result of this investment transaction, the Company contributed cash of $0.3 million and its controlling interest in one center in exchange for a noncontrolling interests in the new investment. This investment is jointly owned by a health system and the Company. The newly formed investment (including the contributed center) are controlled by the health system. Also, as part of this transaction, the Company obtained a non-controlling interest in one additional center which was contributed by the health system. As a result of these transactions, for the years ended December 31, 2015 and 2014 , the Company recorded the fair value of the Company's investment in these entities of approximately $83.1 million and $56.4 million , respectively, in the accompanying consolidated balance sheets, as a component of investments in unconsolidated affiliates. 10% to 50% which were primarily based on third party valuations received by the Company. Accordingly, the Company recognized a net gain on deconsolidations in the accompanying consolidated statements of earnings of approximately $36.7 million , $3.4 million , and $2.2 million during the years ended December 31, 2015 , 2014 and 2013 . Included in the Company’s investments in unconsolidated affiliates are certain investments which the Company has determined meet the definition of a variable interest entity. The Company has a variable interest in these investments through its equity interests; however, the Company is not the primary beneficiary of these entities as it only holds 50% of the voting rights and does not have the power to direct the activities that most significantly impact the entities' economic performance as a result of the Company’s shared control. As a result, the Company has accounted for these investments under the equity method of accounting. The Company's investment in these entities was $89.6 million and $53.2 million as of December 31, 2015 and 2014 , respectively, and are reflected in the accompanying consolidated balance sheets as a component of investments in unconsolidated affiliates. During the year ended December 31, 2015 , the Company contributed four centers which were previously controlled into an entity deemed by the Company to meet the definition of a variable interest entity which resulted in the Company’s recording the fair value of its retained noncontrolling interest of approximately $27.1 million as a component of investments in unconsolidated affiliates in the accompanying consolidated balance sheets. During the year ended December 31, 2014 , as part of the acquisition of Sheridan, the Company acquired an interest in an entity deemed to be a variable interest entity and recorded the estimated fair value of the investment of $49.4 million on the acquisition date. The Company’s ownership interest in these investments ranges from 49% to 51% and under the terms of the operating agreements, the Company earns billing and management fees and receives its share of earnings distributions from each entity. The Company has no other material obligations or guarantees related to these entities. The Company has recorded its share of the earnings of these investments of $11.0 million and $3.4 million as a component of equity in earnings of unconsolidated affiliates in the accompanying consolidated statement of earnings during 2015 and 2014 , respectively. In addition, the Company recognized management and billing fees totaling $14.3 million and $4.7 million during 2015 and 2014 , respectively, which are included in net revenue in the accompanying consolidated statement of earnings. Additionally, the Company has recorded receivables from these entities in the amount of $2.3 million and $3.5 million as of December 31, 2015 and 2014 , respectively. These receivables are included in other current assets in the accompanying consolidated balance sheets.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Dispositions	Discontinued Operations During the years ended December 31, 2014 and 2013, the Company discontinued the operations of certain centers in its ambulatory services segment due to management’s assessment of the Company’s strategy in the market and due to the limited growth opportunities at these centers. For centers discontinued in 2014 and prior, the results of operations of those centers have been classified as discontinued operations in all periods presented. As of January 1, 2015, the Company adopted ASU 2014-08 which raised the threshold for a disposal to qualify as a discontinued operation. As a result, the Company expects that any future disposals of its centers will no longer meet the definition to be accounted for as discontinued operations, and any gain or loss from such disposals will be included in continuing operations. The Company did not dispose of any centers during the year ended December 31, 2015 , but continues to have operating activity associated with centers previously classified as discontinued operations. Results of operations and associated gain (loss) on discontinued centers for the years ended December 31, 2015 , 2014 and 2013 are as follows (in thousands): 2015 2014 2013 Revenues $ — $ 9,545 $ 25,373 Earnings before income taxes — 893 5,607 Results of discontinued operations, net of tax: Earnings (loss) from operations of discontinued interests in surgery centers (1,013 ) 710 4,449 Gain (loss) on disposal of discontinued interests in surgery centers — (2,006 ) 2,602 Net earnings (loss) from discontinued operations (1,013 ) (1,296 ) 7,051 Less: Net earnings (loss) from discontinued operations attributable to noncontrolling interests (12 ) 283 5,357 Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders $ (1,001 ) $ (1,579 ) $ 1,694 Cash proceeds from centers discontinued for the years ended December 31, 2014 and 2013 were $7.1 million and $3.6 million , respectively. There were no cash proceeds during 2015.

Prepaid and Other Current Asset

Prepaid and Other Current Assets	12 Months Ended
	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid and Other Current Assets	Prepaid and Other Current Assets The following table presents a summary of items comprising prepaid and other current assets in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 (in thousands): 2015 2014 Income taxes receivable $ 7,908 $ 28,694 Prepaid expenses 18,900 18,682 Deferred compensation plan assets 16,623 17,320 Other 32,340 28,204 Total prepaid and other current assets $ 75,771 $ 92,900

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Equipment held under capital leases is stated at the present value of minimum lease payments at the inception of the related leases. Depreciation for buildings and improvements is recognized under the straight-line method over 20 to 40 years or, for leasehold improvements, over the remaining term of the lease plus renewal options for which failure to renew the lease imposes a penalty on the Company in such an amount that a renewal appears, at the inception of the lease, to be reasonably assured. The primary penalty to which the Company is subject is the economic detriment associated with existing leasehold improvements which might be impaired if a decision is made not to continue the use of the leased property. Depreciation for movable equipment is recognized over useful lives of three to ten years . Property and equipment at December 31, 2015 and 2014 were as follows (in thousands): 2015 2014 Building and improvements $ 177,253 $ 170,420 Movable equipment 237,312 215,444 Construction in progress 8,676 11,940 423,241 397,804 Less accumulated depreciation (234,073 ) (217,356 ) Property and equipment, net $ 189,168 $ 180,448 At December 31, 2015 , the Company and its partnerships had unfunded construction and equipment purchases of approximately $18.3 million in order to complete construction in progress primarily associated with the construction of the Company's new physician services headquarters. Depreciation expense for continuing and discontinued operations for the years ended December 31, 2015 , 2014 and 2013 was $35.4 million , $33.2 million and $29.8 million , respectively.

Goodwill And Intangible Assets

Goodwill And Intangible Assets	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill And Intangible Assets	Goodwill and Intangible Assets The Company’s intangible assets include goodwill and other intangibles, which include the fair value of both the customer relationships with hospitals and trade names acquired in the Company's physician services segment. The Company's indefinite lived intangibles include goodwill and trade names. Goodwill represents the excess of purchase price over the fair value of net assets acquired. The Company evaluates indefinite lived intangible assets, including goodwill, for impairment at least on an annual basis and more frequently if certain indicators are encountered. Indefinite lived intangibles are to be tested at the reporting unit level, defined as an operating segment or one level below an operating segment (referred to as a component), with the fair value of the reporting unit being compared to its carrying amount. If the fair value of a reporting unit exceeds its carrying amount, the indefinite lived intangibles associated with the reporting unit is not considered to be impaired. The Company completed its annual impairment test as of October 1, 2015 , and determined that its indefinite lived intangibles were not impaired. The Company's finite-lived intangibles includes its customer relationship with hospitals. The Company tests its finite-lived intangibles for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable. The Company's policy is to recognize an impairment charge when the carrying amount is not recoverable and such amount exceeds fair value. During the year ended December 31, 2015 , there were no events or circumstances that indicated a potential impairment in the Company's finite-lived intangibles. The changes in the carrying amount of goodwill for the years ended December 31, 2015 and 2014 are as follows (in thousands): 2015 2014 Balance, beginning of year $ 3,381,149 $ 1,758,970 Goodwill acquired, including post acquisition adjustments 674,476 1,636,521 Goodwill disposed, including impact of deconsolidation transactions (85,415 ) (14,342 ) Balance, end of year $ 3,970,210 $ 3,381,149 As of December 31, 2015 , the ambulatory services segment and the physician services segment each had approximately $2.0 billion of goodwill compared to $1.9 billion for ambulatory services and $1.5 billion for physician services, respectively, at December 31, 2014 . During the year ended December 31, 2015 , goodwill increased $123.4 million for the ambulatory services segment primarily due to the acquisition of seven centers, net of nine deconsolidations. During the year ended December 31, 2015 , goodwill increased by $465.7 million for the physician services segment primarily due to the acquisition of nine physician practices, net of three deconsolidations. For the years ended December 31, 2015 and 2014 approximately $295.7 million and $64.5 million , respectively, of goodwill recorded was deductible for tax purposes. Intangible assets consist primarily of customer relationships with hospitals, deferred financing costs, capitalized software and certain amortizable and non-amortizable non-compete and customer agreements. Customer relationships with hospitals are initially recorded at their estimated fair value and amortized on a straight-line basis over 20 years . Deferred financing costs and amortizable non-compete agreements and customer agreements are amortized over the term of the related debt as interest expense and the contractual term or estimated life ( five to ten years ) of the agreements as amortization expense. Capitalized software is amortized over estimated useful lives of three to eight years. Intangible assets at December 31, 2015 and 2014 consisted of the following (in thousands): 2015 2014 Gross Gross Carrying Accumulated Carrying Accumulated Amount Amortization Net Amount Amortization Net Amortizable intangible assets: Customer relationships with hospitals $ 1,379,977 $ (74,490 ) $ 1,305,487 $ 971,645 $ (22,145 ) $ 949,500 Deferred financing costs 60,664 (13,490 ) 47,174 59,574 (5,151 ) 54,423 Capitalized software 71,462 (28,125 ) 43,337 50,387 (19,197 ) 31,190 Agreements, contracts and other 11,267 (2,449 ) 8,818 3,523 (2,752 ) 771 Total amortizable intangible assets 1,523,370 (118,554 ) 1,404,816 1,085,129 (49,245 ) 1,035,884 Non-amortizable intangible assets: Trade name 228,000 — 228,000 228,000 — 228,000 Restrictive covenant arrangements 8,995 — 8,995 9,995 — 9,995 Total non-amortizable intangible assets 236,995 — 236,995 237,995 — 237,995 Total intangible assets $ 1,760,365 $ (118,554 ) $ 1,641,811 $ 1,323,124 $ (49,245 ) $ 1,273,879 Amortization of intangible assets for the years ended December 31, 2015 , 2014 and 2013 was $70.5 million , $32.5 million and $2.2 million , respectively. Included in the 2014 amount above is also $12.8 million that was charged to interest expenses related to a write-off of a commitment fee for bridge financing, which the Company had secured in order to complete the acquisition of Sheridan but did not require upon obtaining permanent financing. Estimated amortization of intangible assets for the five years and thereafter subsequent to December 31, 2015 is $90.3 million , $89.1 million , $87.8 million , $84.8 million , $81.6 million and $971.2 million , respectively. The Company expects to recognize amortization of all intangible assets over a weighted average period of 17.8 years with no expected residual values.

Other Accrued Liabilities

Other Accrued Liabilities	12 Months Ended
	Dec. 31, 2015
Accrued Liabilities, Current [Abstract]
Other Current Liabilities	Other Accrued Liabilities The following table presents a summary of items comprising other accrued liabilities in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 (in thousands): 2015 2014 Accrued professional liabilities $ 14,362 $ 11,983 Contingent purchase price payable 5,509 12,213 Current income taxes payable 7,892 — Refunds payable 48,415 17,752 Other 43,059 26,038 Total other accrued liabilities $ 119,237 $ 67,986

Accrued Professional Liabilitie

Accrued Professional Liabilities	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Accounts Professional Liabilities	Accrued Professional Liabilities The Company maintains professional liability insurance policies with third-party insurers generally on a claims-made basis, subject to self-insured retention, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. The Company records an estimate of liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss patterns, which are not discounted. At December 31, 2015 , the Company's accrued professional liabilities are presented in the accompanying consolidated balance sheets as a component of other accrued liabilities and other long-term liabilities as follows (in thousands): 2015 2014 Estimated losses under self-insured programs $ 30,748 $ 25,337 Incurred but not reported losses 36,166 28,448 Total accrued professional liabilities 66,914 53,785 Less estimated losses payable within one year 14,362 11,983 Total $ 52,552 $ 41,802 The changes to the Company's estimated losses under self-insured programs as of December 31, 2015 and 2014 were as follows (in thousands): 2015 2014 Balance, beginning of year $ 53,785 $ 1,171 Assumed liabilities through acquisitions 13,317 53,512 Provision related to current period reserves 15,943 5,423 Payments for current period reserves (4,475 ) (1,595 ) Benefit related to changes in prior period reserves (425 ) (661 ) Payments for prior period reserves (8,863 ) (6,055 ) Other, net (2,368 ) 1,990 Balance, end of year $ 66,914 $ 53,785

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Long-Term Debt	Long-term Debt Long-term debt at December 31, 2015 and 2014 consisted of the following (in thousands): 2015 2014 Revolving credit agreement $ 175,000 $ — Term Loan 856,950 865,650 Senior Unsecured Notes due 2020 (5.625%) 250,000 250,000 Senior Unsecured Notes due 2022 (5.625%) 1,100,000 1,100,000 Other debt at an average interest rate of 3.4%, due through 2022 24,944 20,156 Capitalized lease arrangements at an average interest rate of 5.4%, due through 2021 18,613 15,206 2,425,507 2,251,012 Less current portion 20,377 18,826 Long-term debt $ 2,405,130 $ 2,232,186 Principal payments required on the Company’s long-term debt and capital leases in the five years and thereafter subsequent to December 31, 2015 are $20.4 million , $18.0 million , $14.8 million , $187.0 million , $261.0 million , and $1.9 billion . The fair value of the Company's fixed rate long-term debt and variable rate long-term debt approximated its carrying values of $1.4 billion and $1.0 billion at December 31, 2015 , respectively. With the exception of the Company’s 2020 and 2022 Senior Unsecured Notes, the fair value of fixed rate debt (Level 2) is determined based on an estimation of discounted future cash flows of the debt at rates currently quoted or offered to the Company for similar debt instruments of comparable maturities by its lenders. The fair value of the Company’s 2020 and 2022 Senior Unsecured Notes (Level 1) is determined based on quoted prices in an active market. a. Term Loan and Credit Facility On July 16, 2014, the Company entered into a credit facility that is comprised of an $870.0 million term loan and a $300.0 million revolving credit facility. On October 21, 2015, the Company exercised the accordion feature of its revolving credit facility and increased the Company's borrowing capacity by $200.0 million to $500.0 million . As of December 31, 2015 , the Company had available $325.0 million under the revolving credit facility. The term loan matures on July 16, 2021 and bears interest at a rate equal to, at the Company’s option, the alternative base rate as defined in the agreement (ABR) plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00% , with a LIBOR floor of 0.75% , or a combination thereof ( 3.75% on December 31, 2015 ). The term loan requires quarterly principal payments of 0.25% of the face amount totaling $8.7 million annually. The revolving credit facility matures on July 16, 2019 and permits the Company to borrow at an interest rate equal to, at the Company’s option, the ABR plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00% , or a combination thereof; and provides for a fee of 0.375% of unused commitments. The Company has the option to increase borrowings under the senior secured credit facility by an unlimited amount as long as certain financial covenants are met and lender approval is obtained. The senior credit facility contains certain covenants relating to the ratio of debt to operating performance measurements and interest coverage ratios and is secured by a pledge of the stock of the Company’s wholly-owned subsidiaries and certain of the Company’s less than wholly-owned subsidiaries. As of December 31, 2015 , the Company was in compliance with the covenants contained in the term loan and credit facility. Prior to entering into the Company's credit facility, the Company maintained a revolving credit facility which had a maturity of June 2018 . On July 3, 2014, the Company utilized proceeds received from its common and preferred stock offerings to repay its outstanding obligation under the existing revolving credit facility. As a result of the early termination, the Company recognized approximately $4.5 million as debt extinguishment costs in the accompanying statements of earnings during the year ended December 31, 2014 related to the write-off of net deferred loan costs. b. Senior Unsecured Notes 2020 Senior Unsecured Notes On November 20, 2012, the Company completed a private offering of $250.0 million aggregate principal amount of 5.625% senior unsecured notes due 2020 (2020 Senior Unsecured Notes). On May 31, 2013, the Company completed an offer to exchange the outstanding 2020 Senior Unsecured Notes for an equal amount of such notes that are registered under the Securities Act of 1933, as amended (Securities Act). The net proceeds from the issuance of the 2020 Senior Unsecured Notes were used to reduce the outstanding indebtedness under the Company’s revolving credit agreement. The 2020 Senior Unsecured Notes are unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized wholly-owned domestic subsidiaries. The 2020 Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the 2020 Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on May 30 and November 30, through the maturity date of November 30, 2020 . The Company may redeem the 2020 Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on November 30 of the years indicated below: Period Redemption Price 2015 104.219 % 2016 102.813 % 2017 101.406 % 2018 and thereafter 100.000 % The 2020 Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. The Company was in compliance with the covenants contained in the indenture relating to the 2020 Senior Unsecured Notes at December 31, 2015 . 2022 Senior Unsecured Notes On July 16, 2014, the Company completed a private offering of $1.1 billion aggregate principal amount of 5.625% senior unsecured notes due 2022 (2022 Senior Unsecured Notes). On February 19, 2015, the Company completed an offer to exchange the outstanding 2022 Senior Unsecured Notes, for an equal amount of such notes that are registered under the Securities Act. The 2022 Senior Unsecured Notes are unsecured obligations of the Company and are guaranteed by the Company and existing and subsequently acquired or organized wholly-owned domestic subsidiaries. The 2022 Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the 2022 Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on January 15 and July 15, beginning on January 15, 2015, and ending on the maturity date of July 15, 2022. Prior to July 15, 2017, the Company may redeem up to 35% of the aggregate principal amount of the 2022 Senior Unsecured Notes at a redemption price of 105.625% of the principal amount thereof, plus accrued and unpaid interest and liquidated damages, if any, using proceeds of one or more equity offerings. On or after July 15, 2017, the Company may redeem the 2022 Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on July 15 of the years indicated below: Period Redemption Price 2017 104.219 % 2018 102.813 % 2019 101.406 % 2020 and thereafter 100.000 % The 2022 Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. Based on the terms of the 2022 Notes, the Company has adequate ability to meet its obligations to pay dividends as required under the terms of its mandatory preferred stock. The Company was in compliance with the covenants contained in the indenture relating to the 2022 Senior Unsecured Notes at December 31, 2015 . c. Senior Secured Notes During 2010, the Company issued $75.0 million principal amount of senior secured notes due 2020 (Senior Secured Notes) pursuant to a note purchase agreement. The Senior Secured Notes had a maturity date of May 28, 2020 . On July 16, 2014, the Company redeemed the Senior Secured Notes utilizing proceeds received from its common and preferred stock offerings. As a result of the early extinguishment, the Company paid an early termination fee of approximately $12.4 million to the holders of the Senior Secured Notes, which is recognized as a component of debt extinguishment costs during the year ended December 31, 2014 in the accompanying statements of earnings. d. Other debt Certain partnerships included in the Company’s consolidated financial statements have loans with local lending institutions, included above in other debt, which are collateralized by certain assets of the surgery centers with a book value of approximately $41.7 million . The Company and the partners have guaranteed payment of the loans in proportion to the relative partnership interests.

Other Long-term Liabilities

Other Long-term Liabilities	12 Months Ended
	Dec. 31, 2015
Other Liabilities Disclosure [Abstract]
Other Long-term Liabilities	Other Long-term Liabilities The following table presents a summary of items comprising other long-term liabilities in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 (in thousands): 2015 2014 Accrued professional liabilities $ 52,552 $ 41,802 Contingent purchase price payable — 8,470 Deferred rent 18,958 16,814 Tax-effected unrecognized benefits 3,426 8,353 Other 21,247 14,004 Other long-term liabilities $ 96,183 $ 89,443

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company files a consolidated federal income tax return. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes. In addition, it is the Company’s policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its statement of earnings. The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months. The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal or state income tax examinations for years prior to 2012 . Total income taxes expense (benefit) for the years ended December 31, 2015 , 2014 and 2013 was included within the following sections of the consolidated financial statements as follows (in thousands): 2015 2014 2013 Earnings from continuing operations $ 113,790 $ 48,103 $ 48,654 Discontinued operations (694 ) (643 ) 9 Shareholders’ equity (2,227 ) (3,177 ) (7,381 ) Total $ 110,869 $ 44,283 $ 41,282 Income tax expense from continuing operations for the years ended December 31, 2015 , 2014 and 2013 was comprised of the following (in thousands): 2015 2014 2013 Current: Federal $ 83,228 $ 8,640 $ 7,895 State 14,268 4,396 3,598 Deferred: Federal 11,715 27,505 31,509 State 4,579 7,562 5,652 Income tax expense $ 113,790 $ 48,103 $ 48,654 Income tax expense from continuing operations for the years ended December 31, 2015 , 2014 and 2013 differed from the amount computed by applying the U.S. federal income tax rate of 35% to earnings before income taxes as a result of the following (in thousands): 2015 2014 2013 Statutory federal income tax $ 173,572 $ 102,967 $ 106,101 Less federal income tax assumed directly by noncontrolling interests (76,364 ) (66,783 ) (64,219 ) State income taxes, net of federal income tax benefit 11,604 6,616 5,539 Increase in valuation allowances 317 4,662 924 Interest related to unrecognized tax benefits (548 ) (161 ) (155 ) Other 5,209 802 464 Income tax expense $ 113,790 $ 48,103 $ 48,654 The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. Decreases in interest and penalty obligations of $0.2 million , $0.1 million and $0.2 million were recognized in the consolidated statement of earnings for the years ended December 31, 2015 , 2014 and 2013 , respectively, resulting in a total recognition of interest and penalty obligations of approximately $0.8 million and $1.2 million in the consolidated balance sheet at December 31, 2015 and 2014 , respectively. The Company primarily has unrecognized tax benefits that represent an amortization deduction which is temporary in nature. A reconciliation of the beginning and ending amount of the liability associated with unrecognized tax benefits for the years ended December 31, 2015 , 2014 and 2013 is as follows (in thousands): 2015 2014 2013 Balance at beginning of year $ 7,336 $ 6,330 $ 9,235 Additions for tax positions of current year — 204 46 Increases (decreases) for tax positions taken during a prior period (1,006 ) 1,069 — Lapse of statute of limitations (3,178 ) (267 ) (2,951 ) Balance at end of year $ 3,152 $ 7,336 $ 6,330 The Company believes that the total amount of increases in unrecognized tax benefits within the next 12 months is not considered significant. The total amount of unrecognized tax benefits that would affect the Company’s effective tax rate if recognized is approximately $0.1 million . The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2015 and 2014 were as follows (in thousands): 2015 2014 Deferred tax assets: Allowance for uncollectible accounts $ 3,276 $ 1,096 Accrued assets and other 36,600 27,537 Share-based compensation 10,710 7,719 Interest on unrecognized tax benefits 113 245 Accrued liabilities and other 4,080 3,931 Medical malpractice 19,035 16,240 Operating and capital loss carryforwards 29,718 22,709 Valuation allowances (21,814 ) (17,457 ) Total deferred tax assets 81,718 62,020 Deferred tax liabilities: Prepaid expenses 1,789 2,435 Property and equipment, principally due to differences in depreciation 16,787 15,235 Goodwill, intangible assets and other, principally due to differences in amortization 762,640 655,358 Total deferred tax liabilities 781,216 673,028 Net deferred tax liabilities $ 699,498 $ 611,008 The Company has provided valuation allowances on its gross deferred tax assets to the extent that management does not believe that it is more likely than not that such asset will be realized. Capital loss carryforwards began to expire in 2014, and state net operating losses began to expire in 2015.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Shareholders' Equity	Shareholders’ Equity a. Common Stock During December 2015, the Company issued 5,835,000 shares of its common stock in a public offering, at $80.00 per share, prior to underwriting discounts, commissions and other related offering expenses of approximately $19.1 million . Proceeds were used to repay a portion of the Company's revolving credit facility, to fund a portion of the acquisitions completed during the year ended 2015 and for general corporate purposes. On July 2, 2014, the Company issued 9,775,000 shares of its common stock in a public offering, at $45.00 per share, prior to underwriting discounts, commissions and other related offering expenses of approximately $18.5 million . Proceeds from the issuance were used to satisfy certain debt obligations with the remaining amount utilized to fund a portion of the Sheridan acquisition. In addition, on July 16, 2014, the Company issued 5,713,909 shares of its common stock directly to the former owners of Sheridan as part of the total consideration for the Sheridan acquisition. The Company registered these shares with the SEC in October of 2014. The former owners of Sheridan subsequently sold their shares in November of 2014. During 2013, under a board authorized stock repurchase program, the Company purchased 1,154,378 shares of the Company's common stock for approximately $42.7 million , at an average price of $36.93 per share, in order to mitigate the dilutive effect of shares issued upon the exercise of stock options pursuant to the Company's stock incentive plans. The stock repurchase program expired during 2014. In addition, the Company repurchases shares by withholding a portion of employee restricted stock that vested to cover payroll withholding taxes in accordance with the restricted stock agreements. During 2015 and 2014 , the Company repurchased 67,000 shares and 100,720 shares, respectively, of common stock for approximately $3.7 million and $4.6 million , respectively. b. Preferred Stock On July 2, 2014, the Company issued 1,725,000 shares of its mandatory convertible preferred stock in a public offering, at $100.00 per share, prior to underwriting discounts, commissions and other related offering expenses of approximately $5.9 million . The mandatory convertible preferred stock pays dividends at an annual rate of 5.25% of the initial liquidation preference of $100 per share. Dividends accrue and cumulate from the date of issuance and, to the extent lawful and declared by the Company's Board of Directors, will be paid on each January 1, April 1, July 1 and October 1 in cash or, at the Company's election (subject to certain limitations), by delivery of any combination of cash and shares of common stock. Each share of the mandatory convertible preferred stock has a liquidation preference of $100 , plus an amount equal to accrued and unpaid dividends. Each share of the mandatory convertible preferred stock will automatically convert on July 1, 2017 (subject to postponement in certain cases), into between 1.8141 and 2.2222 shares of common stock (the “minimum conversion rate” and “maximum conversion rate,” respectively), each subject to adjustment. The number of shares of common stock issuable on conversion will be determined based on the average volume weighted average price per share of the Company's common stock over the 20 consecutive trading day period commencing on and including the 22nd scheduled trading day prior to July 1, 2017. At any time prior to July 1, 2017, holders may elect to convert all or a portion of their shares of mandatory convertible preferred stock into shares of common stock at the minimum conversion rate. If any holder elects to convert shares of mandatory convertible preferred stock during a specified period beginning on the effective date of a fundamental change the conversion rate will be adjusted under certain circumstances and such holder will also be entitled to a fundamental change dividend make-whole amount. During the year ended December 31, 2015 , the Company's Board of Directors declared four dividends each totaling $1.3125 per share in cash, or $2.3 million , for the Company's mandatory convertible preferred stock. All dividends declared during 2015 have been paid except those dividends declared on November 19, 2015, which were funded to the paying agent to be paid on January 1, 2016 to the shareholders of record as of December 15, 2015. On August 29, 2014, the Company's Board of Directors declared its first dividend of $1.2979 per share in cash, or $2.2 million and on November 25, 2014, the Company's Board of Directors declared a dividend for $1.3125 per share, or $2.3 million for the Company's mandatory convertible preferred stock. c. Stock Incentive Plans Transactions in which the Company receives employee and non-employee services in exchange for the Company’s equity instruments or liabilities that are based on the fair value of the Company’s equity securities or may be settled by the issuance of these securities are accounted using a fair value method. The Company applies the Black-Scholes method of valuation in determining share-based compensation expense for option awards. Benefits of tax deductions in excess of recognized compensation cost are reported as a financing cash flow, thus reducing the Company’s net operating cash flows and increasing its financing cash flows by $4.0 million , $3.2 million and $7.2 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. The Company examines its concentrations of holdings, its historical patterns of award exercises and forfeitures as well as forward-looking factors, in an effort to determine if there were any discernible employee populations. From this analysis, the Company has identified three employee populations, consisting of senior executives, officers and all other recipients. The expected volatility rate applied was estimated based on historical volatility. The expected term assumption applied is based on contractual terms, historical exercise and cancellation patterns and forward-looking factors where present for each population identified. The risk-free interest rate used is based on the U.S. Treasury yield curve in effect at the time of the grant. The pre-vesting forfeiture rate is based on historical rates and forward-looking factors for each population identified. The Company will adjust the estimated forfeiture rate to its actual experience. The Company intends to retain its earnings to finance growth and development of the business and does not expect to declare or pay any cash dividends in the foreseeable future except as required in accordance with the terms of the Company's mandatory convertible preferred stock. In May 2014, the Company adopted the AmSurg Corp. 2014 Equity and Incentive Plan. The Company also has unvested restricted stock and fully vested options outstanding under the AmSurg Corp. 2006 Stock Incentive Plan, as amended, and the AmSurg Corp. 1997 Stock Incentive Plan, as amended, under which no additional awards may be granted. Under these plans, the Company has granted restricted stock and non-qualified options to purchase shares of common stock to employees and outside directors from its authorized but unissued common stock. At December 31, 2015 , 1,200,000 shares were authorized for grant under the 2014 Equity and Incentive Plan and 900,039 shares were available for future equity grants. Restricted stock granted to outside directors vests on the first anniversary of the date of grant. Restricted stock granted to employees vests over four years in three equal installments beginning on the second anniversary of the date of grant. The fair value of restricted stock is determined based on the closing bid price of the Company’s common stock on the grant date. Under Company policy, shares held by outside directors and senior management are subject to certain holding requirements and restrictions. The Company has not issued options subsequent to 2008, and all outstanding options are fully vested. Options were granted at market value on the date of the grant and vested over four years. Outstanding options have a term of ten years from the date of grant. Other information pertaining to share-based activity for the years ended December 31, 2015 , 2014 and 2013 was as follows (in thousands): 2015 2014 2013 Share-based compensation expense $ 15,009 $ 10,104 $ 8,321 Fair value of shares vested 13,220 15,126 11,742 Cash received from option exercises 2,584 2,630 33,349 Tax benefit from option exercises 4,001 3,177 7,247 As of December 31, 2015 , the Company had total unrecognized compensation cost of approximately $16.6 million related to non-vested awards, which the Company expects to recognize through 2019 and over a weighted average period of 1.1 years. During the years ended December 31, 2015 , 2014 and 2013 , there were no options that were anti-dilutive. A summary of the status of and changes for non-vested restricted shares for the three years ended December 31, 2015 , is as follows: Weighted Number Average of Shares Grant Price Non-vested shares at January 1, 2013 828,686 $ 22.50 Shares granted 291,863 31.66 Shares vested (360,337 ) 21.55 Shares forfeited (16,343 ) 23.11 Non-vested shares at December 31, 2013 743,869 $ 26.54 Shares granted 272,780 43.12 Shares vested (336,160 ) 25.69 Shares forfeited (12,380 ) 38.94 Non-vested shares at December 31, 2014 668,109 $ 33.51 Shares granted 313,498 56.19 Shares vested (233,831 ) 28.19 Shares forfeited (13,675 ) 42.15 Non-vested shares at December 31, 2015 734,101 $ 44.73 In addition to the non-vested restricted shares, during the year ended December 31, 2015 , the Company granted 68,533 performance-based restricted stock units (RSUs) to certain of its officers and physician employees. The fair value of the Company's common stock on the grant date of these RSUs was $55.40 . The RSUs will vest ratably over a three year period from the grant date. The conversion of the RSUs to restricted stock is contingent on the Company’s achievement of a specified one -year financial performance goal for the year ended December 31, 2015 and, if achieved, would occur during the first quarter of 2016. If the financial performance goal is not achieved, the RSUs will be forfeited. The number of RSUs that will ultimately be received by the holders range from 0% to 150% of the units granted, depending on the Company’s level of achievement with respect to the financial performance goal. At December 31, 2015 , the financial performance goal was achieved at a level that will result in the conversion of the RSUs to restricted stock at 150% . A summary of stock option activity for the three years ended December 31, 2015 is summarized as follows: Weighted Weighted Average Average Remaining Number Exercise Contractual of Shares Price Term (in years) Outstanding at January 1, 2013 1,662,830 $ 23.82 2.9 Options exercised with total intrinsic value of $33.3 million (1,392,366 ) 23.95 Outstanding at December 31, 2013 270,464 $ 23.16 2.5 Options exercised with total intrinsic value of $2.6 million (111,743 ) 23.53 Outstanding at December 31, 2014 158,721 $ 22.89 1.7 Options exercised with total intrinsic value of $4.9 million (113,220 ) 22.81 Options terminated (11,750 ) 23.42 Outstanding, Vested and Exercisable at December 31, 2015 with an aggregate intrinsic value of $1.8 million 33,751 $ 22.98 1.1 The aggregate intrinsic value represents the total pre-tax intrinsic value received by the option holders on the exercise date or that would have been received by the option holders had all holders of in-the-money outstanding options at December 31, 2015 exercised their options at the Company’s closing stock price on December 31, 2015 . d. Earnings per Share Basic net earnings attributable to AmSurg Corp. common stockholders, per common share, excludes dilution and is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net earnings attributable to AmSurg common stockholders, per common share is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period plus any potential dilutive common share equivalents, including shares issuable (1) upon the vesting of restricted stock awards as determined under the treasury stock method and (2) upon conversion of the Company's mandatory convertible preferred stock as determined under the if-converted method. For purposes of calculating diluted earnings per share, preferred stock dividends have been subtracted from both net earnings from continuing operations attributable to AmSurg Corp. and net earnings attributable to AmSurg Corp. common shareholders in periods in which utilizing the if-converted method would be anti-dilutive. The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts): Earnings Shares Per Share (Numerator) (Denominator) Amount For the year ended December 31, 2015: Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic) $ 154,892 48,058 $ 3.22 Preferred stock dividends 9,056 — Effect of dilutive securities, options and non-vested shares — 3,554 Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted) $ 163,948 51,612 $ 3.18 For the year ended December 31, 2014: Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic) $ 50,777 39,311 $ 1.29 Effect of dilutive securities, options and non-vested shares — 314 Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted) $ 50,777 39,625 $ 1.28 For the year ended December 31, 2013: Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic) $ 71,009 31,338 $ 2.27 Effect of dilutive securities, options and non-vested shares — 616 Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted) $ 71,009 31,954 $ 2.22

Leases

Leases	12 Months Ended
	Dec. 31, 2015
Leases [Abstract]
Leases	Leases The Company has entered into various building and equipment capital and operating leases in operation and under development and for office space, expiring at various dates through 2037 . Future minimum lease payments, including payments during expected renewal option periods, at December 31, 2015 were as follows (in thousands): Year Ended December 31, Capital Leases Operating Leases 2016 $ 3,021 $ 55,636 2017 2,776 55,857 2018 2,502 53,515 2019 2,068 52,034 2020 1,866 50,378 Thereafter 12,991 331,746 Total minimum rentals 25,224 $ 599,166 Less amounts representing interest at rates ranging from 1.7% to 13.4% 6,611 Capital lease obligations $ 18,613 At December 31, 2015 , buildings and equipment with a cost of approximately $23.4 million and accumulated depreciation of approximately $5.6 million were held under capital leases. The Company and the partners in the partnerships have guaranteed payment of certain of these leases. Rental expense for operating leases for the years ended December 31, 2015 , 2014 and 2013 was approximately $74.6 million , $66.1 million and $52.6 million , respectively.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Certain surgery centers lease space from entities affiliated with their physician partners at negotiated rates that management believes were equal to fair market value at the inception of the leases based on relevant market data. Certain surgery centers reimburse their physician partners for salaries and benefits and billing fees related to time spent by employees of their practices on activities of the centers at current market rates. In addition, certain centers compensate at market rates their physician partners for physician advisory services provided to the surgery centers, including medical director and performance improvement services. Excluding transactions with investments in unconsolidated affiliates disclosed in Note 5, related party payments for the years ended December 31, 2015 , 2014 and 2013 were as follows (in thousands): 2015 2014 2013 Operating leases $ 27,622 $ 27,559 $ 29,240 Salaries and benefits 62,590 66,763 72,892 Billing fees 10,873 9,899 11,591 Medical advisory services 2,635 2,811 2,993 The Company also reimburses their physician partners for operating expenses paid by the physician partners to third party providers on the behalf of the surgery center. The Company believes that the foregoing transactions are reasonably expected to benefit the Company and that the amount of reimbursed expenses included in other operating expenses in the accompanying consolidated statements of earnings for each of the years ended December 31, 2015 , 2014 and 2013 were not significant. It is the Company’s policy that all transactions by the Company with officers, directors, five percent shareholders and their affiliates be entered into only if such transactions are on terms no less favorable to the Company than could be obtained from unaffiliated third parties, are reasonably expected to benefit the Company and are approved by the Nominating and Corporate Governance Committee of the Company’s Board of Directors.

Employee Benefit Programs

Employee Benefit Programs	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plans	Employee Benefit Programs The Company maintains multiple qualified contributory savings plans as allowed under Section 401(k) of the Internal Revenue Code. These plans are defined contribution plans covering substantially all employees of the Company and provide for voluntary contributions by employees, subject to certain limits. Company contributions are primarily based on specified percentages of employee compensation. In some instances, the plan may allow for elective or required Company contributions subject to the limits defined by each plan. The Company funds contributions as accrued. The Company’s contributions for the years ended December 31, 2015 , 2014 and 2013 were approximately $14.1 million , $1.6 million and $1.1 million , respectively, and vest immediately or incrementally over a period of four to five years , depending on the plan and the tenures of the respective employees for which the contributions were made. During 2014, the Company recorded expenses of approximately $5.6 million related to Sheridan which represented the period July 16, 2014 through December 31, 2014. The Company maintains the Supplemental Executive and Director Retirement Savings Plan. This plan is a defined contribution plan covering all officers of the Company and provides for voluntary contributions of up to 50% of employee annual compensation. Company contributions are at the discretion of the Compensation Committee of the Board of Directors and vest incrementally over five years. The employee and employer contributions are placed in a Rabbi Trust and recorded in the accompanying consolidated balance sheets in prepaid and other current assets. Employer contributions to this plan for the years ended December 31, 2015 , 2014 and 2013 were approximately $5.2 million , $0.8 million and $2.3 million , respectively. As of December 31, 2015 and 2014 , the cash surrender value of the supplemental executive and director retirement savings plan investments, which are included in prepaid and other current assets in the accompanying consolidated balance sheets, was $16.6 million and $17.3 million , respectively.

Commitments And Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies	Commitments and Contingencies Litigation From time to time the Company is named as a party to legal claims and proceedings in the ordinary course of business. The Company's management is not aware of any claims or proceedings that are expected to have a material adverse impact on the Company's consolidated financial condition, results of operations or cash flows. Insurance Programs Given the nature of the services provided, the Company and its subsidiaries are subject to professional and general liability claims and related lawsuits in the ordinary course of business. The Company maintains professional insurance with third-party insurers generally on a claims-made basis, subject to self-insured retentions, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. In addition, the captive provides stop loss coverage for the Company’s self-insured employee health program. The assets, liabilities and results of operations of the wholly-owned captive are consolidated in the accompanying consolidated financial statements. The liabilities for self-insurance in the accompanying consolidated balance sheets include estimates of the ultimate costs related to both reported claims on an individual and aggregate basis and unreported claims. The Company also obtains professional liability insurance on a claims-made basis from third party insurers for its surgery centers and certain of its owned practices and employed physicians. The Company’s reserves for professional liability claims within the self-insured retention are based upon periodic actuarial calculations. These actuarial estimates consider historical claims frequency and severity, loss development patterns and other actuarial assumptions and are not discounted to present value. The Company also maintains insurance for director and officer liability, workers’ compensation liability and property damage. Certain policies are subject to deductibles. In addition to the insurance coverage provided, the Company indemnifies its officers and directors for actions taken on behalf of the Company and its subsidiaries. Redeemable Noncontrolling Interests Certain of the Company’s wholly-owned subsidiaries are responsible for all debts incurred but unpaid by the Company's less than wholly-owned partnerships as these subsidiaries are the general partner. As manager of the operations of these partnerships, the Company has the ability to limit potential liabilities by curtailing operations or taking other operating actions. In the event of a change in current law that would prohibit the physicians’ current form of ownership in the partnerships, the Company would be obligated to purchase the physicians’ interests in a substantial majority of the Company’s partnerships. The purchase price to be paid in such event would be determined by a predefined formula, as specified in the partnership agreements. The Company believes the likelihood of a change in current law that would trigger such purchases was remote as of December 31, 2015 . As a result, the noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets. Physician Services Headquarters Operating Lease On January 16, 2015, the Company entered into an agreement to lease approximately 222,000 square feet of office space in Plantation, Florida which it intends to be the future headquarters of its physician services operations. The Company took possession of the space in the fourth quarter of 2015 and began tenant improvements on approximately 167,000 square feet of space, which it intends to occupy during the third quarter of 2016. In addition, the Company plans to begin tenant improvements on an additional 55,000 square feet of space during the third quarter of 2016, which it intends to occupy during the fourth quarter of 2016. Annual rent expense is expected to be approximately $2.9 million . The initial term of this lease agreement expires in February 2029.

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting Prior to the Sheridan acquisition, the Company operated its centers as individual components of one operating and reportable segment. Upon completion of the Sheridan acquisition, the Company operates in two major lines of business - the operation of ambulatory surgery centers and providing multi-specialty outsourced physician services, which have been identified as its operating and reportable segments. Through the ambulatory services segment, the Company acquires, develops and operates ambulatory surgery centers in partnership with physicians. Through the physician services segment, the Company provides outsourced physician services in multiple specialties to hospitals, ambulatory surgery centers and other healthcare facilities, primarily in the areas of anesthesiology, radiology, children’s services and emergency medicine. The Company’s financial information by operating segment is prepared on an internal management reporting basis and includes allocations of corporate overhead to each segment. This financial information is used by the chief operating decision maker to allocate resources and assess the performance of the operating segments. The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker which is its Chief Executive Officer. The following table presents financial information for each reportable segment (in thousands): Year ended December 31, 2015 2014 2013 Net Revenue: Ambulatory Services $ 1,230,050 $ 1,109,935 $ 1,057,196 Physician Services (1) 1,336,834 512,014 — Total $ 2,566,884 $ 1,621,949 $ 1,057,196 Adjusted Segment EBITDA: Ambulatory Services $ 226,229 $ 197,377 $ 187,972 Physician Services (1) 266,031 107,105 — Total $ 492,260 $ 304,482 $ 187,972 Adjusted Segment EBITDA: $ 492,260 $ 304,482 $ 187,972 Earnings from continuing operations attributable to noncontrolling interests 218,181 190,809 183,484 Interest expense, net (121,586 ) (83,285 ) (29,525 ) Depreciation and amortization (97,493 ) (60,344 ) (32,400 ) Share-based compensation (15,009 ) (10,104 ) (8,321 ) Net change in fair value of contingent consideration (8,804 ) — — Transaction costs (8,324 ) (33,890 ) (300 ) Debt extinguishment costs — (16,887 ) — Net gain on deconsolidations 36,694 3,411 2,237 Earnings from continuing operations before income taxes $ 495,919 $ 294,192 $ 303,147 Acquisition and Capital Expenditures: Ambulatory Services (2) $ 168,593 $ 81,156 $ 102,450 Physician Services 854,401 28,909 — Total $ 1,022,994 $ 110,065 $ 102,450 2015 2014 Assets: Ambulatory Services $ 2,609,479 $ 2,526,625 Physician Services 3,937,003 2,974,437 Total $ 6,546,482 $ 5,501,062 (1) On July 16, 2014, the Company completed the acquisition of Sheridan. Accordingly, historical amounts for periods prior to that date are not included. (2) Excludes the purchase price to acquire Sheridan in 2014.

Financial Information for the C

Financial Information for the Company and Its Subsidiaries	12 Months Ended
	Dec. 31, 2015
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Financial Information for the Company and Its Subsidiaries	Financial Information for the Company and Its Subsidiaries The 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes are senior unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized 100% owned domestic subsidiaries. The 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes are guaranteed on a full and unconditional and joint and several basis, with limited exceptions considered customary for such guarantees, including the release of the guarantee when a subsidiary's assets are sold. The following condensed consolidating financial statements present the Company (as parent issuer), the subsidiary guarantors, the subsidiary non-guarantors and consolidating adjustments. These condensed consolidating financial statements have been prepared and presented in accordance with Rule 3-10 of Regulation S-X “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” The operating and investing activities of the separate legal entities are fully interdependent and integrated. Accordingly, the results of the separate legal entities are not representative of what the operating results would be on a stand-alone basis. Condensed Consolidating Balance Sheet - December 31, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Assets Current assets: Cash and cash equivalents $ 20,437 $ 27,507 $ 58,716 $ — $ 106,660 Restricted cash and marketable securities — — 13,506 — 13,506 Accounts receivable, net — 223,434 113,896 — 337,330 Supplies inventory — — 21,406 — 21,406 Prepaid and other current assets 28,739 39,046 16,062 (8,076 ) 75,771 Total current assets 49,176 289,987 223,586 (8,076 ) 554,673 Property and equipment, net 12,515 14,601 162,052 — 189,168 Investments in and receivables from unconsolidated affiliates 4,901,026 1,775,272 — (6,507,128 ) 169,170 Goodwill — 1,956,741 — 2,013,469 3,970,210 Intangible assets, net 59,928 1,579,537 2,346 — 1,641,811 Other assets 4,653 1,717 17,078 (1,998 ) 21,450 Total assets $ 5,027,298 $ 5,617,855 $ 405,062 $ (4,503,733 ) $ 6,546,482 Liabilities and Equity Current liabilities: Current portion of long-term debt $ 8,700 $ — $ 11,677 $ — $ 20,377 Accounts payable 2,816 3,760 29,837 (3,852 ) 32,561 Accrued salaries and benefits 31,510 158,705 12,322 — 202,537 Accrued interest 30,463 — 17 — 30,480 Other accrued liabilities 13,962 76,590 32,909 (4,224 ) 119,237 Total current liabilities 87,451 239,055 86,762 (8,076 ) 405,192 Long-term debt 2,373,251 — 55,275 (23,396 ) 2,405,130 Deferred income taxes 268,573 432,923 — (1,998 ) 699,498 Other long-term liabilities 4,560 71,509 20,114 — 96,183 Intercompany payable — 1,228,157 — (1,228,157 ) — Noncontrolling interests – redeemable — — 63,060 112,672 175,732 Equity: Total AmSurg Corp. equity 2,293,463 3,646,211 132,267 (3,778,478 ) 2,293,463 Noncontrolling interests – non-redeemable — — 47,584 423,700 471,284 Total equity 2,293,463 3,646,211 179,851 (3,354,778 ) 2,764,747 Total liabilities and equity $ 5,027,298 $ 5,617,855 $ 405,062 $ (4,503,733 ) $ 6,546,482 Condensed Consolidating Balance Sheet - December 31, 2014 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Assets Current assets: Cash and cash equivalents $ 134,351 $ 23,471 $ 50,257 $ — $ 208,079 Restricted cash and marketable securities — — 10,219 — 10,219 Accounts receivable, net — 123,772 109,281 — 233,053 Supplies inventory — 301 19,673 — 19,974 Prepaid and other current assets 46,097 37,826 13,795 (4,818 ) 92,900 Total current assets 180,448 185,370 203,225 (4,818 ) 564,225 Property and equipment, net 10,391 9,972 160,085 — 180,448 Investments in and receivables from unconsolidated affiliates 3,912,804 1,587,881 — (5,425,210 ) 75,475 Goodwill — 1,490,981 — 1,890,168 3,381,149 Intangible assets, net 67,678 1,203,218 2,983 — 1,273,879 Other assets 3,323 943 23,086 (1,466 ) 25,886 Total assets $ 4,174,644 $ 4,478,365 $ 389,379 $ (3,541,326 ) $ 5,501,062 Liabilities and Equity Current liabilities: Current portion of long-term debt $ 8,700 $ — $ 10,126 $ — $ 18,826 Accounts payable 1,849 35 31,781 (4,080 ) 29,585 Accrued salaries and benefits 25,035 101,395 13,614 — 140,044 Accrued interest 29,621 — 23 — 29,644 Other accrued liabilities 8,051 44,305 16,368 (738 ) 67,986 Total current liabilities 73,256 145,735 71,912 (4,818 ) 286,085 Long-term debt 2,206,950 — 53,648 (28,412 ) 2,232,186 Deferred income taxes 207,500 404,984 — (1,466 ) 611,018 Other long-term liabilities 7,391 63,616 18,436 — 89,443 Intercompany payable — 1,219,979 8,010 (1,227,989 ) — Noncontrolling interests – redeemable — — 63,544 120,555 184,099 Equity: Total AmSurg Corp. equity 1,679,547 2,644,051 130,206 (2,774,257 ) 1,679,547 Noncontrolling interests – non-redeemable — — 43,623 375,061 418,684 Total equity 1,679,547 2,644,051 173,829 (2,399,196 ) 2,098,231 Total liabilities and equity $ 4,174,644 $ 4,478,365 $ 389,379 $ (3,541,326 ) $ 5,501,062 Condensed Consolidating Statement of Earnings - Year Ended December 31, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Net revenue $ 28,554 $ 1,331,042 $ 1,245,292 $ (38,004 ) $ 2,566,884 Operating expenses: Salaries and benefits 69,102 937,484 308,313 (507 ) 1,314,392 Supply cost — 2,436 181,866 (80 ) 184,222 Other operating expenses 24,682 145,369 265,160 (37,417 ) 397,794 Transaction costs 1,762 6,562 — — 8,324 Depreciation and amortization 3,912 61,658 31,923 — 97,493 Total operating expenses 99,458 1,153,509 787,262 (38,004 ) 2,002,225 Gain (loss) on deconsolidations — 37,350 (656 ) — 36,694 Equity in earnings of unconsolidated affiliates 349,139 251,093 — (584,080 ) 16,152 Operating income 278,235 465,976 457,374 (584,080 ) 617,505 Interest expense, net 41,140 77,947 2,499 — 121,586 Earnings from continuing operations before income taxes 237,095 388,029 454,875 (584,080 ) 495,919 Income tax expense 73,159 38,891 1,740 — 113,790 Net earnings from continuing operations 163,936 349,138 453,135 (584,080 ) 382,129 Net loss from discontinued operations (989 ) — (24 ) — (1,013 ) Net earnings 162,947 349,138 453,111 (584,080 ) 381,116 Net earnings attributable to noncontrolling interests — — 218,169 — 218,169 Net earnings attributable to AmSurg Corp. shareholders 162,947 349,138 234,942 (584,080 ) 162,947 Preferred stock dividends (9,056 ) — — — (9,056 ) Net earnings attributable to AmSurg Corp. common shareholders $ 153,891 $ 349,138 $ 234,942 $ (584,080 ) $ 153,891 Amounts attributable to AmSurg Corp. common shareholders: Earnings from continuing operations, net of income tax $ 154,880 $ 349,138 $ 234,954 $ (584,080 ) $ 154,892 Loss from discontinued operations, net of income tax (989 ) — (12 ) — (1,001 ) Net earnings attributable to AmSurg Corp. common shareholders $ 153,891 $ 349,138 $ 234,942 $ (584,080 ) $ 153,891 Condensed Consolidating Statement of Earnings - Year Ended December 31, 2014 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Net revenue $ 24,773 $ 508,572 $ 1,112,940 $ (24,336 ) $ 1,621,949 Operating expenses: Salaries and benefits 65,697 350,615 284,050 (5,786 ) 694,576 Supply cost — 1,292 163,004 — 164,296 Other operating expenses 18,667 53,413 231,398 (18,550 ) 284,928 Transaction costs 29,004 4,886 — — 33,890 Depreciation and amortization 4,044 25,610 30,690 — 60,344 Total operating expenses 117,412 435,816 709,142 (24,336 ) 1,238,034 Gain on deconsolidation — 3,411 — — 3,411 Equity in earnings of unconsolidated affiliates 237,657 211,889 — (442,508 ) 7,038 Operating income 145,018 288,056 403,798 (442,508 ) 394,364 Interest expense, net 47,997 33,026 2,262 — 83,285 Debt extinguishment costs 16,887 — — — 16,887 Earnings from continuing operations before income taxes 80,134 255,030 401,536 (442,508 ) 294,192 Income tax expense 29,166 17,373 1,564 — 48,103 Net earnings from continuing operations 50,968 237,657 399,972 (442,508 ) 246,089 Net earnings (loss) from discontinued operations 2,733 — (4,029 ) — (1,296 ) Net earnings 53,701 237,657 395,943 (442,508 ) 244,793 Net earnings attributable to noncontrolling interests — 21 191,071 — 191,092 Net earnings attributable to AmSurg Corp. shareholders 53,701 237,636 204,872 (442,508 ) 53,701 Preferred stock dividends (4,503 ) — — — (4,503 ) Net earnings attributable to AmSurg Corp. common shareholders $ 49,198 $ 237,636 $ 204,872 $ (442,508 ) $ 49,198 Amounts attributable to AmSurg Corp. common shareholders: Earnings from continuing operations, net of income tax $ 46,465 $ 237,636 $ 209,184 $ (442,508 ) $ 50,777 Earnings (loss) from discontinued operations, net of income tax 2,733 — (4,312 ) — (1,579 ) Net earnings attributable to AmSurg Corp. common shareholders $ 49,198 $ 237,636 $ 204,872 $ (442,508 ) $ 49,198 Condensed Consolidating Statement of Earnings - Year Ended December 31, 2013 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Net revenue $ 24,167 $ — $ 1,050,547 $ (17,518 ) $ 1,057,196 Operating expenses: Salaries and benefits 61,038 — 267,014 (467 ) 327,585 Supply cost — — 153,126 — 153,126 Other operating expenses 22,360 — 211,192 (17,051 ) 216,501 Transaction costs 300 — — — 300 Depreciation and amortization 3,186 — 29,214 — 32,400 Total operating expenses 86,884 — 660,546 (17,518 ) 729,912 Gain on deconsolidation — 2,237 — — 2,237 Equity in earnings of unconsolidated affiliates 207,199 204,962 — (409,010 ) 3,151 Operating income 144,482 207,199 390,001 (409,010 ) 332,672 Interest expense, net 27,282 — 2,243 — 29,525 Earnings from continuing operations before income taxes 117,200 207,199 387,758 (409,010 ) 303,147 Income tax expense 47,139 — 1,515 — 48,654 Net earnings from continuing operations 70,061 207,199 386,243 (409,010 ) 254,493 Net earnings from discontinued operations 2,642 — 4,409 — 7,051 Net earnings 72,703 207,199 390,652 (409,010 ) 261,544 Net earnings attributable to noncontrolling interests — — 188,841 — 188,841 Net earnings attributable to AmSurg Corp. common shareholders $ 72,703 $ 207,199 $ 201,811 $ (409,010 ) $ 72,703 Amounts attributable to AmSurg Corp. common shareholders: Earnings from continuing operations, net of income tax $ 70,061 $ 207,199 $ 202,759 $ (409,010 ) $ 71,009 Earnings (loss) from discontinued operations, net of income tax 2,642 — (948 ) — 1,694 Net earnings attributable to AmSurg Corp. common shareholders $ 72,703 $ 207,199 $ 201,811 $ (409,010 ) $ 72,703 Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Cash flows from operating activities: Net cash flows provided by operating activities $ 40,432 $ 353,932 $ 489,820 $ (346,225 ) $ 537,959 Cash flows from investing activities: Acquisitions and related transactions (757,775 ) (969,259 ) — 764,345 (962,689 ) Acquisition of property and equipment (5,876 ) (22,988 ) (31,441 ) — (60,305 ) Proceeds from sale of interests in surgery centers — 7,114 — — 7,114 Purchases of marketable securities — — (3,984 ) — (3,984 ) Maturities of marketable securities — — 4,233 — 4,233 Other — (2,927 ) 1,733 — (1,194 ) Net cash flows used in investing activities (763,651 ) (988,060 ) (29,459 ) 764,345 (1,016,825 ) Cash flows from financing activities: Proceeds from long-term borrowings 546,000 — 14,133 — 560,133 Repayment on long-term borrowings (379,700 ) — (12,886 ) — (392,586 ) Distributions to owners, including noncontrolling interests — (109,862 ) (451,262 ) 346,225 (214,899 ) Capital contributions — 757,775 — (757,775 ) — Proceeds from common stock offering 466,777 — — — 466,777 Payments of equity issuance costs (19,058 ) — — — (19,058 ) Financing cost incurred (1,101 ) — (10 ) — (1,111 ) Changes in intercompany balances with affiliates, net 5,016 — (5,016 ) — — Other financing activities, net (8,629 ) (9,749 ) 3,139 (6,570 ) (21,809 ) Net cash flows provided by (used in) financing activities 609,305 638,164 (451,902 ) (418,120 ) 377,447 Net increase (decrease) in cash and cash equivalents (113,914 ) 4,036 8,459 — (101,419 ) Cash and cash equivalents, beginning of period 134,351 23,471 50,257 — 208,079 Cash and cash equivalents, end of period $ 20,437 $ 27,507 $ 58,716 $ — $ 106,660 Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2014 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Cash flows from operating activities: Net cash flows provided by operating activities $ 96,681 $ 298,415 $ 430,880 $ (413,605 ) $ 412,371 Cash flows from investing activities: Acquisitions and related transactions (2,124,124 ) (2,188,191 ) 1,520 2,126,737 (2,184,058 ) Acquisition of property and equipment (7,877 ) (9,933 ) (22,407 ) — (40,217 ) Proceeds from sale of interests in surgery centers — 7,069 — — 7,069 Purchases of marketable securities — — (6,474 ) — (6,474 ) Maturities of marketable securities — — 3,486 — 3,486 Other (3,068 ) (6,594 ) 4,721 — (4,941 ) Net cash flows used in investing activities (2,135,069 ) (2,197,649 ) (19,154 ) 2,126,737 (2,225,135 ) Cash flows from financing activities: Proceeds from long-term borrowings 2,040,000 — 8,958 — 2,048,958 Repayment on long-term borrowings (396,493 ) — (11,982 ) — (408,475 ) Distributions to owners, including noncontrolling interests — (202,247 ) (401,455 ) 413,605 (190,097 ) Capital contributions — 2,124,124 — (2,124,124 ) — Proceeds from preferred stock offering 172,500 — — — 172,500 Proceeds from common stock offering 439,875 — — — 439,875 Payments of equity issuance costs (24,494 ) — — — (24,494 ) Financing cost incurred (65,811 ) — — — (65,811 ) Changes in intercompany balances with affiliates, net 2,965 — (2,965 ) — — Other financing activities, net (2,513 ) 828 1,845 (2,613 ) (2,453 ) Net cash flows provided by (used in) financing activities 2,166,029 1,922,705 (405,599 ) (1,713,132 ) 1,970,003 Net increase in cash and cash equivalents 127,641 23,471 6,127 — 157,239 Cash and cash equivalents, beginning of period 6,710 — 44,130 — 50,840 Cash and cash equivalents, end of period $ 134,351 $ 23,471 $ 50,257 $ — $ 208,079 Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2013 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Cash flows from operating activities: Net cash flows provided by operating activities $ 45,127 $ 208,773 $ 426,572 $ (347,648 ) $ 332,824 Cash flows from investing activities: Acquisitions and related transactions — (74,288 ) — 694 (73,594 ) Acquisition of property and equipment (3,693 ) — (25,163 ) — (28,856 ) Proceeds from sale of interests in surgery centers — 3,553 — — 3,553 Other — 159 — — 159 Net cash flows used in investing activities (3,693 ) (70,576 ) (25,163 ) 694 (98,738 ) Cash flows from financing activities: Proceeds from long-term borrowings 152,700 — 9,504 — 162,204 Repayment on long-term borrowings (188,081 ) — (14,002 ) — (202,083 ) Distributions to owners, including noncontrolling interests — (138,875 ) (392,922 ) 347,648 (184,149 ) Changes in intercompany balances with affiliates, net 88 — (88 ) — — Other financing activities, net (6,690 ) 678 1,090 (694 ) (5,616 ) Net cash flows used in financing activities (41,983 ) (138,197 ) (396,418 ) 346,954 (229,644 ) Net increase (decrease) in cash and cash equivalents (549 ) — 4,991 — 4,442 Cash and cash equivalents, beginning of period 7,259 — 39,139 — 46,398 Cash and cash equivalents, end of period $ 6,710 $ — $ 44,130 $ — $ 50,840

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company assessed events occurring subsequent to December 31, 2015 for potential recognition and disclosure in the consolidated financial statements. No events have occurred that would require adjustment to or disclosure in the consolidated financial statements.

Quarterly Statement of Earnings

Quarterly Statement of Earnings Data (Unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Statement of Earnings Data (Unaudited)	Quarterly Statement of Earnings Data (Unaudited) The following table presents certain quarterly statement of earnings data for the years ended December 31, 2015 and 2014 . The quarterly statement of earnings data set forth below was derived from the Company’s unaudited financial statements and includes all adjustments, consisting of normal recurring adjustments, which the Company considers necessary for a fair presentation thereof. Results of operations for any particular quarter are not necessarily indicative of results of operations for a full year or predictive of future periods. 2015 2014 Q1 Q2 Q3 Q4 Q1 Q2 Q3 (1) Q4 (In thousands, except per share data) Net revenues $ 570,445 $ 641,950 $ 650,227 $ 704,262 $ 259,561 $ 278,227 $ 502,350 $ 581,811 Earnings from continuing operations before income taxes 83,004 115,940 135,797 161,178 73,028 80,487 39,142 101,535 Net earnings from continuing operations 68,755 90,747 98,279 124,348 60,046 67,689 39,120 79,234 Net earnings (loss) from discontinued operations — — — (1,013 ) 68 483 (1,697 ) (150 ) Net earnings 68,755 90,747 98,279 123,335 60,114 68,172 37,423 79,084 Net earnings (loss) attributable to AmSurg Corp. common shareholders: Continuing 18,774 31,411 40,397 64,310 17,392 18,771 (10,697 ) 25,311 Discontinued — — — (1,001 ) (197 ) 190 (1,376 ) (196 ) Net earnings (loss) $ 18,774 $ 31,411 $ 40,397 $ 63,309 $ 17,195 $ 18,961 $ (12,073 ) $ 25,115 Basic net earnings (loss) from continuing operations per share $ 0.39 $ 0.66 $ 0.85 $ 1.31 $ 0.55 $ 0.59 $ (0.23 ) $ 0.53 Basic net earnings (loss) per share $ 0.39 $ 0.66 $ 0.85 $ 1.28 $ 0.54 $ 0.60 $ (0.26 ) $ 0.53 Diluted net earnings (loss) from continuing operations per share $ 0.39 $ 0.65 $ 0.83 $ 1.26 $ 0.54 $ 0.58 $ (0.23 ) $ 0.53 Diluted net earnings (loss) per share $ 0.39 $ 0.65 $ 0.83 $ 1.24 $ 0.54 $ 0.59 $ (0.26 ) $ 0.53 (1) The results of operations for Sheridan are effective July 16, 2014. Additionally, $16.9 million of debt extinguishment costs and $25.1 million of transaction costs were incurred during the quarter.

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2015
Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	AmSurg Corp. Schedule II – Valuation and Qualifying Accounts For the Years Ended December 31, 2015 , 2014 and 2013 (In thousands ) Balance at Charged to Charge-off Balance Beginning Cost and Against at End of of Period Expenses Allowances Period Allowance for uncollectible accounts included under the balance sheet caption “Accounts receivable”: Year ended December 31, 2015 $ 113,357 $ 287,427 $ (233,373 ) $ 167,411 Year ended December 31, 2014 27,862 139,274 (53,779 ) 113,357 Year ended December 31, 2013 22,379 21,983 (16,500 ) 27,862

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation Ambulatory Services AmSurg Corp. (the “Company”), through its wholly-owned subsidiaries, owns interests, primarily 51%, in limited liability companies (LLCs) and limited partnerships (LPs) which own and operate ASCs primarily in the following specialties: gastroenterology; multi-specialty; ophthalmology; and orthopaedics. All LLCs and LPs and noncontrolling partners are referred to herein as “partnerships” and “partners”, respectively. The Company does not have an ownership interest in a partnership greater than 51% which it does not consolidate. The Company has ownership interests of less than 51% in 23 partnerships, 2 of which it consolidates as the Company has substantive participation rights and 21 of which it does not consolidate as the Company’s rights are limited to protective rights only. Consolidation of certain less than wholly owned partnerships is necessary as the Company’s wholly-owned subsidiaries have primarily 51% or more of the financial interest of the partnership, are the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the partnership, and have control of the entities. The responsibilities of the Company’s noncontrolling partners (LPs and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests. Intercompany profits, transactions and balances have been eliminated. Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company’s equity. However, for instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the noncontrolling interests are identified and presented on the consolidated statements of earnings; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary are measured at fair value. Certain transactions with noncontrolling interests are also classified within financing activities in the statements of cash flows. As further described in note 19, upon the occurrence of various fundamental regulatory changes, the Company would be obligated, under the terms of certain partnership and operating agreements, to purchase the noncontrolling interests related to a substantial majority of the Company’s partnerships. While the Company believes that the likelihood of a change in current law that would trigger such purchases was remote as of December 31, 2015 , the occurrence of such regulatory changes is outside the control of the Company. As a result, these noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets. Center profits and losses of consolidated entities are allocated to the Company’s partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests. The partners of the Company’s center partnerships typically are organized as general partnerships, LLCs or LPs that are not subject to federal income tax. Each partner shares in the pre-tax earnings of the center in which it is a partner. Accordingly, the earnings attributable to noncontrolling interests in each of the Company’s consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings. However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its income tax expense. In addition, distributions from the partnerships are made to both the Company’s wholly-owned subsidiaries and the partners on a pre-tax basis. Physician Services On July 16, 2014, the Company completed its acquisition of Sheridan Healthcare (Sheridan). Sheridan is a national provider of multi-specialty physician and administrative services to hospitals, ambulatory surgery centers and other healthcare facilities. Sheridan focuses on delivering comprehensive physician services, primarily in the areas of anesthesiology, radiology, children's services and emergency medicine to healthcare facilities. Through its contracts with healthcare facilities, Sheridan is authorized to bill and collect charges for fee for service medical services rendered by its healthcare professionals and employees in exchange for the provision of services to the patients of these facilities. Contract revenue is earned directly from hospital customers through a variety of payment arrangements that are established to supplement payments from third-party payors. Sheridan also provides physician services and manages office-based practices in the areas of gynecology, obstetrics and perinatology. The consolidated financial statements include the accounts of Sheridan and its wholly-owned subsidiaries along with the accounts of affiliated professional corporations (PCs) with which Sheridan has certain management arrangements. Sheridan's agreements with these PCs provide that the term of the arrangements is permanent, subject only to termination by the Company, except in the case of gross negligence, fraud or bankruptcy of the Company. The PC structure is primarily used in states which prohibit the corporate practice of medicine. The arrangements are captive in nature as a majority of the outstanding voting equity instruments of the PCs are owned by nominee shareholders appointed at the sole discretion of the Company. The nominee shareholder is generally a medical doctor who is generally a senior corporate employee of the Company. The Company has a contractual right to transfer the ownership of the PCs at any time to any person it designates as the nominee shareholder. The Company has the right to all assets and to receive income, both as ongoing fees and as proceeds from the sale of any interest in the PCs, in an amount that fluctuates based on the performance of the PCs and the change in the fair value of the interest in the PCs. The Company has exclusive responsibility for the provision of all non-medical services required for the day-to-day operation and management of the PCs and establishes the guidelines for the employment and compensation of the physicians and other employees of the PCs which is consistent with the operation of the Company's wholly-owned affiliates. Based on the provisions of these agreements, the Company has determined that the PCs are variable interest entities and that the Company is the primary beneficiary as defined in ASC 810 “ Consolidations. ”
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents are comprised principally of demand deposits at banks and other highly liquid short-term investments with maturities of less than three months when purchased. Cash and cash equivalents are reflected in the financial statements at cost, which approximates fair value.
Restricted Cash	Restricted Cash and Marketable Securities As of December 31, 2015 and 2014 , the Company had $27.4 million and $30.3 million , respectively, of restricted cash and marketable securities in the accompanying consolidated balance sheets which is restricted for the purpose of satisfying the obligations of the Company's wholly-owned captive insurance company. The Company has reflected $13.9 million and $20.1 million as of December 31, 2015 and 2014 , respectively, of its restricted cash and marketable securities as a component of other assets in the accompanying consolidated balance sheets. Restricted cash and marketable securities reflected as a component of total current assets in the accompanying consolidated balance sheets represent amounts available to satisfy the claims payments estimated to occur in the next 12 months. As of December 31, 2015 and 2014 , the Company had $2.7 million and $3.0 million , respectively, included in restricted cash and marketable securities at cost, consisting of certificates of deposit with maturities less than 180 days, which approximates fair value.
Supplies Inventory	Supplies Inventory Supplies inventory consists of medical and drug supplies and is recorded at cost on a first-in, first-out basis.
Fair Value Measurements	Fair Value Measurements The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The inputs used by the Company to measure fair value are classified into the following hierarchy: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date. Level 3: Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. In determining the fair value of assets and liabilities that are measured on a recurring basis at December 31, 2015 and 2014 , with the exception of contingent purchase price payables and the retained interests of investments in unconsolidated affiliates (further discussed in note 4 and note 5, respectively), the Company utilized Level 1 and 2 inputs to perform such measurements methods, which were commensurate with the market approach. There were no transfers to or from Levels 1 and 2 during the year ended December 31, 2015 . The Company's non-patient receivables and accounts payable are reflected in the financial statements at cost, which approximates fair value.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Reclassifications	Reclassifications Certain amounts in the consolidated financial statements and these notes have been reclassified for the retrospective adoption of the Financial Accounting Standards Board's (FASB) Accounting Standards Update (ASU) 2015-17
Recent Accounting Pronouncements	Recent Accounting Pronouncements In April 2014, the FASB issued ASU 2014-08 “Presentation of Financial Statements and Property, Plant and Equipment,” which raised the threshold for a disposal to qualify as a discontinued operation and requires certain new disclosures for individually material disposals that do not meet the new definition of a discontinued operation. The ASU’s intent is to reduce the number of disposals reported as discontinued operations by focusing on strategic shifts that have or will have a major effect on the Company’s operations and financial results rather than routine disposals that are not a change in the Company’s strategy. The guidance is effective for interim and annual periods beginning after December 15, 2014, with earlier adoption permitted. From time to time, the Company will dispose of certain of its entities due to management’s assessment of the Company’s strategy in the market and due to limited growth opportunities at those entities. Historically, these dispositions were classified as discontinued operations and recorded separately from continuing operations. The Company adopted this ASU effective January 1, 2015. In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers,” which will eliminate the transaction and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach using the following steps: identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. In August 2015, the FASB issued ASU 2015-14 “ Revenue from Contracts with Customers (Topic 606), Deferral of the Effective Date” which granted a one-year deferral of this ASU. The guidance in ASU 2014-09 will now be effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. Early adoption will be permitted for annual reporting periods beginning after December 15, 2016, including interim periods therein. The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows. In February 2015, the FASB issued ASU No. 2015-02, “ Consolidations (Topic 810) - Amendments to the Consolidation Analysis”. The new guidance makes amendments to the current consolidation guidance, including introducing a separate consolidation analysis specific to limited partnerships and other similar entities. Under this analysis, limited partnerships and other similar entities will be considered a variable-interest entity unless the limited partners hold substantive kick-out rights or participating rights. The standard is effective for annual periods beginning after December 15, 2015, including interim periods therein. The Company does not believe this ASU will impact the Company's consolidated financial position, results of operations or cash flows. However, the Company continues to evaluate the disclosures required under this ASU and has not yet determined the impact, if any. In April 2015, the FASB issued ASU No. 2015-03, “ Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. ASU 2015-03 amends current presentation guidance by requiring that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU 2015-15 “Interest - Imputation of Interest (Subtopic 835-50), Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements - Amendments to Securities and Exchange Commission (SEC) Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (SEC Update)” which incorporates into the Accounting Standards Codification an SEC staff announcement that the SEC staff will not object to an entity presenting the cost of securing a revolving line of credit as an asset, regardless of whether a balance is outstanding. The standards are effective for annual periods beginning after December 15, 2015, and interim periods within those fiscal years. Upon adoption, the Company will reclassify debt issuance costs which are currently presented as a component of intangible assets in the accompanying consolidated balance sheets to long-term debt, except those debt issuance costs associated with the Company's revolving credit facility. The Company expects the adoption of this standard will not have a significant impact on the Company's consolidated financial position and will have no impact on the results of operations or cash flows. In September 2015, the FASB issued ASU 2015-16 “Business Combinations (Topic 805), Simplifying the Accounting for Measurement-Period Adjustments” which eliminates the requirement that an acquirer in a business combination account for measurement-period adjustments retrospectively. Instead, an acquirer will recognize a measurement-period adjustment during the period in which it determines the amount of the adjustment, including the effect on earnings of any amounts it would have recorded in previous periods if the accounting had been completed at the acquisition date. The guidance is effective for fiscal years, including interim periods within those fiscal years, beginning after December 31, 2015 with early adoption permitted. The Company adopted this standard as of September 2015. The adoption of this ASU did not have a material effect on the Company's consolidated financial position, results of operations or cash flows as of December 31, 2015. In November 2015, the FASB issued ASU 2015-17 “Balance Sheet Classification of Deferred Taxes” which requires companies to classify all deferred tax assets and liabilities as noncurrent on the balance sheet instead of separating deferred taxes into current and non-current. The guidance is effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. Early adoption is permitted and companies may adopt the guidance prospectively or retrospectively. The Company adopted this standard retrospectively as of December 31, 2015 and as a result, reclassified $22.5 million from prepaid and other current assets to noncurrent deferred income taxes at December 31, 2014 in the accompanying consolidated balance sheets.
Revenue Recognition	Ambulatory Services Ambulatory services revenues consist of billing for the use of the centers’ facilities directly to the patient or third-party payor and, at certain of the Company’s centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by the Company’s centers. Such revenues are recognized when the related surgical procedures are performed. Revenues exclude any amounts billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor. Revenues from ambulatory services are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid. During the years ended December 31, 2015 , 2014 and 2013 , the Company derived approximately 26% , 25% and 25% , respectively, of its ambulatory services revenues from governmental healthcare programs, primarily Medicare and managed Medicare programs. Physician Services Physician services revenues primarily consist of fee for service revenue and contract revenue and is derived principally from the provision of physician services to patients of the healthcare facilities the Company serves. Contract revenue represents income earned from the Company's hospital customers to supplement payments from third-party payors. The Company records revenue at the time services are provided, net of a contractual allowance and a provision for uncollectibles. Revenue less the contractual allowance represents the net revenue expected to be collected from third-party payors (including managed care, commercial and governmental payors such as Medicare and Medicaid) and patients insured by these payors. The Company also recognizes revenue for services provided during the period but are not yet billed. Expected collections are estimated based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient's healthcare plan, mandated payment rates under the Medicare and Medicaid programs, and historical cash collections. The Company's provision for uncollectibles includes its estimate of uncollectible balances due from uninsured patients, uncollectible co-pay and deductible balances due from insured patients and special charges, if any, for uncollectible balances due from managed care, commercial and governmental payors. The Company records net revenue from uninsured patients at its estimated realizable value, which includes a provision for uncollectible balances, based on historical cash collections (net of recoveries).
Accounts Receivable	Accounts Receivable The Company manages accounts receivable by regularly reviewing its accounts and contracts and by providing appropriate allowances for contractual adjustments and uncollectible amounts. Some of the factors considered by management in determining the amount of such allowances are the historical trends of cash collections, contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors, changes in payor mix and procedure statistics. Assessment of actual collections of accounts receivable in subsequent periods may require changes in the estimated contractual allowance and provision for uncollectibles. The Company routinely tests its analysis by comparing cash collections to net patient revenues and monitoring self-pay utilization. In addition, when actual collection percentages differ from expected results, for each facility or contract, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by the Company to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectability of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. The Company may also supplement its allowance for doubtful accounts policy for its physician services using a hindsight calculation that utilizes write-off data for all payor classes during the previous periods to estimate the allowance for doubtful accounts at a point in time. Material changes in estimates may result from unforeseen write-offs of patient or third party accounts receivable, unsuccessful disputes with managed care payors, adverse macro-economic conditions which limit patients’ ability to meet their financial obligations for the care provided by physicians, or broad changes to government regulations that adversely impact reimbursement rates for services provided by the Company. Significant changes in payor mix, specialty mix, acuity, business office operations, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on the Company’s estimates and significantly affect its results of operations and cash flows.
Acquisitions	Acquisitions The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.
Investments in Unconsolidated Affiliates	Investments in Unconsolidated Affiliates Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest. Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value. The fair value measurement utilizes Level 3 inputs, which include unobservable data, to measure the fair value of the retained noncontrolling interest. The fair value determination are generally based on a combination of multiple valuation methods which can include discounted cash flow, income approach, or market value approach which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. These investments are included as investments in unconsolidated affiliates in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments is reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statements of earnings. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Equipment held under capital leases is stated at the present value of minimum lease payments at the inception of the related leases. Depreciation for buildings and improvements is recognized under the straight-line method over 20 to 40 years or, for leasehold improvements, over the remaining term of the lease plus renewal options for which failure to renew the lease imposes a penalty on the Company in such an amount that a renewal appears, at the inception of the lease, to be reasonably assured. The primary penalty to which the Company is subject is the economic detriment associated with existing leasehold improvements which might be impaired if a decision is made not to continue the use of the leased property. Depreciation for movable equipment is recognized over useful lives of three to ten years .
Goodwill and Intangible Assets	Goodwill and Intangible Assets The Company’s intangible assets include goodwill and other intangibles, which include the fair value of both the customer relationships with hospitals and trade names acquired in the Company's physician services segment. The Company's indefinite lived intangibles include goodwill and trade names. Goodwill represents the excess of purchase price over the fair value of net assets acquired. The Company evaluates indefinite lived intangible assets, including goodwill, for impairment at least on an annual basis and more frequently if certain indicators are encountered. Indefinite lived intangibles are to be tested at the reporting unit level, defined as an operating segment or one level below an operating segment (referred to as a component), with the fair value of the reporting unit being compared to its carrying amount. If the fair value of a reporting unit exceeds its carrying amount, the indefinite lived intangibles associated with the reporting unit is not considered to be impaired. The Company completed its annual impairment test as of October 1, 2015 , and determined that its indefinite lived intangibles were not impaired. The Company's finite-lived intangibles includes its customer relationship with hospitals. The Company tests its finite-lived intangibles for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable. The Company's policy is to recognize an impairment charge when the carrying amount is not recoverable and such amount exceeds fair value. During the year ended December 31, 2015 , there were no events or circumstances that indicated a potential impairment in the Company's finite-lived intangibles.
Amortization of Intangible Assets	Intangible assets consist primarily of customer relationships with hospitals, deferred financing costs, capitalized software and certain amortizable and non-amortizable non-compete and customer agreements. Customer relationships with hospitals are initially recorded at their estimated fair value and amortized on a straight-line basis over 20 years . Deferred financing costs and amortizable non-compete agreements and customer agreements are amortized over the term of the related debt as interest expense and the contractual term or estimated life ( five to ten years ) of the agreements as amortization expense. Capitalized software is amortized over estimated useful lives of three to eight years.
Insurance Programs	The Company maintains professional liability insurance policies with third-party insurers generally on a claims-made basis, subject to self-insured retention, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. The Company records an estimate of liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss patterns, which are not discounted. Insurance Programs Given the nature of the services provided, the Company and its subsidiaries are subject to professional and general liability claims and related lawsuits in the ordinary course of business. The Company maintains professional insurance with third-party insurers generally on a claims-made basis, subject to self-insured retentions, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. In addition, the captive provides stop loss coverage for the Company’s self-insured employee health program. The assets, liabilities and results of operations of the wholly-owned captive are consolidated in the accompanying consolidated financial statements. The liabilities for self-insurance in the accompanying consolidated balance sheets include estimates of the ultimate costs related to both reported claims on an individual and aggregate basis and unreported claims. The Company also obtains professional liability insurance on a claims-made basis from third party insurers for its surgery centers and certain of its owned practices and employed physicians.
Income Taxes	Income Taxes The Company files a consolidated federal income tax return. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes. In addition, it is the Company’s policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its statement of earnings. The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months. The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal or state income tax examinations for years prior to 2012 .
Stock Incentive Plans	Stock Incentive Plans Transactions in which the Company receives employee and non-employee services in exchange for the Company’s equity instruments or liabilities that are based on the fair value of the Company’s equity securities or may be settled by the issuance of these securities are accounted using a fair value method. The Company applies the Black-Scholes method of valuation in determining share-based compensation expense for option awards. Benefits of tax deductions in excess of recognized compensation cost are reported as a financing cash flow, thus reducing the Company’s net operating cash flows and increasing its financing cash flows by $4.0 million , $3.2 million and $7.2 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. The Company examines its concentrations of holdings, its historical patterns of award exercises and forfeitures as well as forward-looking factors, in an effort to determine if there were any discernible employee populations. From this analysis, the Company has identified three employee populations, consisting of senior executives, officers and all other recipients. The expected volatility rate applied was estimated based on historical volatility. The expected term assumption applied is based on contractual terms, historical exercise and cancellation patterns and forward-looking factors where present for each population identified. The risk-free interest rate used is based on the U.S. Treasury yield curve in effect at the time of the grant. The pre-vesting forfeiture rate is based on historical rates and forward-looking factors for each population identified. The Company will adjust the estimated forfeiture rate to its actual experience. The Company intends to retain its earnings to finance growth and development of the business and does not expect to declare or pay any cash dividends in the foreseeable future except as required in accordance with the terms of the Company's mandatory convertible preferred stock.
Earnings per Share	Earnings per Share Basic net earnings attributable to AmSurg Corp. common stockholders, per common share, excludes dilution and is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net earnings attributable to AmSurg common stockholders, per common share is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period plus any potential dilutive common share equivalents, including shares issuable (1) upon the vesting of restricted stock awards as determined under the treasury stock method and (2) upon conversion of the Company's mandatory convertible preferred stock as determined under the if-converted method. For purposes of calculating diluted earnings per share, preferred stock dividends have been subtracted from both net earnings from continuing operations attributable to AmSurg Corp. and net earnings attributable to AmSurg Corp. common shareholders in periods in which utilizing the if-converted method would be anti-dilutive.
Related Party Transactions	It is the Company’s policy that all transactions by the Company with officers, directors, five percent shareholders and their affiliates be entered into only if such transactions are on terms no less favorable to the Company than could be obtained from unaffiliated third parties, are reasonably expected to benefit the Company and are approved by the Nominating and Corporate Governance Committee of the Company’s Board of Directors.
Segment Reporting	Segment Reporting Prior to the Sheridan acquisition, the Company operated its centers as individual components of one operating and reportable segment. Upon completion of the Sheridan acquisition, the Company operates in two major lines of business - the operation of ambulatory surgery centers and providing multi-specialty outsourced physician services, which have been identified as its operating and reportable segments. Through the ambulatory services segment, the Company acquires, develops and operates ambulatory surgery centers in partnership with physicians. Through the physician services segment, the Company provides outsourced physician services in multiple specialties to hospitals, ambulatory surgery centers and other healthcare facilities, primarily in the areas of anesthesiology, radiology, children’s services and emergency medicine. The Company’s financial information by operating segment is prepared on an internal management reporting basis and includes allocations of corporate overhead to each segment. This financial information is used by the chief operating decision maker to allocate resources and assess the performance of the operating segments. The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker which is its Chief Executive Officer.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2015
Revenue Recognition [Abstract]
Schedule of Revenue and Fees by Segment and Major Payors	Net revenue for the physician services segment consists of the following major payors (in thousands): Year Ended December 31, 2015 Period from July 16, 2014 - December 31, 2014 (1) Medicare $ 172,783 12.9 % $ 61,378 12.0 % Medicaid 69,607 5.2 28,224 5.5 Commercial and managed care 1,007,902 75.4 382,343 74.7 Self-pay 222,830 16.7 102,727 20.1 Net fee for service revenue 1,473,122 110.2 574,672 112.3 Contract and other revenue 129,786 9.7 54,343 10.6 Provision for uncollectibles (266,074 ) (19.9 ) (117,001 ) (22.9 ) Net revenue for physician services $ 1,336,834 100.0 % $ 512,014 100.0 % (1) On July 16, 2014, the Company completed the acquisition of Sheridan. Accordingly, historical amounts for periods prior to that date are not included.

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition	The acquisitions completed during the year ended December 31, 2015 consist of the following: Acquired Operations Location Date Acquired Specialty River Drive Surgery & Laser Center, LLC Elmwood Park, NJ February 2015 Ophthalmology Campus Surgery Center, LLC Daly City, CA June 2015 Multi-Specialty Waverly Surgery Center, LLC Palo Alto, CA June 2015 Multi-Specialty Surgical Center at Millburn, LLC Millburn-East Willow, NJ July 2015 Multi-Specialty Eye Surgery Center of Western Ohio, LLC Lima, OH August 2015 Ophthalmology Surgical Specialty Center of Northeastern PA, LLC Forty Fort, PA October 2015 Multi-Specialty South Portland Surgical Center, LLC Tualatin, OR November 2015 Multi-Specialty The acquisition date fair value of the total consideration transferred and acquisition date fair value of each major class of consideration for the acquisitions completed during 2015 and 2014 , including post acquisition date adjustments recorded to purchase price allocations, are as follows (in thousands): 2015 2014 Individual Individual Acquisitions (1) Acquisitions Sheridan Accounts receivable $ 62,216 $ 1,816 $ 130,260 Other current assets 21,477 1,075 105,757 Property and equipment 15,484 3,294 20,185 Goodwill 682,458 101,865 1,534,656 Intangible assets 420,414 14,207 1,200,028 Other long-term assets 342 — 50,304 Accounts payable (3,641 ) (2,519 ) (5,862 ) Other accrued liabilities (45,386 ) (626 ) (118,548 ) Deferred income taxes (88,728 ) — (432,792 ) Other long-term liabilities (4,958 ) (8,588 ) (69,456 ) Long-term debt (6,046 ) (717 ) (4,594 ) Total fair value 1,053,632 109,807 2,409,938 Less: Fair value attributable to noncontrolling interests 85,443 39,371 24,365 Acquisition date fair value of total consideration transferred $ 968,189 $ 70,436 $ 2,385,573 (1) Represents the preliminary allocation of fair value of acquired assets and liabilities associated with these acquisitions at December 31, 2015 . The acquisitions completed during the year ended December 31, 2015 consist of the following: Acquired Operations Location Date Acquired Specialty Ambulatory Anesthesia Care, PC Mountainside, NJ January 2015 Anesthesia Sheridan Radiology Management Services, Inc. Beachwood, OH January 2015 Radiology Radiology Associates of Hollywood, P.A. Pembroke Pines, FL March 2015 Radiology Halifax Anesthesiology Associates, P.A. Daytona Beach, FL April 2015 Anesthesia Coastal Anesthesiology Consultants, P.A. St. Augustine, FL July 2015 Anesthesia Bay Area Anesthesia, LLC Tampa, FL August 2015 Anesthesia Valley Anesthesia Consultants, Ltd. Phoenix, AZ November 2015 Anesthesia Chandler Emergency Medical Group, LLC Phoenix, AZ December 2015 Emergency Northside Anesthesiology Consultants, LLC Atlanta, GA December 2015 Anesthesia
Revenues And Net Earnings Associated With Acquisitions	Revenues and net earnings included in the years ended December 31, 2015 and 2014 associated with completed acquisitions are as follows (in thousands): 2015 2014 Individual Individual Acquisitions Acquisitions Sheridan Net revenue $ 179,113 $ 20,844 517,213 Net earnings 26,901 5,155 26,776 Less: Net earnings attributable to noncontrolling interests 7,448 2,859 459 Net earnings attributable to AmSurg Corp. common shareholders $ 19,453 $ 2,296 $ 26,317
Consolidated Pro Forma Results Of Acquisition	The unaudited consolidated pro forma results for the years ended December 31, 2015 and 2014 , assuming all 2015 acquisitions had been consummated on January 1, 2014 , all 2014 acquisitions had been consummated on January 1, 2013 are as follows (in thousands): 2015 2014 Net revenue $ 2,858,544 $ 2,680,273 Net earnings 401,950 322,653 Amounts attributable to AmSurg Corp. common shareholders: Net earnings 170,453 104,548 Net earnings per common share: Basic $ 3.55 $ 2.21 Diluted $ 3.48 $ 2.20

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Results Of Operations Of Centers Discontinued	Results of operations and associated gain (loss) on discontinued centers for the years ended December 31, 2015 , 2014 and 2013 are as follows (in thousands): 2015 2014 2013 Revenues $ — $ 9,545 $ 25,373 Earnings before income taxes — 893 5,607 Results of discontinued operations, net of tax: Earnings (loss) from operations of discontinued interests in surgery centers (1,013 ) 710 4,449 Gain (loss) on disposal of discontinued interests in surgery centers — (2,006 ) 2,602 Net earnings (loss) from discontinued operations (1,013 ) (1,296 ) 7,051 Less: Net earnings (loss) from discontinued operations attributable to noncontrolling interests (12 ) 283 5,357 Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders $ (1,001 ) $ (1,579 ) $ 1,694

Prepaid and Other Current Ass35

Prepaid and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid and Other Current Assets	The following table presents a summary of items comprising prepaid and other current assets in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 (in thousands): 2015 2014 Income taxes receivable $ 7,908 $ 28,694 Prepaid expenses 18,900 18,682 Deferred compensation plan assets 16,623 17,320 Other 32,340 28,204 Total prepaid and other current assets $ 75,771 $ 92,900

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment at December 31, 2015 and 2014 were as follows (in thousands): 2015 2014 Building and improvements $ 177,253 $ 170,420 Movable equipment 237,312 215,444 Construction in progress 8,676 11,940 423,241 397,804 Less accumulated depreciation (234,073 ) (217,356 ) Property and equipment, net $ 189,168 $ 180,448

Goodwill And Intangible Assets

Goodwill And Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Changes In Carrying Amount Of Goodwill	The changes in the carrying amount of goodwill for the years ended December 31, 2015 and 2014 are as follows (in thousands): 2015 2014 Balance, beginning of year $ 3,381,149 $ 1,758,970 Goodwill acquired, including post acquisition adjustments 674,476 1,636,521 Goodwill disposed, including impact of deconsolidation transactions (85,415 ) (14,342 ) Balance, end of year $ 3,970,210 $ 3,381,149
Schedule of Finite-Lived Intangible Assets	Intangible assets at December 31, 2015 and 2014 consisted of the following (in thousands): 2015 2014 Gross Gross Carrying Accumulated Carrying Accumulated Amount Amortization Net Amount Amortization Net Amortizable intangible assets: Customer relationships with hospitals $ 1,379,977 $ (74,490 ) $ 1,305,487 $ 971,645 $ (22,145 ) $ 949,500 Deferred financing costs 60,664 (13,490 ) 47,174 59,574 (5,151 ) 54,423 Capitalized software 71,462 (28,125 ) 43,337 50,387 (19,197 ) 31,190 Agreements, contracts and other 11,267 (2,449 ) 8,818 3,523 (2,752 ) 771 Total amortizable intangible assets 1,523,370 (118,554 ) 1,404,816 1,085,129 (49,245 ) 1,035,884 Non-amortizable intangible assets: Trade name 228,000 — 228,000 228,000 — 228,000 Restrictive covenant arrangements 8,995 — 8,995 9,995 — 9,995 Total non-amortizable intangible assets 236,995 — 236,995 237,995 — 237,995 Total intangible assets $ 1,760,365 $ (118,554 ) $ 1,641,811 $ 1,323,124 $ (49,245 ) $ 1,273,879
Schedule of Indefinite-Lived Intangible Assets	Intangible assets at December 31, 2015 and 2014 consisted of the following (in thousands): 2015 2014 Gross Gross Carrying Accumulated Carrying Accumulated Amount Amortization Net Amount Amortization Net Amortizable intangible assets: Customer relationships with hospitals $ 1,379,977 $ (74,490 ) $ 1,305,487 $ 971,645 $ (22,145 ) $ 949,500 Deferred financing costs 60,664 (13,490 ) 47,174 59,574 (5,151 ) 54,423 Capitalized software 71,462 (28,125 ) 43,337 50,387 (19,197 ) 31,190 Agreements, contracts and other 11,267 (2,449 ) 8,818 3,523 (2,752 ) 771 Total amortizable intangible assets 1,523,370 (118,554 ) 1,404,816 1,085,129 (49,245 ) 1,035,884 Non-amortizable intangible assets: Trade name 228,000 — 228,000 228,000 — 228,000 Restrictive covenant arrangements 8,995 — 8,995 9,995 — 9,995 Total non-amortizable intangible assets 236,995 — 236,995 237,995 — 237,995 Total intangible assets $ 1,760,365 $ (118,554 ) $ 1,641,811 $ 1,323,124 $ (49,245 ) $ 1,273,879

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Accrued Liabilities, Current [Abstract]
Schedule of Other Accrued Liabilities	The following table presents a summary of items comprising other accrued liabilities in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 (in thousands): 2015 2014 Accrued professional liabilities $ 14,362 $ 11,983 Contingent purchase price payable 5,509 12,213 Current income taxes payable 7,892 — Refunds payable 48,415 17,752 Other 43,059 26,038 Total other accrued liabilities $ 119,237 $ 67,986

Accrued Professional Liabilit39

Accrued Professional Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Professional Liabilities	At December 31, 2015 , the Company's accrued professional liabilities are presented in the accompanying consolidated balance sheets as a component of other accrued liabilities and other long-term liabilities as follows (in thousands): 2015 2014 Estimated losses under self-insured programs $ 30,748 $ 25,337 Incurred but not reported losses 36,166 28,448 Total accrued professional liabilities 66,914 53,785 Less estimated losses payable within one year 14,362 11,983 Total $ 52,552 $ 41,802
Schedule of Self Insurance Reserve Roll Forward	The changes to the Company's estimated losses under self-insured programs as of December 31, 2015 and 2014 were as follows (in thousands): 2015 2014 Balance, beginning of year $ 53,785 $ 1,171 Assumed liabilities through acquisitions 13,317 53,512 Provision related to current period reserves 15,943 5,423 Payments for current period reserves (4,475 ) (1,595 ) Benefit related to changes in prior period reserves (425 ) (661 ) Payments for prior period reserves (8,863 ) (6,055 ) Other, net (2,368 ) 1,990 Balance, end of year $ 66,914 $ 53,785

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Components Of Long-Term Debt	Long-term debt at December 31, 2015 and 2014 consisted of the following (in thousands): 2015 2014 Revolving credit agreement $ 175,000 $ — Term Loan 856,950 865,650 Senior Unsecured Notes due 2020 (5.625%) 250,000 250,000 Senior Unsecured Notes due 2022 (5.625%) 1,100,000 1,100,000 Other debt at an average interest rate of 3.4%, due through 2022 24,944 20,156 Capitalized lease arrangements at an average interest rate of 5.4%, due through 2021 18,613 15,206 2,425,507 2,251,012 Less current portion 20,377 18,826 Long-term debt $ 2,405,130 $ 2,232,186
Redemption Price Percentage	The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on November 30 of the years indicated below: Period Redemption Price 2015 104.219 % 2016 102.813 % 2017 101.406 % 2018 and thereafter 100.000 % The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on July 15 of the years indicated below: Period Redemption Price 2017 104.219 % 2018 102.813 % 2019 101.406 % 2020 and thereafter 100.000 %

Other Long-term Liabilities (Ta

Other Long-term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Other Liabilities Disclosure [Abstract]
Other Long-term Liabilities	The following table presents a summary of items comprising other long-term liabilities in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 (in thousands): 2015 2014 Accrued professional liabilities $ 52,552 $ 41,802 Contingent purchase price payable — 8,470 Deferred rent 18,958 16,814 Tax-effected unrecognized benefits 3,426 8,353 Other 21,247 14,004 Other long-term liabilities $ 96,183 $ 89,443

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule Of Total Income Tax Expense	Total income taxes expense (benefit) for the years ended December 31, 2015 , 2014 and 2013 was included within the following sections of the consolidated financial statements as follows (in thousands): 2015 2014 2013 Earnings from continuing operations $ 113,790 $ 48,103 $ 48,654 Discontinued operations (694 ) (643 ) 9 Shareholders’ equity (2,227 ) (3,177 ) (7,381 ) Total $ 110,869 $ 44,283 $ 41,282
Schedule of Components of Income Tax Expense (Benefit)	Income tax expense from continuing operations for the years ended December 31, 2015 , 2014 and 2013 was comprised of the following (in thousands): 2015 2014 2013 Current: Federal $ 83,228 $ 8,640 $ 7,895 State 14,268 4,396 3,598 Deferred: Federal 11,715 27,505 31,509 State 4,579 7,562 5,652 Income tax expense $ 113,790 $ 48,103 $ 48,654
Schedule of Effective Income Tax Rate Reconciliation	Income tax expense from continuing operations for the years ended December 31, 2015 , 2014 and 2013 differed from the amount computed by applying the U.S. federal income tax rate of 35% to earnings before income taxes as a result of the following (in thousands): 2015 2014 2013 Statutory federal income tax $ 173,572 $ 102,967 $ 106,101 Less federal income tax assumed directly by noncontrolling interests (76,364 ) (66,783 ) (64,219 ) State income taxes, net of federal income tax benefit 11,604 6,616 5,539 Increase in valuation allowances 317 4,662 924 Interest related to unrecognized tax benefits (548 ) (161 ) (155 ) Other 5,209 802 464 Income tax expense $ 113,790 $ 48,103 $ 48,654
Summary of Income Tax Contingencies	A reconciliation of the beginning and ending amount of the liability associated with unrecognized tax benefits for the years ended December 31, 2015 , 2014 and 2013 is as follows (in thousands): 2015 2014 2013 Balance at beginning of year $ 7,336 $ 6,330 $ 9,235 Additions for tax positions of current year — 204 46 Increases (decreases) for tax positions taken during a prior period (1,006 ) 1,069 — Lapse of statute of limitations (3,178 ) (267 ) (2,951 ) Balance at end of year $ 3,152 $ 7,336 $ 6,330
Schedule of Deferred Tax Assets and Liabilities	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2015 and 2014 were as follows (in thousands): 2015 2014 Deferred tax assets: Allowance for uncollectible accounts $ 3,276 $ 1,096 Accrued assets and other 36,600 27,537 Share-based compensation 10,710 7,719 Interest on unrecognized tax benefits 113 245 Accrued liabilities and other 4,080 3,931 Medical malpractice 19,035 16,240 Operating and capital loss carryforwards 29,718 22,709 Valuation allowances (21,814 ) (17,457 ) Total deferred tax assets 81,718 62,020 Deferred tax liabilities: Prepaid expenses 1,789 2,435 Property and equipment, principally due to differences in depreciation 16,787 15,235 Goodwill, intangible assets and other, principally due to differences in amortization 762,640 655,358 Total deferred tax liabilities 781,216 673,028 Net deferred tax liabilities $ 699,498 $ 611,008

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Share-Based Activity	Other information pertaining to share-based activity for the years ended December 31, 2015 , 2014 and 2013 was as follows (in thousands): 2015 2014 2013 Share-based compensation expense $ 15,009 $ 10,104 $ 8,321 Fair value of shares vested 13,220 15,126 11,742 Cash received from option exercises 2,584 2,630 33,349 Tax benefit from option exercises 4,001 3,177 7,247
Schedule Of Changes In Non-Vested Restricted Shares	A summary of the status of and changes for non-vested restricted shares for the three years ended December 31, 2015 , is as follows: Weighted Number Average of Shares Grant Price Non-vested shares at January 1, 2013 828,686 $ 22.50 Shares granted 291,863 31.66 Shares vested (360,337 ) 21.55 Shares forfeited (16,343 ) 23.11 Non-vested shares at December 31, 2013 743,869 $ 26.54 Shares granted 272,780 43.12 Shares vested (336,160 ) 25.69 Shares forfeited (12,380 ) 38.94 Non-vested shares at December 31, 2014 668,109 $ 33.51 Shares granted 313,498 56.19 Shares vested (233,831 ) 28.19 Shares forfeited (13,675 ) 42.15 Non-vested shares at December 31, 2015 734,101 $ 44.73
Schedule Of Stock Option Activity	A summary of stock option activity for the three years ended December 31, 2015 is summarized as follows: Weighted Weighted Average Average Remaining Number Exercise Contractual of Shares Price Term (in years) Outstanding at January 1, 2013 1,662,830 $ 23.82 2.9 Options exercised with total intrinsic value of $33.3 million (1,392,366 ) 23.95 Outstanding at December 31, 2013 270,464 $ 23.16 2.5 Options exercised with total intrinsic value of $2.6 million (111,743 ) 23.53 Outstanding at December 31, 2014 158,721 $ 22.89 1.7 Options exercised with total intrinsic value of $4.9 million (113,220 ) 22.81 Options terminated (11,750 ) 23.42 Outstanding, Vested and Exercisable at December 31, 2015 with an aggregate intrinsic value of $1.8 million 33,751 $ 22.98 1.1
Schedule Of Reconciliation Of Numerator And Denominators Of Basic And Diluted Earnings Per Share	The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts): Earnings Shares Per Share (Numerator) (Denominator) Amount For the year ended December 31, 2015: Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic) $ 154,892 48,058 $ 3.22 Preferred stock dividends 9,056 — Effect of dilutive securities, options and non-vested shares — 3,554 Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted) $ 163,948 51,612 $ 3.18 For the year ended December 31, 2014: Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic) $ 50,777 39,311 $ 1.29 Effect of dilutive securities, options and non-vested shares — 314 Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted) $ 50,777 39,625 $ 1.28 For the year ended December 31, 2013: Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic) $ 71,009 31,338 $ 2.27 Effect of dilutive securities, options and non-vested shares — 616 Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted) $ 71,009 31,954 $ 2.22

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2015
Leases [Abstract]
Future Minimum Lease Payment Schedule	Future minimum lease payments, including payments during expected renewal option periods, at December 31, 2015 were as follows (in thousands): Year Ended December 31, Capital Leases Operating Leases 2016 $ 3,021 $ 55,636 2017 2,776 55,857 2018 2,502 53,515 2019 2,068 52,034 2020 1,866 50,378 Thereafter 12,991 331,746 Total minimum rentals 25,224 $ 599,166 Less amounts representing interest at rates ranging from 1.7% to 13.4% 6,611 Capital lease obligations $ 18,613

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Schedule of Related Party Payments	elated party payments for the years ended December 31, 2015 , 2014 and 2013 were as follows (in thousands): 2015 2014 2013 Operating leases $ 27,622 $ 27,559 $ 29,240 Salaries and benefits 62,590 66,763 72,892 Billing fees 10,873 9,899 11,591 Medical advisory services 2,635 2,811 2,993

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following table presents financial information for each reportable segment (in thousands): Year ended December 31, 2015 2014 2013 Net Revenue: Ambulatory Services $ 1,230,050 $ 1,109,935 $ 1,057,196 Physician Services (1) 1,336,834 512,014 — Total $ 2,566,884 $ 1,621,949 $ 1,057,196 Adjusted Segment EBITDA: Ambulatory Services $ 226,229 $ 197,377 $ 187,972 Physician Services (1) 266,031 107,105 — Total $ 492,260 $ 304,482 $ 187,972 Adjusted Segment EBITDA: $ 492,260 $ 304,482 $ 187,972 Earnings from continuing operations attributable to noncontrolling interests 218,181 190,809 183,484 Interest expense, net (121,586 ) (83,285 ) (29,525 ) Depreciation and amortization (97,493 ) (60,344 ) (32,400 ) Share-based compensation (15,009 ) (10,104 ) (8,321 ) Net change in fair value of contingent consideration (8,804 ) — — Transaction costs (8,324 ) (33,890 ) (300 ) Debt extinguishment costs — (16,887 ) — Net gain on deconsolidations 36,694 3,411 2,237 Earnings from continuing operations before income taxes $ 495,919 $ 294,192 $ 303,147 Acquisition and Capital Expenditures: Ambulatory Services (2) $ 168,593 $ 81,156 $ 102,450 Physician Services 854,401 28,909 — Total $ 1,022,994 $ 110,065 $ 102,450 2015 2014 Assets: Ambulatory Services $ 2,609,479 $ 2,526,625 Physician Services 3,937,003 2,974,437 Total $ 6,546,482 $ 5,501,062 (1) On July 16, 2014, the Company completed the acquisition of Sheridan. Accordingly, historical amounts for periods prior to that date are not included. (2) Excludes the purchase price to acquire Sheridan in 2014.

Financial Information for the47

Financial Information for the Company and Its Subsidiaries (Tables)	12 Months Ended
	Dec. 31, 2015
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheet - December 31, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Assets Current assets: Cash and cash equivalents $ 20,437 $ 27,507 $ 58,716 $ — $ 106,660 Restricted cash and marketable securities — — 13,506 — 13,506 Accounts receivable, net — 223,434 113,896 — 337,330 Supplies inventory — — 21,406 — 21,406 Prepaid and other current assets 28,739 39,046 16,062 (8,076 ) 75,771 Total current assets 49,176 289,987 223,586 (8,076 ) 554,673 Property and equipment, net 12,515 14,601 162,052 — 189,168 Investments in and receivables from unconsolidated affiliates 4,901,026 1,775,272 — (6,507,128 ) 169,170 Goodwill — 1,956,741 — 2,013,469 3,970,210 Intangible assets, net 59,928 1,579,537 2,346 — 1,641,811 Other assets 4,653 1,717 17,078 (1,998 ) 21,450 Total assets $ 5,027,298 $ 5,617,855 $ 405,062 $ (4,503,733 ) $ 6,546,482 Liabilities and Equity Current liabilities: Current portion of long-term debt $ 8,700 $ — $ 11,677 $ — $ 20,377 Accounts payable 2,816 3,760 29,837 (3,852 ) 32,561 Accrued salaries and benefits 31,510 158,705 12,322 — 202,537 Accrued interest 30,463 — 17 — 30,480 Other accrued liabilities 13,962 76,590 32,909 (4,224 ) 119,237 Total current liabilities 87,451 239,055 86,762 (8,076 ) 405,192 Long-term debt 2,373,251 — 55,275 (23,396 ) 2,405,130 Deferred income taxes 268,573 432,923 — (1,998 ) 699,498 Other long-term liabilities 4,560 71,509 20,114 — 96,183 Intercompany payable — 1,228,157 — (1,228,157 ) — Noncontrolling interests – redeemable — — 63,060 112,672 175,732 Equity: Total AmSurg Corp. equity 2,293,463 3,646,211 132,267 (3,778,478 ) 2,293,463 Noncontrolling interests – non-redeemable — — 47,584 423,700 471,284 Total equity 2,293,463 3,646,211 179,851 (3,354,778 ) 2,764,747 Total liabilities and equity $ 5,027,298 $ 5,617,855 $ 405,062 $ (4,503,733 ) $ 6,546,482 Condensed Consolidating Balance Sheet - December 31, 2014 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Assets Current assets: Cash and cash equivalents $ 134,351 $ 23,471 $ 50,257 $ — $ 208,079 Restricted cash and marketable securities — — 10,219 — 10,219 Accounts receivable, net — 123,772 109,281 — 233,053 Supplies inventory — 301 19,673 — 19,974 Prepaid and other current assets 46,097 37,826 13,795 (4,818 ) 92,900 Total current assets 180,448 185,370 203,225 (4,818 ) 564,225 Property and equipment, net 10,391 9,972 160,085 — 180,448 Investments in and receivables from unconsolidated affiliates 3,912,804 1,587,881 — (5,425,210 ) 75,475 Goodwill — 1,490,981 — 1,890,168 3,381,149 Intangible assets, net 67,678 1,203,218 2,983 — 1,273,879 Other assets 3,323 943 23,086 (1,466 ) 25,886 Total assets $ 4,174,644 $ 4,478,365 $ 389,379 $ (3,541,326 ) $ 5,501,062 Liabilities and Equity Current liabilities: Current portion of long-term debt $ 8,700 $ — $ 10,126 $ — $ 18,826 Accounts payable 1,849 35 31,781 (4,080 ) 29,585 Accrued salaries and benefits 25,035 101,395 13,614 — 140,044 Accrued interest 29,621 — 23 — 29,644 Other accrued liabilities 8,051 44,305 16,368 (738 ) 67,986 Total current liabilities 73,256 145,735 71,912 (4,818 ) 286,085 Long-term debt 2,206,950 — 53,648 (28,412 ) 2,232,186 Deferred income taxes 207,500 404,984 — (1,466 ) 611,018 Other long-term liabilities 7,391 63,616 18,436 — 89,443 Intercompany payable — 1,219,979 8,010 (1,227,989 ) — Noncontrolling interests – redeemable — — 63,544 120,555 184,099 Equity: Total AmSurg Corp. equity 1,679,547 2,644,051 130,206 (2,774,257 ) 1,679,547 Noncontrolling interests – non-redeemable — — 43,623 375,061 418,684 Total equity 1,679,547 2,644,051 173,829 (2,399,196 ) 2,098,231 Total liabilities and equity $ 4,174,644 $ 4,478,365 $ 389,379 $ (3,541,326 ) $ 5,501,062
Condensed Consolidating Statement of Earnings	Condensed Consolidating Statement of Earnings - Year Ended December 31, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Net revenue $ 28,554 $ 1,331,042 $ 1,245,292 $ (38,004 ) $ 2,566,884 Operating expenses: Salaries and benefits 69,102 937,484 308,313 (507 ) 1,314,392 Supply cost — 2,436 181,866 (80 ) 184,222 Other operating expenses 24,682 145,369 265,160 (37,417 ) 397,794 Transaction costs 1,762 6,562 — — 8,324 Depreciation and amortization 3,912 61,658 31,923 — 97,493 Total operating expenses 99,458 1,153,509 787,262 (38,004 ) 2,002,225 Gain (loss) on deconsolidations — 37,350 (656 ) — 36,694 Equity in earnings of unconsolidated affiliates 349,139 251,093 — (584,080 ) 16,152 Operating income 278,235 465,976 457,374 (584,080 ) 617,505 Interest expense, net 41,140 77,947 2,499 — 121,586 Earnings from continuing operations before income taxes 237,095 388,029 454,875 (584,080 ) 495,919 Income tax expense 73,159 38,891 1,740 — 113,790 Net earnings from continuing operations 163,936 349,138 453,135 (584,080 ) 382,129 Net loss from discontinued operations (989 ) — (24 ) — (1,013 ) Net earnings 162,947 349,138 453,111 (584,080 ) 381,116 Net earnings attributable to noncontrolling interests — — 218,169 — 218,169 Net earnings attributable to AmSurg Corp. shareholders 162,947 349,138 234,942 (584,080 ) 162,947 Preferred stock dividends (9,056 ) — — — (9,056 ) Net earnings attributable to AmSurg Corp. common shareholders $ 153,891 $ 349,138 $ 234,942 $ (584,080 ) $ 153,891 Amounts attributable to AmSurg Corp. common shareholders: Earnings from continuing operations, net of income tax $ 154,880 $ 349,138 $ 234,954 $ (584,080 ) $ 154,892 Loss from discontinued operations, net of income tax (989 ) — (12 ) — (1,001 ) Net earnings attributable to AmSurg Corp. common shareholders $ 153,891 $ 349,138 $ 234,942 $ (584,080 ) $ 153,891 Condensed Consolidating Statement of Earnings - Year Ended December 31, 2014 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Net revenue $ 24,773 $ 508,572 $ 1,112,940 $ (24,336 ) $ 1,621,949 Operating expenses: Salaries and benefits 65,697 350,615 284,050 (5,786 ) 694,576 Supply cost — 1,292 163,004 — 164,296 Other operating expenses 18,667 53,413 231,398 (18,550 ) 284,928 Transaction costs 29,004 4,886 — — 33,890 Depreciation and amortization 4,044 25,610 30,690 — 60,344 Total operating expenses 117,412 435,816 709,142 (24,336 ) 1,238,034 Gain on deconsolidation — 3,411 — — 3,411 Equity in earnings of unconsolidated affiliates 237,657 211,889 — (442,508 ) 7,038 Operating income 145,018 288,056 403,798 (442,508 ) 394,364 Interest expense, net 47,997 33,026 2,262 — 83,285 Debt extinguishment costs 16,887 — — — 16,887 Earnings from continuing operations before income taxes 80,134 255,030 401,536 (442,508 ) 294,192 Income tax expense 29,166 17,373 1,564 — 48,103 Net earnings from continuing operations 50,968 237,657 399,972 (442,508 ) 246,089 Net earnings (loss) from discontinued operations 2,733 — (4,029 ) — (1,296 ) Net earnings 53,701 237,657 395,943 (442,508 ) 244,793 Net earnings attributable to noncontrolling interests — 21 191,071 — 191,092 Net earnings attributable to AmSurg Corp. shareholders 53,701 237,636 204,872 (442,508 ) 53,701 Preferred stock dividends (4,503 ) — — — (4,503 ) Net earnings attributable to AmSurg Corp. common shareholders $ 49,198 $ 237,636 $ 204,872 $ (442,508 ) $ 49,198 Amounts attributable to AmSurg Corp. common shareholders: Earnings from continuing operations, net of income tax $ 46,465 $ 237,636 $ 209,184 $ (442,508 ) $ 50,777 Earnings (loss) from discontinued operations, net of income tax 2,733 — (4,312 ) — (1,579 ) Net earnings attributable to AmSurg Corp. common shareholders $ 49,198 $ 237,636 $ 204,872 $ (442,508 ) $ 49,198 Condensed Consolidating Statement of Earnings - Year Ended December 31, 2013 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Net revenue $ 24,167 $ — $ 1,050,547 $ (17,518 ) $ 1,057,196 Operating expenses: Salaries and benefits 61,038 — 267,014 (467 ) 327,585 Supply cost — — 153,126 — 153,126 Other operating expenses 22,360 — 211,192 (17,051 ) 216,501 Transaction costs 300 — — — 300 Depreciation and amortization 3,186 — 29,214 — 32,400 Total operating expenses 86,884 — 660,546 (17,518 ) 729,912 Gain on deconsolidation — 2,237 — — 2,237 Equity in earnings of unconsolidated affiliates 207,199 204,962 — (409,010 ) 3,151 Operating income 144,482 207,199 390,001 (409,010 ) 332,672 Interest expense, net 27,282 — 2,243 — 29,525 Earnings from continuing operations before income taxes 117,200 207,199 387,758 (409,010 ) 303,147 Income tax expense 47,139 — 1,515 — 48,654 Net earnings from continuing operations 70,061 207,199 386,243 (409,010 ) 254,493 Net earnings from discontinued operations 2,642 — 4,409 — 7,051 Net earnings 72,703 207,199 390,652 (409,010 ) 261,544 Net earnings attributable to noncontrolling interests — — 188,841 — 188,841 Net earnings attributable to AmSurg Corp. common shareholders $ 72,703 $ 207,199 $ 201,811 $ (409,010 ) $ 72,703 Amounts attributable to AmSurg Corp. common shareholders: Earnings from continuing operations, net of income tax $ 70,061 $ 207,199 $ 202,759 $ (409,010 ) $ 71,009 Earnings (loss) from discontinued operations, net of income tax 2,642 — (948 ) — 1,694 Net earnings attributable to AmSurg Corp. common shareholders $ 72,703 $ 207,199 $ 201,811 $ (409,010 ) $ 72,703
Condensed Consolidating Statement of Cash Flows	Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2015 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Cash flows from operating activities: Net cash flows provided by operating activities $ 40,432 $ 353,932 $ 489,820 $ (346,225 ) $ 537,959 Cash flows from investing activities: Acquisitions and related transactions (757,775 ) (969,259 ) — 764,345 (962,689 ) Acquisition of property and equipment (5,876 ) (22,988 ) (31,441 ) — (60,305 ) Proceeds from sale of interests in surgery centers — 7,114 — — 7,114 Purchases of marketable securities — — (3,984 ) — (3,984 ) Maturities of marketable securities — — 4,233 — 4,233 Other — (2,927 ) 1,733 — (1,194 ) Net cash flows used in investing activities (763,651 ) (988,060 ) (29,459 ) 764,345 (1,016,825 ) Cash flows from financing activities: Proceeds from long-term borrowings 546,000 — 14,133 — 560,133 Repayment on long-term borrowings (379,700 ) — (12,886 ) — (392,586 ) Distributions to owners, including noncontrolling interests — (109,862 ) (451,262 ) 346,225 (214,899 ) Capital contributions — 757,775 — (757,775 ) — Proceeds from common stock offering 466,777 — — — 466,777 Payments of equity issuance costs (19,058 ) — — — (19,058 ) Financing cost incurred (1,101 ) — (10 ) — (1,111 ) Changes in intercompany balances with affiliates, net 5,016 — (5,016 ) — — Other financing activities, net (8,629 ) (9,749 ) 3,139 (6,570 ) (21,809 ) Net cash flows provided by (used in) financing activities 609,305 638,164 (451,902 ) (418,120 ) 377,447 Net increase (decrease) in cash and cash equivalents (113,914 ) 4,036 8,459 — (101,419 ) Cash and cash equivalents, beginning of period 134,351 23,471 50,257 — 208,079 Cash and cash equivalents, end of period $ 20,437 $ 27,507 $ 58,716 $ — $ 106,660 Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2014 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Cash flows from operating activities: Net cash flows provided by operating activities $ 96,681 $ 298,415 $ 430,880 $ (413,605 ) $ 412,371 Cash flows from investing activities: Acquisitions and related transactions (2,124,124 ) (2,188,191 ) 1,520 2,126,737 (2,184,058 ) Acquisition of property and equipment (7,877 ) (9,933 ) (22,407 ) — (40,217 ) Proceeds from sale of interests in surgery centers — 7,069 — — 7,069 Purchases of marketable securities — — (6,474 ) — (6,474 ) Maturities of marketable securities — — 3,486 — 3,486 Other (3,068 ) (6,594 ) 4,721 — (4,941 ) Net cash flows used in investing activities (2,135,069 ) (2,197,649 ) (19,154 ) 2,126,737 (2,225,135 ) Cash flows from financing activities: Proceeds from long-term borrowings 2,040,000 — 8,958 — 2,048,958 Repayment on long-term borrowings (396,493 ) — (11,982 ) — (408,475 ) Distributions to owners, including noncontrolling interests — (202,247 ) (401,455 ) 413,605 (190,097 ) Capital contributions — 2,124,124 — (2,124,124 ) — Proceeds from preferred stock offering 172,500 — — — 172,500 Proceeds from common stock offering 439,875 — — — 439,875 Payments of equity issuance costs (24,494 ) — — — (24,494 ) Financing cost incurred (65,811 ) — — — (65,811 ) Changes in intercompany balances with affiliates, net 2,965 — (2,965 ) — — Other financing activities, net (2,513 ) 828 1,845 (2,613 ) (2,453 ) Net cash flows provided by (used in) financing activities 2,166,029 1,922,705 (405,599 ) (1,713,132 ) 1,970,003 Net increase in cash and cash equivalents 127,641 23,471 6,127 — 157,239 Cash and cash equivalents, beginning of period 6,710 — 44,130 — 50,840 Cash and cash equivalents, end of period $ 134,351 $ 23,471 $ 50,257 $ — $ 208,079 Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2013 (In thousands) Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Consolidating Adjustments Total Consolidated Cash flows from operating activities: Net cash flows provided by operating activities $ 45,127 $ 208,773 $ 426,572 $ (347,648 ) $ 332,824 Cash flows from investing activities: Acquisitions and related transactions — (74,288 ) — 694 (73,594 ) Acquisition of property and equipment (3,693 ) — (25,163 ) — (28,856 ) Proceeds from sale of interests in surgery centers — 3,553 — — 3,553 Other — 159 — — 159 Net cash flows used in investing activities (3,693 ) (70,576 ) (25,163 ) 694 (98,738 ) Cash flows from financing activities: Proceeds from long-term borrowings 152,700 — 9,504 — 162,204 Repayment on long-term borrowings (188,081 ) — (14,002 ) — (202,083 ) Distributions to owners, including noncontrolling interests — (138,875 ) (392,922 ) 347,648 (184,149 ) Changes in intercompany balances with affiliates, net 88 — (88 ) — — Other financing activities, net (6,690 ) 678 1,090 (694 ) (5,616 ) Net cash flows used in financing activities (41,983 ) (138,197 ) (396,418 ) 346,954 (229,644 ) Net increase (decrease) in cash and cash equivalents (549 ) — 4,991 — 4,442 Cash and cash equivalents, beginning of period 7,259 — 39,139 — 46,398 Cash and cash equivalents, end of period $ 6,710 $ — $ 44,130 $ — $ 50,840

Quarterly Statement of Earnin48

Quarterly Statement of Earnings Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	The following table presents certain quarterly statement of earnings data for the years ended December 31, 2015 and 2014 . The quarterly statement of earnings data set forth below was derived from the Company’s unaudited financial statements and includes all adjustments, consisting of normal recurring adjustments, which the Company considers necessary for a fair presentation thereof. Results of operations for any particular quarter are not necessarily indicative of results of operations for a full year or predictive of future periods. 2015 2014 Q1 Q2 Q3 Q4 Q1 Q2 Q3 (1) Q4 (In thousands, except per share data) Net revenues $ 570,445 $ 641,950 $ 650,227 $ 704,262 $ 259,561 $ 278,227 $ 502,350 $ 581,811 Earnings from continuing operations before income taxes 83,004 115,940 135,797 161,178 73,028 80,487 39,142 101,535 Net earnings from continuing operations 68,755 90,747 98,279 124,348 60,046 67,689 39,120 79,234 Net earnings (loss) from discontinued operations — — — (1,013 ) 68 483 (1,697 ) (150 ) Net earnings 68,755 90,747 98,279 123,335 60,114 68,172 37,423 79,084 Net earnings (loss) attributable to AmSurg Corp. common shareholders: Continuing 18,774 31,411 40,397 64,310 17,392 18,771 (10,697 ) 25,311 Discontinued — — — (1,001 ) (197 ) 190 (1,376 ) (196 ) Net earnings (loss) $ 18,774 $ 31,411 $ 40,397 $ 63,309 $ 17,195 $ 18,961 $ (12,073 ) $ 25,115 Basic net earnings (loss) from continuing operations per share $ 0.39 $ 0.66 $ 0.85 $ 1.31 $ 0.55 $ 0.59 $ (0.23 ) $ 0.53 Basic net earnings (loss) per share $ 0.39 $ 0.66 $ 0.85 $ 1.28 $ 0.54 $ 0.60 $ (0.26 ) $ 0.53 Diluted net earnings (loss) from continuing operations per share $ 0.39 $ 0.65 $ 0.83 $ 1.26 $ 0.54 $ 0.58 $ (0.23 ) $ 0.53 Diluted net earnings (loss) per share $ 0.39 $ 0.65 $ 0.83 $ 1.24 $ 0.54 $ 0.59 $ (0.26 ) $ 0.53 (1) The results of operations for Sheridan are effective July 16, 2014. Additionally, $16.9 million of debt extinguishment costs and $25.1 million of transaction costs were incurred during the quarter.

Summary of Significant Accoun49

Summary of Significant Accounting Policies (Details) $ in Millions	Dec. 31, 2015USD ($)center	Dec. 31, 2014USD ($)
Ownership Interests [Line Items]
Number of centers with ownership interest of less than 51% | center	23
Restricted Cash and Marketable Securities
Restricted cash and marketable securities, total	$ 27.4	$ 30.3
Restricted cash and marketable securities, noncurrent	13.9	20.1
Restricted marketable securities	$ 2.7	3
Consolidated [Member]
Ownership Interests [Line Items]
Number of centers with ownership interest of less than 51% | center	2
Nonconsolidated [Member]
Ownership Interests [Line Items]
Number of centers with ownership interest of less than 51% | center	21
New Accounting Pronouncement, Early Adoption, Effect [Member]
Ownership Interests [Line Items]
Deferred tax assets, net, current		$ 22.5

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended								6 Months Ended	12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenue, Major Customer [Line Items]
Provision for uncollectibles										$ (287,427)	$ (139,274)	$ (21,947)
Net revenue	$ 704,262	$ 650,227	$ 641,950	$ 570,445	$ 581,811	$ 502,350	$ 278,227	$ 259,561		2,566,884	1,621,949	1,057,196
Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue									$ 574,672	1,473,122
Contract and other revenue									54,343	129,786
Provision for uncollectibles									(117,001)	(266,074)	(117,001)	0
Net revenue									512,014	$ 1,336,834	$ 512,014	$ 0
Ambulatory Services [Member]
Revenue, Major Customer [Line Items]
Percentage of revenues from governmental healthcare programs										26.00%	25.00%	25.00%
Net revenue										$ 1,230,050	$ 1,109,935	$ 1,057,196
Medicare [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue									61,378	172,783
Medicaid [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue									28,224	69,607
Commercial and Managed Care [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue									382,343	1,007,902
Self-Pay [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue									$ 102,727	$ 222,830
Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over									100.00%	100.00%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over									112.30%	110.20%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Medicare [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over									12.00%	12.90%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Medicaid [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over									5.50%	5.20%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Commercial and Managed Care [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over									74.70%	75.40%
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Self-Pay [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over									20.10%	16.70%
Contract and Other Revenue [Member] | Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over									10.60%	9.70%
Provision for Uncollectibles [Member] | Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over									22.90%	19.90%

Accounts Receivable (Details)

Accounts Receivable (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]
Bad debt expense		$ 287,427	$ 139,274	$ 21,947
Allowances for accounts receivable	$ 113,357	$ 167,411	$ 113,357
Product Concentration Risk [Member] | Allowance for Doubtful Accounts [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts related to fee for service patient visits		80.00%	73.00%
Ambulatory Services [Member] | Other Operating Expenses [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Bad debt expense		$ 21,400	$ 21,900	21,700
Physician Services [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Bad debt expense	$ 117,001	$ 266,074	$ 117,001	$ 0

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details)	Jul. 16, 2014USD ($)shares	Jul. 02, 2014shares	Dec. 31, 2015USD ($)shares	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)physician_practice	Dec. 31, 2015USD ($)physician_practicecenter	Dec. 31, 2014USD ($)center	Dec. 31, 2013USD ($)center	Oct. 21, 2015USD ($)
Business Acquisition [Line Items]
Acquisitions and related expenses, net						$ 962,689,000	$ 2,184,058,000	$ 73,594,000
Acquisition accounting, change in the contingent consideration						8,804,000	0	0
Proceeds from common stock offering						466,777,000	439,875,000	0
Proceeds from preferred stock offering						0	172,500,000	0
Payments of equity issuance costs						(19,058,000)	(24,494,000)	0
Transaction costs				$ 25,100,000		8,324,000	33,890,000	300,000
Debt extinguishment costs						0	(16,887,000)	$ 0
Contingent purchase price payable			$ 0		$ 8,470,000	0	8,470,000
Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Cash paid to acquire business	$ 2,100,000,000
Value of common stock issued for acquisition	272,000,000
Fees and expenses associated with acquisition					139,100,000		139,100,000
Deferred financing costs					$ 53,000,000		53,000,000
Goodwill, Purchase Accounting Adjustments						8,300,000
Transaction costs							31,900,000
Common Stock [Member]
Business Acquisition [Line Items]
Issuance of common stock (in shares) | shares		9,775,000	5,835,000
Proceeds from common stock offering	$ 421,300,000
Common Stock [Member] | Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Shares of common stock issued for acquisition | shares	5,713,909
Mandatory Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Issuance of common stock (in shares) | shares		1,725,000
Proceeds from preferred stock offering	$ 166,600,000
Senior Secured Credit Facility - Term Loan [Member]
Business Acquisition [Line Items]
Maximum borrowing capacity	870,000,000
Revolving Credit Facility [Member]
Business Acquisition [Line Items]
Maximum borrowing capacity	300,000,000								$ 500,000,000
Debt extinguishment costs						4,500,000
Senior Notes [Member] | 2022 Senior Unsecured Notes [Member]
Business Acquisition [Line Items]
Face amount	$ 1,100,000,000
Interest rate	5.625%
Bridge Loan [Member] | Interest Expense [Member] | Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Fees paid to obtain a commitment for financing							12,800,000
Ambulatory Services [Member]
Business Acquisition [Line Items]
Acquisitions and related expenses, net						$ 131,300,000	$ 50,900,000
Ambulatory Services [Member] | Controlling Interest [Member]
Business Acquisition [Line Items]
Number of business acquisitions | center						7	8
Ambulatory Services [Member] | Sheridan Healthcare [Member] | Controlling Interest [Member]
Business Acquisition [Line Items]
Number of business acquisitions | center							3
Ambulatory Services [Member] | Series of Individually Immaterial Business Acquisitions [Member] | Controlling Interest [Member]
Business Acquisition [Line Items]
Number of business acquisitions | center							5
Physician Services [Member]
Business Acquisition [Line Items]
Acquisition accounting, change in the contingent consideration						$ 10,000,000
Physician Services [Member] | Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Acquisition accounting, change in the contingent consideration						$ 3,500,000
Physician Services [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Number of business acquisitions | physician_practice					2	9
Cash paid to acquire business					$ 19,000,000	$ 831,400,000
Estimate of fair values of the contingent consideration			$ 5,500,000		$ 20,700,000	5,500,000	$ 20,700,000
Payments for contingent consideration						28,700,000
Payment to settle amount recorded at the acquisition date						15,700,000
Estimate contingent consideration payment, low			5,000,000			5,000,000
Estimate contingent consideration payment, high			$ 6,000,000			$ 6,000,000
Joint Venture [Member] | Ambulatory Services [Member] | Controlling Interest [Member]
Business Acquisition [Line Items]
Number Of Consolidated Entities Contributed To Joint Venture | center						9	4	1
Joint Venture [Member] | Physician Services [Member] | Controlling Interest [Member]
Business Acquisition [Line Items]
Number Of Consolidated Entities Contributed To Joint Venture | center						3

Acquisitions (Fair Value Of Tot

Acquisitions (Fair Value Of Total Consideration Transferred And Major Class Of Consideration) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Goodwill	$ 3,970,210	$ 3,381,149	$ 1,758,970
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Accounts receivable	62,216	1,816
Other current assets	21,477	1,075
Property and equipment	15,484	3,294
Goodwill	682,458	101,865
Intangible assets	420,414	14,207
Other long-term assets	342	0
Accounts payable	(3,641)	(2,519)
Other accrued liabilities	(45,386)	(626)
Deferred income taxes	(88,728)	0
Other long-term liabilities	(4,958)	(8,588)
Long-term debt	(6,046)	(717)
Total fair value	1,053,632	109,807
Less: Fair value attributable to noncontrolling interests	85,443	39,371
Acquisition date fair value of total consideration transferred	968,189	70,436
Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Accounts receivable		130,260
Other current assets		105,757
Property and equipment		20,185
Goodwill		1,534,656
Intangible assets		1,200,028
Other long-term assets		50,304
Accounts payable		(5,862)
Other accrued liabilities		(118,548)
Deferred income taxes		(432,792)
Other long-term liabilities		(69,456)
Long-term debt		(4,594)
Total fair value		2,409,938
Less: Fair value attributable to noncontrolling interests		24,365
Acquisition date fair value of total consideration transferred		2,385,573
Physician Services [Member]
Business Acquisition [Line Items]
Goodwill	$ 2,000,000	$ 1,500,000

Acquisitions (Revs and Earnings

Acquisitions (Revs and Earnings) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Revenues	$ 704,262	$ 650,227	$ 641,950	$ 570,445	$ 581,811	$ 502,350	$ 278,227	$ 259,561	$ 2,566,884	$ 1,621,949	$ 1,057,196
Net earnings	123,335	98,279	90,747	68,755	79,084	37,423	68,172	60,114	381,116	244,793	261,544
Less: Net earnings attributable to noncontrolling interests									218,169	191,092	188,841
Net earnings attributable to AmSurg Corp. common shareholders	$ 63,309	$ 40,397	$ 31,411	$ 18,774	$ 25,115	$ (12,073)	$ 18,961	$ 17,195	153,891	49,198	$ 72,703
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Revenues									179,113	20,844
Net earnings									26,901	5,155
Less: Net earnings attributable to noncontrolling interests									7,448	2,859
Net earnings attributable to AmSurg Corp. common shareholders									$ 19,453	2,296
Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Revenues										517,213
Net earnings										26,776
Less: Net earnings attributable to noncontrolling interests										459
Net earnings attributable to AmSurg Corp. common shareholders										$ 26,317

Acquisitions (Consolidated Pro

Acquisitions (Consolidated Pro Forma Results Of Acquisition) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Business Combinations [Abstract]
Net revenue	$ 2,858,544	$ 2,680,273
Net earnings	401,950	322,653
Net earnings attributable to AmSurg Corp. common shareholders	$ 170,453	$ 104,548
Net earnings per common share, Basic (usd per share)	$ 3.55	$ 2.21
Net earnings per common share, Diluted (usd per share)	$ 3.48	$ 2.20

Investments in Unconsolidated56

Investments in Unconsolidated Affiliates (Details) $ in Thousands	3 Months Ended								6 Months Ended	12 Months Ended
	Dec. 31, 2015USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Sep. 30, 2014USD ($)	Jun. 30, 2014USD ($)	Mar. 31, 2014USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2015USD ($)entityequity_method_investmentcenter	Dec. 31, 2014USD ($)equity_method_investmentcenter	Dec. 31, 2013USD ($)equity_method_investmentcenter
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates	$ 169,170				$ 75,475				$ 75,475	$ 169,170	$ 75,475
Equity in earnings of unconsolidated affiliates										16,152	7,038	$ 3,151
Net gain on deconsolidations										36,694	3,411	2,237
Management and billing fees included in net revenue	704,262	$ 650,227	$ 641,950	$ 570,445	581,811	$ 502,350	$ 278,227	$ 259,561		2,566,884	1,621,949	1,057,196
Receivables from VIEs included in other current assets	75,771				92,900				92,900	75,771	92,900
Variable Interest Entity, Not Primary Beneficiary, Aggregated Disclosure [Member]
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates	89,600				53,200				53,200	89,600	53,200
Equity in earnings of unconsolidated affiliates										$ 11,000	3,400
Ownership percentage										50.00%
Management and billing fees included in net revenue										$ 14,300	4,700
Receivables from VIEs included in other current assets	2,300				3,500				3,500	$ 2,300	3,500
Variable Interest Entity, Not Primary Beneficiary, Aggregated Disclosure [Member] | Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage										49.00%
Variable Interest Entity, Not Primary Beneficiary, Aggregated Disclosure [Member] | Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage										51.00%
Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Increase in equity method investments										$ 83,100	56,400
Joint Venture [Member] | Variable Interest Entity, Not Primary Beneficiary, Aggregated Disclosure [Member]
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates	$ 27,100									$ 27,100
Number consolidated centers contributed to joint venture | center										4
Sheridan Healthcare [Member] | Variable Interest Entity, Not Primary Beneficiary, Aggregated Disclosure [Member]
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates					$ 49,400				49,400		49,400
Ambulatory Services [Member]
Schedule of Equity Method Investments [Line Items]
Management and billing fees included in net revenue										$ 1,230,050	$ 1,109,935	$ 1,057,196
Ambulatory Services [Member] | Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Estimated probability of fair value variables range										10.00%
Ambulatory Services [Member] | Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Estimated probability of fair value variables range										50.00%
Ambulatory Services [Member] | Controlling Interest [Member] | Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Number consolidated centers contributed to joint venture | center										9	4	1
Ambulatory Services [Member] | Noncontrolling Interest In Centers [Member] | Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Number of equity investments acquired in the period | equity_method_investment										5	4	1
Number of joint venture entities acquired | center										3	1	1
Ambulatory Services [Member] | Noncontrolling Interest In Surgical Hospital [Member] | Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Number of joint venture entities acquired | entity										1
Physician Services [Member]
Schedule of Equity Method Investments [Line Items]
Management and billing fees included in net revenue									$ 512,014	$ 1,336,834	$ 512,014	$ 0
Physician Services [Member] | Controlling Interest [Member] | Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Number consolidated centers contributed to joint venture | center										3
Deconsolidation [Member] | Ambulatory Services [Member]
Schedule of Equity Method Investments [Line Items]
Net cash received in exchange for noncontrolling interests in new investments										$ 8,500	$ 1,200
Cash contributed from divestiture of interest in consolidated subsidiaries												$ 300

Discontinued Operations (Result

Discontinued Operations (Results Of Operations Of Centers Discontinued) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Results of discontinued operations, net of tax:
Net earnings (loss) from discontinued operations	$ (1,013)	$ 0	$ 0	$ 0	$ (150)	$ (1,697)	$ 483	$ 68	$ (1,013)	$ (1,296)	$ 7,051
Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders	$ (1,001)	$ 0	$ 0	$ 0	$ (196)	$ (1,376)	$ 190	$ (197)	(1,001)	(1,579)	1,694
Cash proceeds from disposal									7,114	7,069	3,553
Discontinued Operations, Disposed Of By Sale Or Abandonment [Member]
Disposal Groups, Including Discontinued Operations [Line Items]
Revenues									0	9,545	25,373
Earnings before income taxes									0	893	5,607
Results of discontinued operations, net of tax:
Earnings (loss) from operations of discontinued interests in surgery centers									(1,013)	710	4,449
Gain (loss) on disposal of discontinued interests in surgery centers									0	(2,006)	2,602
Net earnings (loss) from discontinued operations									(1,013)	(1,296)	7,051
Less: Net earnings (loss) from discontinued operations attributable to noncontrolling interests									(12)	283	5,357
Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders									(1,001)	(1,579)	1,694
Cash proceeds from disposal									$ 0	$ 7,100	$ 3,600

Prepaid and Other Current Ass58

Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Income taxes receivable	$ 7,908	$ 28,694
Prepaid expenses	18,900	18,682
Deferred compensation plan assets	16,623	17,320
Other	32,340	28,204
Total prepaid and other current assets	$ 75,771	$ 92,900

Property and Equipment (Narrati

Property and Equipment (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Unfunded construction and equipment purchases	$ 18.3
Depreciation expense	$ 35.4	$ 33.2	$ 29.8
Building and Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life	20 years
Building and Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life	40 years
Movable Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life	3 years
Movable Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life	10 years

Property and Equipment (PPE Sch

Property and Equipment (PPE Schedule) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Building and improvements	$ 177,253	$ 170,420
Movable equipment	237,312	215,444
Construction in progress	8,676	11,940
Property and equipment, gross	423,241	397,804
Less accumulated depreciation	(234,073)	(217,356)
Property and equipment, net	$ 189,168	$ 180,448

Goodwill And Intangible Asset61

Goodwill And Intangible Assets (Narrative) (Details) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2014USD ($)physician_practice	Dec. 31, 2015USD ($)physician_practicecenter	Dec. 31, 2014USD ($)center	Dec. 31, 2013USD ($)center
Segment Reporting Information [Line Items]
Goodwill	$ 3,381,149	$ 3,970,210	$ 3,381,149	$ 1,758,970
Increase in goodwill		674,476	1,636,521
Goodwill deductible for tax purposes	64,500	$ 295,700	64,500
Amortization period		17 years 292 days
Debt extinguishment costs		$ 0	4,536	0
Amortization of Intangible Assets		70,500	32,500	$ 2,200
Estimated amortization of intangible assets, 2016		90,300
Estimated amortization of intangible assets, 2017		89,100
Estimated amortization of intangible assets, 2018		87,800
Estimated amortization of intangible assets, 2019		84,800
Estimated amortization of intangible assets, 2020		81,600
Estimated amortization of intangible assets, 2021 and thereafter		971,200
Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Goodwill	1,900,000	2,000,000	1,900,000
Increase in goodwill		123,400
Physician Services [Member]
Segment Reporting Information [Line Items]
Goodwill	1,500,000	2,000,000	1,500,000
Increase in goodwill		465,700
Sheridan Healthcare [Member]
Segment Reporting Information [Line Items]
Goodwill	1,534,656		1,534,656
Deferred financing costs	53,000		53,000
Intangible assets	1,200,028		1,200,028
Series of Individually Immaterial Business Acquisitions [Member]
Segment Reporting Information [Line Items]
Goodwill	101,865	682,458	101,865
Intangible assets	$ 14,207	$ 420,414	14,207
Series of Individually Immaterial Business Acquisitions [Member] | Physician Services [Member]
Segment Reporting Information [Line Items]
Number of business acquisitions | physician_practice	2	9
Interest Expense [Member] | Bridge Loan [Member] | Sheridan Healthcare [Member]
Segment Reporting Information [Line Items]
Fees paid to obtain a commitment for financing			$ 12,800
Customer Relationships [Member]
Segment Reporting Information [Line Items]
Amortization period		20 years
Deferred Financing Costs, Amortizable Non-Compete Agreements, and Customer Agreements [Member] | Minimum [Member]
Segment Reporting Information [Line Items]
Amortization period		5 years
Deferred Financing Costs, Amortizable Non-Compete Agreements, and Customer Agreements [Member] | Maximum [Member]
Segment Reporting Information [Line Items]
Amortization period		10 years
Capitalized software [Member] | Minimum [Member]
Segment Reporting Information [Line Items]
Amortization period		3 years
Capitalized software [Member] | Maximum [Member]
Segment Reporting Information [Line Items]
Amortization period		8 years
Controlling Interest [Member] | Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Number of business acquisitions | center		7	8
Controlling Interest [Member] | Sheridan Healthcare [Member] | Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Number of business acquisitions | center			3
Controlling Interest [Member] | Series of Individually Immaterial Business Acquisitions [Member] | Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Number of business acquisitions | center			5
Joint Venture [Member] | Controlling Interest [Member] | Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Number Of Consolidated Entities Contributed To Joint Venture | center		9	4	1
Joint Venture [Member] | Controlling Interest [Member] | Physician Services [Member]
Segment Reporting Information [Line Items]
Number Of Consolidated Entities Contributed To Joint Venture | center		3

Goodwill And Intangible Asset62

Goodwill And Intangible Assets (Changes In Carrying Amount Of Goodwill) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Goodwill [Roll Forward]
Balance, beginning of year	$ 3,381,149	$ 1,758,970
Goodwill acquired, including post acquisition adjustments	674,476	1,636,521
Goodwill disposed, including impact of deconsolidation transactions	(85,415)	(14,342)
Balance, end of year	$ 3,970,210	$ 3,381,149

Goodwill And Intangible Asset63

Goodwill And Intangible Assets (Summary Of Intangible Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangible assets	$ 236,995	$ 237,995
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,523,370	1,085,129
Accumulated Amortization	(118,554)	(49,245)
Net	1,404,816	1,035,884
Total intangible assets, gross carrying amount	1,760,365	1,323,124
Total intangible assets, net	1,641,811	1,273,879
Trade name [Member]
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangible assets	228,000	228,000
Restrictive covenant arrangements [Member]
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangible assets	8,995	9,995
Customer relationships with hospitals [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,379,977	971,645
Accumulated Amortization	(74,490)	(22,145)
Net	1,305,487	949,500
Deferred financing cost [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	60,664	59,574
Accumulated Amortization	(13,490)	(5,151)
Net	47,174	54,423
Capitalized software [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	71,462	50,387
Accumulated Amortization	(28,125)	(19,197)
Net	43,337	31,190
Agreements, contracts, and other intangible assets
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	11,267	3,523
Accumulated Amortization	(2,449)	(2,752)
Net	$ 8,818	$ 771

Other Accrued Liabilities (Deta

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Accrued professional liabilities	$ 14,362	$ 11,983
Contingent purchase price payable	5,509	12,213
Current income taxes payable	7,892	0
Refunds payable	48,415	17,752
Other	43,059	26,038
Total other accrued liabilities	$ 119,237	$ 67,986

Accrued Professional Liabilit65

Accrued Professional Liabilities - Components of Reserves (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]
Estimated losses under self-insured programs	$ 30,748	$ 25,337
Incurred but not reported losses	36,166	28,448
Total accrued professional liabilities	66,914	53,785	$ 1,171
Less estimated losses payable within one year	14,362	11,983
Total	$ 52,552	$ 41,802

Accrued Professional Liabilit66

Accrued Professional Liabilities - Rollforward of Reserves (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Self Insurance Reserve [Roll Forward]
Beginning balance	$ 53,785	$ 1,171
Assumed liabilities through acquisitions	13,317	53,512
Provision related to current period reserves	15,943	5,423
Payments for current period reserves	(4,475)	(1,595)
Benefit related to changes in prior period reserves	(425)	(661)
Payments for prior period reserves	(8,863)	(6,055)
Other, net	(2,368)	1,990
Ending balance	$ 66,914	$ 53,785

Long-Term Debt (Narrative) (Det

Long-Term Debt (Narrative) (Details) - USD ($)	Jul. 16, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Oct. 21, 2015	Nov. 20, 2012	May. 28, 2010
Payments required on Company's long-term debt and capital leases
2,016		$ 20,400,000
2,017		18,000,000
2,018		14,800,000
2,019		187,000,000
2,020		261,000,000
Thereafter		1,900,000,000
Term Loan and Credit Facility
Debt extinguishment costs		0	$ (16,887,000)	$ 0
Revolving Credit Facility [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term debt, carrying value		175,000,000	0
Term Loan and Credit Facility
Remaining carrying value under revolving credit facility		325,000,000
Loans Payable [Member]
Other Debt
Book value of certain assets of surgery centers pledged as collateral		41,700,000
Fixed Interest Rate [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term debt, carrying value		1,400,000,000
Long-term debt, fair value		1,400,000,000
Variable Interest Rate [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term debt, carrying value		1,000,000,000
Long-term debt, fair value		1,000,000,000
5.625% Senior Unsecured Notes due 2020 [Member] | Senior Notes [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term debt, carrying value		250,000,000	250,000,000
Senior Unsecured Debt
Face amount						$ 250,000,000
Interest rate						5.625%
Senior Secured Debt
Face amount						$ 250,000,000
Interest rate						5.625%
5.625% Senior Unsecured Notes due 2022 [Member] | Senior Notes [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term debt, carrying value		$ 1,100,000,000	$ 1,100,000,000
Senior Unsecured Debt
Face amount	$ 1,100,000,000
Interest rate	5.625%
Redeemable principal percentage		35.00%
Senior Secured Debt
Face amount	$ 1,100,000,000
Interest rate	5.625%
8.04% Senior Secured Notes due 2020 [Member] | Senior Notes [Member]
Senior Unsecured Debt
Face amount							$ 75,000,000
Senior Secured Debt
Face amount							$ 75,000,000
Early termination fee		$ 12,400,000
Period Prior to July 15, 2017 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member] | Senior Notes [Member]
Senior Unsecured Debt
Redemption price as percent of the principal amount		105.625%
Senior Secured Credit Facility - Term Loan [Member]
Term Loan and Credit Facility
Borrowing capacity of new revolving credit agreement	$ 870,000,000
Quarterly principal payment as a percent of face amount	0.25%
Annual principal payment	$ 8,700,000
Revolving Credit Facility [Member]
Term Loan and Credit Facility
Borrowing capacity of new revolving credit agreement	$ 300,000,000				$ 500,000,000
Line of Credit Facility, Accordion Feature, Increase To Maximum Borrowing Capacity					$ 200,000,000
Unused commitment fee as a percent	0.375%
Debt extinguishment costs		$ 4,500,000
Base Rate [Member] | Senior Secured Credit Facility - Term Loan [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread	2.00%
Base Rate [Member] | Senior Secured Credit Facility - Term Loan [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread	1.75%
Base Rate [Member] | Revolving Credit Facility [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread	2.00%
Base Rate [Member] | Revolving Credit Facility [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread	1.75%
LIBOR [Member] | Senior Secured Credit Facility - Term Loan [Member]
Term Loan and Credit Facility
Floor rate	0.75%
Current variable rate		3.75%
LIBOR [Member] | Senior Secured Credit Facility - Term Loan [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread	3.00%
LIBOR [Member] | Senior Secured Credit Facility - Term Loan [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread	2.75%
LIBOR [Member] | Revolving Credit Facility [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread	3.00%
LIBOR [Member] | Revolving Credit Facility [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread	2.75%

Long-Term Debt (Components Of L

Long-Term Debt (Components Of Long-Term Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Other debt at an average interest rate of 3.4%, due through 2022	$ 24,944	$ 20,156
Capitalized lease arrangements at an average interest rate of 5.4%, due through 2021	18,613	15,206
Long-term debt and capitalized lease arrangements	2,425,507	2,251,012
Less current portion	20,377	18,826
Long-term debt	$ 2,405,130	2,232,186
Other debt, average rate	3.40%
Capitalized lease arrangements, average rate	5.40%
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt	$ 175,000	0
Term Loan [Member]
Debt Instrument [Line Items]
Long-term debt	856,950	865,650
Fixed Interest Rate [Member]
Debt Instrument [Line Items]
Long-term debt	1,400,000
5.625% Senior Unsecured Notes due 2020 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt	250,000	250,000
5.625% Senior Unsecured Notes due 2022 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt	1,100,000	$ 1,100,000
Variable Interest Rate [Member]
Debt Instrument [Line Items]
Long-term debt	$ 1,000,000

Long-Term Debt (Redemption Pric

Long-Term Debt (Redemption Price) (Details) - Senior Notes [Member]	12 Months Ended
	Dec. 31, 2015
2015 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	104.219%
2016 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	102.813%
2017 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	101.406%
2017 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	104.219%
2018 and thereafter [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	100.00%
2018 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	102.813%
2019 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	101.406%
2020 and thereafter [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	100.00%

Other Long-term Liabilities (De

Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Accrued professional liabilities	$ 52,552	$ 41,802
Contingent purchase price payable	0	8,470
Deferred rent	18,958	16,814
Tax-effected unrecognized benefits	3,426	8,353
Other	21,247	14,004
Other long-term liabilities	$ 96,183	$ 89,443

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
U.S. federal income tax rate	35.00%	35.00%	35.00%
Decreases in interest and penalty obligations	$ 0.2	$ 0.1	$ 0.2
Interest obligations	0.8	$ 1.2
Tax-effected unrecognized benefits	$ 0.1

Income Taxes (Total Income Tax

Income Taxes (Total Income Tax Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Earnings from continuing operations	$ 113,790	$ 48,103	$ 48,654
Discontinued operations	(694)	(643)	9
Shareholders’ equity	(2,227)	(3,177)	(7,381)
Total	$ 110,869	$ 44,283	$ 41,282

Income Taxes (Income Tax Expens

Income Taxes (Income Tax Expense from Cont. Ops) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current:
Federal	$ 83,228	$ 8,640	$ 7,895
State	14,268	4,396	3,598
Deferred:
Federal	11,715	27,505	31,509
State	4,579	7,562	5,652
Income tax expense	$ 113,790	$ 48,103	$ 48,654

Income Taxes (Income Tax Expe74

Income Taxes (Income Tax Expense Reconciliation to Federal Rate) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory federal income tax	$ 173,572	$ 102,967	$ 106,101
Less federal income tax assumed directly by noncontrolling interests	(76,364)	(66,783)	(64,219)
State income taxes, net of federal income tax benefit	11,604	6,616	5,539
Increase in valuation allowances	317	4,662	924
Interest related to unrecognized tax benefits	(548)	(161)	(155)
Other	5,209	802	464
Income tax expense	$ 113,790	$ 48,103	$ 48,654

Income Taxes (Unrecognized Tax

Income Taxes (Unrecognized Tax Liability Rec) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of year	$ 7,336	$ 6,330	$ 9,235
Additions for tax positions of current year	0	204	46
Increases (decreases) for tax positions taken during a prior period	(1,006)	1,069	0
Lapse of statute of limitations	(3,178)	(267)	(2,951)
Balance at end of year	$ 3,152	$ 7,336	$ 6,330

Income Taxes (Deferred Assets a

Income Taxes (Deferred Assets and Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Allowance for uncollectible accounts	$ 3,276	$ 1,096
Accrued assets and other	36,600	27,537
Share-based compensation	10,710	7,719
Interest on unrecognized tax benefits	113	245
Accrued liabilities and other	4,080	3,931
Medical malpractice	19,035	16,240
Operating and capital loss carryforwards	29,718	22,709
Valuation allowances	(21,814)	(17,457)
Total deferred tax assets	81,718	62,020
Deferred tax liabilities:
Prepaid expenses	1,789	2,435
Property and equipment, principally due to differences in depreciation	16,787	15,235
Goodwill, intangible assets and other, principally due to differences in amortization	762,640	655,358
Total deferred tax liabilities	781,216	673,028
Net deferred tax liabilities	$ 699,498	$ 611,008

Shareholder's Equity (Narrative

Shareholder's Equity (Narrative) (Details) $ / shares in Units, $ in Thousands	Nov. 25, 2014USD ($)$ / shares	Aug. 29, 2014USD ($)$ / shares	Jul. 16, 2014shares	Jul. 02, 2014USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Sep. 30, 2015USD ($)$ / shares	Jun. 30, 2015USD ($)$ / shares	Mar. 31, 2015USD ($)$ / shares	Dec. 31, 2015USD ($)installment$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares
Preferred Stock
Preferred stock dividends | $										$ 9,056	$ 4,503	$ 0
Stock Incentive Plans:
Excess tax benefit from share-based compensation | $										$ 4,001	$ 3,177	$ 7,247
Number of shares authorized for grant under share incentive plan					1,200,000	1,200,000				1,200,000
Shares available for future grants/issuance under stock incentive plan					900,039	900,039				900,039
Unrecognized compensation cost on non vested awards | $					$ 16,600	$ 16,600				$ 16,600
Weighted average period										1 year 1 month 12 days
Shares granted, Number of Shares										313,498	272,780	291,863
Shares granted, Weighted Average Grant Price (usd per share) | $ / shares										$ 56.19	$ 43.12	$ 31.66
Stock Repurchased Under Repurchase Program [Member]
Common Stock:
Repurchase of common stock, shares												1,154,378
Repurchase of common stock | $												$ 42,700
Average price per share | $ / shares												$ 36.93
Stock Repurchased To Cover Employee Tax Withholdings [Member]
Common Stock:
Repurchase of common stock, shares										67,000	100,720
Repurchase of common stock | $										$ 3,700	$ 4,600
Stock Options [Member]
Stock Incentive Plans:
Award vesting period										4 years
Options term										10 years
Employees [Member] | Restricted Stock [Member]
Stock Incentive Plans:
Award vesting period										4 years
Number of installments in restricted stock granted. | installment										3
Stock Options [Member]
Stock Incentive Plans:
Number of anti-dilutive options										0	0	0
Common Stock [Member]
Common Stock:
Issuance of stock (in shares)				9,775,000	5,835,000
Issuance of stock, price per share | $ / shares				$ 45	$ 80
Stock offering expenses | $				$ 18,500	$ 19,100
Mandatory Convertible Preferred Stock [Member]
Common Stock:
Issuance of stock (in shares)				1,725,000
Issuance of stock, price per share | $ / shares				$ 100
Stock offering expenses | $				$ 5,900
Preferred Stock
Dividend rate										5.25%
Initial liquidation preference (usd per share) | $ / shares					$ 100	$ 100				$ 100
Consecutive trading day										20 days
Dividends declared (usd per share) | $ / shares	$ 1.3125	$ 1.2979				$ 1.3125	$ 1.3125	$ 1.3125	$ 1.3125
Preferred stock dividends | $	$ 2,300	$ 2,200				$ 2,300	$ 2,300	$ 2,300	$ 2,300
Sheridan Healthcare [Member] | Common Stock [Member]
Common Stock:
Shares of common stock issued for acquisition			5,713,909
Minimum [Member] | Mandatory Convertible Preferred Stock [Member]
Preferred Stock
Conversion rate (shares)					1.8141	1.8141				1.8141
Maximum [Member] | Mandatory Convertible Preferred Stock [Member]
Preferred Stock
Conversion rate (shares)					2.2222	2.2222				2.2222
Restricted Stock Units (RSUs) [Member]
Stock Incentive Plans:
Award vesting period										3 years
Shares granted, Number of Shares										68,533
Shares granted, Weighted Average Grant Price (usd per share) | $ / shares										$ 55.40
Financial performance goal term										1 year
Percent of units granted										150.00%
Restricted Stock Units (RSUs) [Member] | Minimum [Member]
Stock Incentive Plans:
Percent of units granted										0.00%
Restricted Stock Units (RSUs) [Member] | Maximum [Member]
Stock Incentive Plans:
Percent of units granted										150.00%

Shareholders' Equity (Share-Bas

Shareholders' Equity (Share-Based Activity) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Equity [Abstract]
Share-based compensation expense	$ 15,009	$ 10,104	$ 8,321
Fair value of shares vested	13,220	15,126	11,742
Cash received from option exercises	2,584	2,630	33,349
Tax benefit from option exercises	$ 4,001	$ 3,177	$ 7,247

Shareholders Equity (Schedule O

Shareholders Equity (Schedule Of Changes In Non-Vested Restricted Shares) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested shares at beginning of period, Number of Shares	668,109	743,869	828,686
Shares granted, Number of Shares	313,498	272,780	291,863
Shares vested, Number of Shares	(233,831)	(336,160)	(360,337)
Shares forfeited, Number of Shares	(13,675)	(12,380)	(16,343)
Non-vested shares at end of period, Number of Shares	734,101	668,109	743,869
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested shares at beginning of period, Weighted Average Grant Price (usd per share)	$ 33.51	$ 26.54	$ 22.50
Shares granted, Weighted Average Grant Price (usd per share)	56.19	43.12	31.66
Shares vested, Weighted Average Grant Price (usd per share)	28.19	25.69	21.55
Shares forfeited, Weighted Average Grant Price (usd per share)	42.15	38.94	23.11
Non-vested shares at end of period, Weighted Average Grant Price (usd per share)	$ 44.73	$ 33.51	$ 26.54

Shareholder's Equity (Schedule

Shareholder's Equity (Schedule of Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period, Number of Shares	158,721	270,464	1,662,830
Options exercised, Number of Shares	(113,220)	(111,743)	(1,392,366)
Options terminated, Number of Shares	(11,750)
Outstanding at end of period, Number of Shares	33,751	158,721	270,464	1,662,830
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period, Weighted Average Exercise Price (usd per share)	$ 22.89	$ 23.16	$ 23.82
Options exercised, Weighted Average Exercise Price (usd per share)	22.81	23.53	23.95
Options terminated, Weighted Average Exercise Price (usd per share)	23.42
Outstanding at end of period, Weighted Average Exercise Price (usd per share)	$ 22.98	$ 22.89	$ 23.16	$ 23.82
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding at beginning of period, Weighted Average Remaining Contractual Life (in years)	1 year 36 days	1 year 256 days	2 years 182 days	2 years 328 days
Outstanding at end of period, Weighted Average Remaining Contractual Life (in years)	1 year 36 days	1 year 256 days	2 years 182 days	2 years 328 days

Shareholder's Equity (Schedul81

Shareholder's Equity (Schedule of Stock Option Activity - Additional) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Equity [Abstract]
Total intrinsic value with options exercised	$ 4.9	$ 2.6	$ 33.3
Aggregate intrinsic value of options outstanding	1.8
Total intrinsic value of options vested or expected to vest	$ 1.8
Vested or expected to vest at end of period, Number of Shares	33,751
Vested or expected to vest at end of period, weighted average exercise price (usd per share)	$ 22.98
Vested or expected to vest at end of period, Weighted Average Remaining Contractual Life (in years)	1 year 36 days
Total Intrinsic value of options exercisable	$ 1.8
Exercisable at end of period, Number of Shares	33,751
Exercisable at end of period, Weighted Average Exercise Price (usd per share)	$ 22.98
Exercisable at end of period, Weighted Average Remaining Contractual Life (in years)	1 year 36 days

Shareholder's Equity (Schedul82

Shareholder's Equity (Schedule Of Reconciliation Of Numerator And Denominators Of Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Equity [Abstract]
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (Numerator)	$ 64,310	$ 40,397	$ 31,411	$ 18,774	$ 25,311	$ (10,697)	$ 18,771	$ 17,392	$ 154,892	$ 50,777	$ 71,009
Convertible Preferred Dividends, Net of Tax									9,056
Net Income (Loss) Attributable to Parent, Diluted									$ 163,948
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic), shares (Numerator)									48,058	39,311	31,338
Effect of dilutive securities options and non-vested shares, shares									3,554	314	616
Net earnings from continuing operations attributable to AmSurg Corp. (diluted), shares (Denominator)									51,612	39,625	31,954
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic) (usd per share)	$ 1.31	$ 0.85	$ 0.66	$ 0.39	$ 0.53	$ (0.23)	$ 0.59	$ 0.55	$ 3.22	$ 1.29	$ 2.27
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted) (usd per share)	$ 1.26	$ 0.83	$ 0.65	$ 0.39	$ 0.53	$ (0.23)	$ 0.58	$ 0.54	$ 3.18	$ 1.28	$ 2.22

Leases (Narrative) (Details)

Leases (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Leases [Abstract]
Lease Expiration Date	Apr. 30, 2037
Capital lease assets	$ 23.4
Capital lease assets, accumulated depreciation	5.6
Operating leases, rental expense	$ 74.6	$ 66.1	$ 52.6

Leases (Future Min Schedule) (D

Leases (Future Min Schedule) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2,016	$ 3,021
2,017	2,776
2,018	2,502
2,019	2,068
2,020	1,866
Thereafter	12,991
Total minimum rentals	25,224
Less amounts representing interest at rates ranging from 1.7% to 13.4%	6,611
Capital lease obligations	18,613	$ 15,206
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2,016	55,636
2,017	55,857
2,018	53,515
2,019	52,034
2,020	50,378
Thereafter	331,746
Total minimum rentals	$ 599,166

Leases (Future Min Schedule - A

Leases (Future Min Schedule - Additional) (Details)	12 Months Ended
	Dec. 31, 2015
Minimum [Member]
Capital Lease Interest Rate Range [Line Items]
Capital lease interest rates	1.70%
Maximum [Member]
Capital Lease Interest Rate Range [Line Items]
Capital lease interest rates	13.40%

Related Party Transactions (Rel

Related Party Transactions (Related Party Payments) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Related Party Transactions [Abstract]
Operating leases	$ 27,622	$ 27,559	$ 29,240
Salaries and benefits	62,590	66,763	72,892
Billing fees	10,873	9,899	11,591
Medical advisory services	$ 2,635	$ 2,811	$ 2,993

Employee Benefit Programs (Deta

Employee Benefit Programs (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Contribution Plan Disclosure [Line Items]
Cash surrender value	$ 17,320	$ 16,623	$ 17,320
AmSurg 401(k) Plan and Trust [Member]
Defined Contribution Plan Disclosure [Line Items]
Employer contributions		14,100	1,600	$ 1,100
401(k) as Part of Sheridan Acquisition [Member]
Defined Contribution Plan Disclosure [Line Items]
Plan expense	5,600
Supplemental Executive And Director Retirement Savings Plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Employer contributions		$ 5,200	800	$ 2,300
Maximum voluntary contribution as a percent of annual compensation		50.00%
Supplemental Executive And Director Retirement Savings Plan [Member] | Prepaid Expenses and Other Current Assets [Member]
Defined Contribution Plan Disclosure [Line Items]
Cash surrender value	$ 17,320	$ 16,623	$ 17,320
Minimum [Member] | AmSurg 401(k) Plan and Trust [Member]
Defined Contribution Plan Disclosure [Line Items]
Requisite service period		4 years
Maximum [Member] | AmSurg 401(k) Plan and Trust [Member]
Defined Contribution Plan Disclosure [Line Items]
Requisite service period		5 years

Commitments and Contingencies (

Commitments and Contingencies (Details) ft² in Thousands, $ in Millions	Jan. 16, 2015USD ($)ft²	Sep. 30, 2016ft²	Dec. 31, 2015ft²
Schedule Of Operating Leases Square Footage [Line Items]
Operating Leases, Area Of Office Space	222		167
Operating Leases, Rent Expense, Per Year | $	$ 2.9
Scenario, Forecast [Member]
Schedule Of Operating Leases Square Footage [Line Items]
Operating Leases, Area Of Office Space		55

Segment Reporting (Details)

Segment Reporting (Details) $ in Thousands	3 Months Ended								6 Months Ended		12 Months Ended
	Dec. 31, 2015USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Sep. 30, 2014USD ($)	Jun. 30, 2014USD ($)	Mar. 31, 2014USD ($)	Dec. 31, 2014USD ($)segment	Jul. 15, 2014segment	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment									2	1
Segment Reporting Information [Line Items]
Net revenue	$ 704,262	$ 650,227	$ 641,950	$ 570,445	$ 581,811	$ 502,350	$ 278,227	$ 259,561			$ 2,566,884	$ 1,621,949	$ 1,057,196
Adjusted EBITDA											492,260	304,482	187,972
Earnings from continuing operations attributable to noncontrolling interests											218,181	190,809	183,484
Interest expense, net											(121,586)	(83,285)	(29,525)
Depreciation and amortization											(97,493)	(60,344)	(32,400)
Share-based compensation											(15,009)	(10,104)	(8,321)
Net change in fair value of contingent consideration											(8,804)	0	0
Transaction costs						(25,100)					(8,324)	(33,890)	(300)
Debt extinguishment costs											0	(16,887)	0
Net gain on deconsolidations											36,694	3,411	2,237
Earnings from continuing operations before income taxes	161,178	$ 135,797	$ 115,940	$ 83,004	101,535	$ 39,142	$ 80,487	$ 73,028			495,919	294,192	303,147
Acquisition and Capital Expenditures											1,022,994	110,065	102,450
Assets	6,546,482				5,501,062				$ 5,501,062		6,546,482	5,501,062
Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Net revenue											1,230,050	1,109,935	1,057,196
Adjusted EBITDA											226,229	197,377	187,972
Acquisition and Capital Expenditures											168,593	81,156	102,450
Assets	2,609,479				2,526,625				2,526,625		2,609,479	2,526,625
Physician Services [Member]
Segment Reporting Information [Line Items]
Net revenue									512,014		1,336,834	512,014	0
Adjusted EBITDA											266,031	107,105	0
Net change in fair value of contingent consideration											(10,000)
Acquisition and Capital Expenditures											854,401	28,909	$ 0
Assets	$ 3,937,003				$ 2,974,437				$ 2,974,437		$ 3,937,003	$ 2,974,437

Financial Information for the90

Financial Information for the Company and Its Subsidiaries (Balance Sheets) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Assets
Cash and cash equivalents	$ 106,660	$ 208,079	$ 50,840	$ 46,398
Restricted cash and marketable securities	13,506	10,219
Accounts receivable, net	337,330	233,053
Supplies inventory	21,406	19,974
Prepaid and other current assets	75,771	92,900
Total current assets	554,673	564,225
Property and equipment, net	189,168	180,448
Investments in and receivables from unconsolidated affiliates	169,170	75,475
Goodwill	3,970,210	3,381,149	1,758,970
Intangible assets, net	1,641,811	1,273,879
Other assets	21,450	25,886
Total assets	6,546,482	5,501,062
Liabilities and Equity
Current portion of long-term debt	20,377	18,826
Accounts payable	32,561	29,585
Accrued salaries and benefits	202,537	140,044
Accrued interest	30,480	29,644
Other accrued liabilities	119,237	67,986
Total current liabilities	405,192	286,085
Long-term debt	2,405,130	2,232,186
Deferred income taxes	699,498	611,018
Other long-term liabilities	96,183	89,443
Intercompany payable	0	0
Noncontrolling interests – redeemable	175,732	184,099
Equity:
Total AmSurg Corp. equity	2,293,463	1,679,547
Noncontrolling interests – non-redeemable	471,284	418,684
Total equity	2,764,747	2,098,231
Total liabilities and equity	6,546,482	5,501,062
Consolidating Adjustments [Member]
Assets
Cash and cash equivalents	0	0	0	0
Restricted cash and marketable securities	0	0
Accounts receivable, net	0	0
Supplies inventory	0	0
Prepaid and other current assets	(8,076)	(4,818)
Total current assets	(8,076)	(4,818)
Property and equipment, net	0	0
Investments in and receivables from unconsolidated affiliates	(6,507,128)	(5,425,210)
Goodwill	2,013,469	1,890,168
Intangible assets, net	0	0
Other assets	(1,998)	(1,466)
Total assets	(4,503,733)	(3,541,326)
Liabilities and Equity
Current portion of long-term debt	0	0
Accounts payable	(3,852)	(4,080)
Accrued salaries and benefits	0	0
Accrued interest	0	0
Other accrued liabilities	(4,224)	(738)
Total current liabilities	(8,076)	(4,818)
Long-term debt	(23,396)	(28,412)
Deferred income taxes	(1,998)	(1,466)
Other long-term liabilities	0	0
Intercompany payable	(1,228,157)	(1,227,989)
Noncontrolling interests – redeemable	112,672	120,555
Equity:
Total AmSurg Corp. equity	(3,778,478)	(2,774,257)
Noncontrolling interests – non-redeemable	423,700	375,061
Total equity	(3,354,778)	(2,399,196)
Total liabilities and equity	(4,503,733)	(3,541,326)
Parent Company [Member]
Assets
Cash and cash equivalents	20,437	134,351	6,710	7,259
Restricted cash and marketable securities	0	0
Accounts receivable, net	0	0
Supplies inventory	0	0
Prepaid and other current assets	28,739	46,097
Total current assets	49,176	180,448
Property and equipment, net	12,515	10,391
Investments in and receivables from unconsolidated affiliates	4,901,026	3,912,804
Goodwill	0	0
Intangible assets, net	59,928	67,678
Other assets	4,653	3,323
Total assets	5,027,298	4,174,644
Liabilities and Equity
Current portion of long-term debt	8,700	8,700
Accounts payable	2,816	1,849
Accrued salaries and benefits	31,510	25,035
Accrued interest	30,463	29,621
Other accrued liabilities	13,962	8,051
Total current liabilities	87,451	73,256
Long-term debt	2,373,251	2,206,950
Deferred income taxes	268,573	207,500
Other long-term liabilities	4,560	7,391
Intercompany payable	0	0
Noncontrolling interests – redeemable	0	0
Equity:
Total AmSurg Corp. equity	2,293,463	1,679,547
Noncontrolling interests – non-redeemable	0	0
Total equity	2,293,463	1,679,547
Total liabilities and equity	5,027,298	4,174,644
Guarantor Subsidiaries [Member]
Assets
Cash and cash equivalents	27,507	23,471	0	0
Restricted cash and marketable securities	0	0
Accounts receivable, net	223,434	123,772
Supplies inventory	0	301
Prepaid and other current assets	39,046	37,826
Total current assets	289,987	185,370
Property and equipment, net	14,601	9,972
Investments in and receivables from unconsolidated affiliates	1,775,272	1,587,881
Goodwill	1,956,741	1,490,981
Intangible assets, net	1,579,537	1,203,218
Other assets	1,717	943
Total assets	5,617,855	4,478,365
Liabilities and Equity
Current portion of long-term debt	0	0
Accounts payable	3,760	35
Accrued salaries and benefits	158,705	101,395
Accrued interest	0	0
Other accrued liabilities	76,590	44,305
Total current liabilities	239,055	145,735
Long-term debt	0	0
Deferred income taxes	432,923	404,984
Other long-term liabilities	71,509	63,616
Intercompany payable	1,228,157	1,219,979
Noncontrolling interests – redeemable	0	0
Equity:
Total AmSurg Corp. equity	3,646,211	2,644,051
Noncontrolling interests – non-redeemable	0	0
Total equity	3,646,211	2,644,051
Total liabilities and equity	5,617,855	4,478,365
Non-Guarantor Subsidiaries [Member]
Assets
Cash and cash equivalents	58,716	50,257	$ 44,130	$ 39,139
Restricted cash and marketable securities	13,506	10,219
Accounts receivable, net	113,896	109,281
Supplies inventory	21,406	19,673
Prepaid and other current assets	16,062	13,795
Total current assets	223,586	203,225
Property and equipment, net	162,052	160,085
Investments in and receivables from unconsolidated affiliates	0	0
Goodwill	0	0
Intangible assets, net	2,346	2,983
Other assets	17,078	23,086
Total assets	405,062	389,379
Liabilities and Equity
Current portion of long-term debt	11,677	10,126
Accounts payable	29,837	31,781
Accrued salaries and benefits	12,322	13,614
Accrued interest	17	23
Other accrued liabilities	32,909	16,368
Total current liabilities	86,762	71,912
Long-term debt	55,275	53,648
Deferred income taxes	0	0
Other long-term liabilities	20,114	18,436
Intercompany payable	0	8,010
Noncontrolling interests – redeemable	63,060	63,544
Equity:
Total AmSurg Corp. equity	132,267	130,206
Noncontrolling interests – non-redeemable	47,584	43,623
Total equity	179,851	173,829
Total liabilities and equity	$ 405,062	$ 389,379

Financial Information for the91

Financial Information for the Company and Its Subsidiaries (Income Statements) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Condensed Financial Statements, Captions [Line Items]
Net revenue	$ 704,262	$ 650,227	$ 641,950	$ 570,445	$ 581,811	$ 502,350	$ 278,227	$ 259,561	$ 2,566,884	$ 1,621,949	$ 1,057,196
Operating expenses:
Salaries and benefits									1,314,392	694,576	327,585
Supply cost									184,222	164,296	153,126
Other operating expenses									397,794	284,928	216,501
Transaction costs						25,100			8,324	33,890	300
Depreciation and amortization									97,493	60,344	32,400
Total operating expenses									2,002,225	1,238,034	729,912
Net gain on deconsolidations									36,694	3,411	2,237
Equity in earnings of unconsolidated affiliates									16,152	7,038	3,151
Operating income									617,505	394,364	332,672
Interest expense, net									121,586	83,285	29,525
Debt extinguishment costs									0	16,887	0
Earnings from continuing operations before income taxes	161,178	135,797	115,940	83,004	101,535	39,142	80,487	73,028	495,919	294,192	303,147
Income tax expense									113,790	48,103	48,654
Net earnings from continuing operations	124,348	98,279	90,747	68,755	79,234	39,120	67,689	60,046	382,129	246,089	254,493
Net earnings (loss) from discontinued operations	(1,013)	0	0	0	(150)	(1,697)	483	68	(1,013)	(1,296)	7,051
Net earnings	123,335	98,279	90,747	68,755	79,084	37,423	68,172	60,114	381,116	244,793	261,544
Less net earnings attributable to noncontrolling interests									218,169	191,092	188,841
Net earnings attributable to AmSurg Corp. shareholders									162,947	53,701	72,703
Preferred stock dividends									(9,056)	(4,503)	0
Net earnings attributable to AmSurg Corp. common shareholders	63,309	40,397	31,411	18,774	25,115	(12,073)	18,961	17,195	153,891	49,198	72,703
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	64,310	40,397	31,411	18,774	25,311	(10,697)	18,771	17,392	154,892	50,777	71,009
Earnings (loss) from discontinued operations, net of income tax	(1,001)	0	0	0	(196)	(1,376)	190	(197)	(1,001)	(1,579)	1,694
Net earnings attributable to AmSurg Corp. common shareholders	$ 63,309	$ 40,397	$ 31,411	$ 18,774	$ 25,115	$ (12,073)	$ 18,961	$ 17,195	153,891	49,198	72,703
Consolidating Adjustments [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenue									(38,004)	(24,336)	(17,518)
Operating expenses:
Salaries and benefits									(507)	(5,786)	(467)
Supply cost									(80)	0	0
Other operating expenses									(37,417)	(18,550)	(17,051)
Transaction costs									0	0	0
Depreciation and amortization									0	0	0
Total operating expenses									(38,004)	(24,336)	(17,518)
Net gain on deconsolidations									0	0	0
Equity in earnings of unconsolidated affiliates									(584,080)	(442,508)	(409,010)
Operating income									(584,080)	(442,508)	(409,010)
Interest expense, net									0	0	0
Debt extinguishment costs										0
Earnings from continuing operations before income taxes									(584,080)	(442,508)	(409,010)
Income tax expense									0	0	0
Net earnings from continuing operations									(584,080)	(442,508)	(409,010)
Net earnings (loss) from discontinued operations									0	0	0
Net earnings									(584,080)	(442,508)	(409,010)
Less net earnings attributable to noncontrolling interests									0	0	0
Net earnings attributable to AmSurg Corp. shareholders									(584,080)	(442,508)
Preferred stock dividends									0	0
Net earnings attributable to AmSurg Corp. common shareholders									(584,080)	(442,508)	(409,010)
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax									(584,080)	(442,508)	(409,010)
Earnings (loss) from discontinued operations, net of income tax									0	0	0
Net earnings attributable to AmSurg Corp. common shareholders									(584,080)	(442,508)	(409,010)
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenue									28,554	24,773	24,167
Operating expenses:
Salaries and benefits									69,102	65,697	61,038
Supply cost									0	0	0
Other operating expenses									24,682	18,667	22,360
Transaction costs									1,762	29,004	300
Depreciation and amortization									3,912	4,044	3,186
Total operating expenses									99,458	117,412	86,884
Net gain on deconsolidations									0	0	0
Equity in earnings of unconsolidated affiliates									349,139	237,657	207,199
Operating income									278,235	145,018	144,482
Interest expense, net									41,140	47,997	27,282
Debt extinguishment costs										16,887
Earnings from continuing operations before income taxes									237,095	80,134	117,200
Income tax expense									73,159	29,166	47,139
Net earnings from continuing operations									163,936	50,968	70,061
Net earnings (loss) from discontinued operations									(989)	2,733	2,642
Net earnings									162,947	53,701	72,703
Less net earnings attributable to noncontrolling interests									0	0	0
Net earnings attributable to AmSurg Corp. shareholders									162,947	53,701
Preferred stock dividends									(9,056)	(4,503)
Net earnings attributable to AmSurg Corp. common shareholders									153,891	49,198	72,703
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax									154,880	46,465	70,061
Earnings (loss) from discontinued operations, net of income tax									(989)	2,733	2,642
Net earnings attributable to AmSurg Corp. common shareholders									153,891	49,198	72,703
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenue									1,331,042	508,572	0
Operating expenses:
Salaries and benefits									937,484	350,615	0
Supply cost									2,436	1,292	0
Other operating expenses									145,369	53,413	0
Transaction costs									6,562	4,886	0
Depreciation and amortization									61,658	25,610	0
Total operating expenses									1,153,509	435,816	0
Net gain on deconsolidations									37,350	3,411	2,237
Equity in earnings of unconsolidated affiliates									251,093	211,889	204,962
Operating income									465,976	288,056	207,199
Interest expense, net									77,947	33,026	0
Debt extinguishment costs										0
Earnings from continuing operations before income taxes									388,029	255,030	207,199
Income tax expense									38,891	17,373	0
Net earnings from continuing operations									349,138	237,657	207,199
Net earnings (loss) from discontinued operations									0	0	0
Net earnings									349,138	237,657	207,199
Less net earnings attributable to noncontrolling interests									0	21	0
Net earnings attributable to AmSurg Corp. shareholders									349,138	237,636
Preferred stock dividends									0	0
Net earnings attributable to AmSurg Corp. common shareholders									349,138	237,636	207,199
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax									349,138	237,636	207,199
Earnings (loss) from discontinued operations, net of income tax									0	0	0
Net earnings attributable to AmSurg Corp. common shareholders									349,138	237,636	207,199
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenue									1,245,292	1,112,940	1,050,547
Operating expenses:
Salaries and benefits									308,313	284,050	267,014
Supply cost									181,866	163,004	153,126
Other operating expenses									265,160	231,398	211,192
Transaction costs									0	0	0
Depreciation and amortization									31,923	30,690	29,214
Total operating expenses									787,262	709,142	660,546
Net gain on deconsolidations									(656)	0	0
Equity in earnings of unconsolidated affiliates									0	0	0
Operating income									457,374	403,798	390,001
Interest expense, net									2,499	2,262	2,243
Debt extinguishment costs										0
Earnings from continuing operations before income taxes									454,875	401,536	387,758
Income tax expense									1,740	1,564	1,515
Net earnings from continuing operations									453,135	399,972	386,243
Net earnings (loss) from discontinued operations									(24)	(4,029)	4,409
Net earnings									453,111	395,943	390,652
Less net earnings attributable to noncontrolling interests									218,169	191,071	188,841
Net earnings attributable to AmSurg Corp. shareholders									234,942	204,872
Preferred stock dividends									0	0
Net earnings attributable to AmSurg Corp. common shareholders									234,942	204,872	201,811
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax									234,954	209,184	202,759
Earnings (loss) from discontinued operations, net of income tax									(12)	(4,312)	(948)
Net earnings attributable to AmSurg Corp. common shareholders									$ 234,942	$ 204,872	$ 201,811

Financial Information for the92

Financial Information for the Company and Its Subsidiaries (Cash Flow Statements) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net cash flows provided by operating activities	$ 537,959	$ 412,371	$ 332,824
Cash flows from investing activities:
Acquisitions and related transactions	(962,689)	(2,184,058)	(73,594)
Acquisition of property and equipment	(60,305)	(40,217)	(28,856)
Proceeds from sale of interests in surgery centers	7,114	7,069	3,553
Purchases of marketable securities	(3,984)	(6,474)	0
Maturities of marketable securities	4,233	3,486	0
Other	(1,194)	(4,941)	159
Net cash flows used in investing activities	(1,016,825)	(2,225,135)	(98,738)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	560,133	2,048,958	162,204
Repayment on long-term borrowings and revolving credit facility	(392,586)	(408,475)	(202,083)
Distributions to owners, including noncontrolling interests	(214,899)	(190,097)	(184,149)
Capital contributions	0	0
Proceeds from preferred stock offering	0	172,500	0
Proceeds from common stock offering	466,777	439,875	0
Payments of equity issuance costs	(19,058)	(24,494)	0
Financing costs incurred	(1,111)	(65,811)	(1,322)
Changes in intercompany balances with affiliates, net	0	0	0
Other financing activities, net	(21,809)	(2,453)	(5,616)
Net cash flows provided by (used in) financing activities	377,447	1,970,003	(229,644)
Net increase (decrease) in cash and cash equivalents	(101,419)	157,239	4,442
Cash and cash equivalents, beginning of period	208,079	50,840	46,398
Cash and cash equivalents, end of period	106,660	208,079	50,840
Consolidating Adjustments [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	(346,225)	(413,605)	(347,648)
Cash flows from investing activities:
Acquisitions and related transactions	764,345	2,126,737	694
Acquisition of property and equipment	0	0	0
Proceeds from sale of interests in surgery centers	0	0	0
Purchases of marketable securities	0	0
Maturities of marketable securities	0	0
Other	0	0	0
Net cash flows used in investing activities	764,345	2,126,737	694
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	0	0	0
Repayment on long-term borrowings and revolving credit facility	0	0	0
Distributions to owners, including noncontrolling interests	346,225	413,605	347,648
Capital contributions	(757,775)	(2,124,124)
Proceeds from preferred stock offering		0
Proceeds from common stock offering	0	0
Payments of equity issuance costs	0	0
Financing costs incurred	0	0
Changes in intercompany balances with affiliates, net	0	0	0
Other financing activities, net	(6,570)	(2,613)	(694)
Net cash flows provided by (used in) financing activities	(418,120)	(1,713,132)	346,954
Net increase (decrease) in cash and cash equivalents	0	0	0
Cash and cash equivalents, beginning of period	0	0	0
Cash and cash equivalents, end of period	0	0	0
Parent Company [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	40,432	96,681	45,127
Cash flows from investing activities:
Acquisitions and related transactions	(757,775)	(2,124,124)	0
Acquisition of property and equipment	(5,876)	(7,877)	(3,693)
Proceeds from sale of interests in surgery centers	0	0	0
Purchases of marketable securities	0	0
Maturities of marketable securities	0	0
Other	0	(3,068)	0
Net cash flows used in investing activities	(763,651)	(2,135,069)	(3,693)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	546,000	2,040,000	152,700
Repayment on long-term borrowings and revolving credit facility	(379,700)	(396,493)	(188,081)
Distributions to owners, including noncontrolling interests	0	0	0
Capital contributions	0	0
Proceeds from preferred stock offering		172,500
Proceeds from common stock offering	466,777	439,875
Payments of equity issuance costs	(19,058)	(24,494)
Financing costs incurred	(1,101)	(65,811)
Changes in intercompany balances with affiliates, net	5,016	2,965	88
Other financing activities, net	(8,629)	(2,513)	(6,690)
Net cash flows provided by (used in) financing activities	609,305	2,166,029	(41,983)
Net increase (decrease) in cash and cash equivalents	(113,914)	127,641	(549)
Cash and cash equivalents, beginning of period	134,351	6,710	7,259
Cash and cash equivalents, end of period	20,437	134,351	6,710
Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	353,932	298,415	208,773
Cash flows from investing activities:
Acquisitions and related transactions	(969,259)	(2,188,191)	(74,288)
Acquisition of property and equipment	(22,988)	(9,933)	0
Proceeds from sale of interests in surgery centers	7,114	7,069	3,553
Purchases of marketable securities	0	0
Maturities of marketable securities	0	0
Other	(2,927)	(6,594)	159
Net cash flows used in investing activities	(988,060)	(2,197,649)	(70,576)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	0	0	0
Repayment on long-term borrowings and revolving credit facility	0	0	0
Distributions to owners, including noncontrolling interests	(109,862)	(202,247)	(138,875)
Capital contributions	757,775	2,124,124
Proceeds from preferred stock offering		0
Proceeds from common stock offering	0	0
Payments of equity issuance costs	0	0
Financing costs incurred	0	0
Changes in intercompany balances with affiliates, net	0	0	0
Other financing activities, net	(9,749)	828	678
Net cash flows provided by (used in) financing activities	638,164	1,922,705	(138,197)
Net increase (decrease) in cash and cash equivalents	4,036	23,471	0
Cash and cash equivalents, beginning of period	23,471	0	0
Cash and cash equivalents, end of period	27,507	23,471	0
Non-Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	489,820	430,880	426,572
Cash flows from investing activities:
Acquisitions and related transactions	0	1,520	0
Acquisition of property and equipment	(31,441)	(22,407)	(25,163)
Proceeds from sale of interests in surgery centers	0	0	0
Purchases of marketable securities	(3,984)	(6,474)
Maturities of marketable securities	4,233	3,486
Other	1,733	4,721	0
Net cash flows used in investing activities	(29,459)	(19,154)	(25,163)
Cash flows from financing activities:
Proceeds from long-term borrowings and revolving credit facility	14,133	8,958	9,504
Repayment on long-term borrowings and revolving credit facility	(12,886)	(11,982)	(14,002)
Distributions to owners, including noncontrolling interests	(451,262)	(401,455)	(392,922)
Capital contributions	0	0
Proceeds from preferred stock offering		0
Proceeds from common stock offering	0	0
Payments of equity issuance costs	0	0
Financing costs incurred	(10)	0
Changes in intercompany balances with affiliates, net	(5,016)	(2,965)	(88)
Other financing activities, net	3,139	1,845	1,090
Net cash flows provided by (used in) financing activities	(451,902)	(405,599)	(396,418)
Net increase (decrease) in cash and cash equivalents	8,459	6,127	4,991
Cash and cash equivalents, beginning of period	50,257	44,130	39,139
Cash and cash equivalents, end of period	$ 58,716	$ 50,257	$ 44,130

Quarterly Statement of Earnin93

Quarterly Statement of Earnings Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Net revenue	$ 704,262	$ 650,227	$ 641,950	$ 570,445	$ 581,811	$ 502,350	$ 278,227	$ 259,561	$ 2,566,884	$ 1,621,949	$ 1,057,196
Earnings from continuing operations before income taxes	161,178	135,797	115,940	83,004	101,535	39,142	80,487	73,028	495,919	294,192	303,147
Net earnings from continuing operations	124,348	98,279	90,747	68,755	79,234	39,120	67,689	60,046	382,129	246,089	254,493
Net earnings (loss) from discontinued operations	(1,013)	0	0	0	(150)	(1,697)	483	68	(1,013)	(1,296)	7,051
Net earnings	123,335	98,279	90,747	68,755	79,084	37,423	68,172	60,114	381,116	244,793	261,544
Net earnings (loss) attributable to AmSurg Corp. common shareholders:
Continuing	64,310	40,397	31,411	18,774	25,311	(10,697)	18,771	17,392	154,892	50,777	71,009
Discontinued	(1,001)	0	0	0	(196)	(1,376)	190	(197)	(1,001)	(1,579)	1,694
Net earnings attributable to AmSurg Corp. common shareholders	$ 63,309	$ 40,397	$ 31,411	$ 18,774	$ 25,115	$ (12,073)	$ 18,961	$ 17,195	$ 153,891	$ 49,198	$ 72,703
Basic net earnings (loss) from continuing operations per share	$ 1.31	$ 0.85	$ 0.66	$ 0.39	$ 0.53	$ (0.23)	$ 0.59	$ 0.55	$ 3.22	$ 1.29	$ 2.27
Basic net earnings (loss) per share	1.28	0.85	0.66	0.39	0.53	(0.26)	0.60	0.54	3.20	1.25	2.32
Diluted net earnings (loss) from continuing operations per share	1.26	0.83	0.65	0.39	0.53	(0.23)	0.58	0.54	3.18	1.28	2.22
Diluted net earnings (loss) per share	$ 1.24	$ 0.83	$ 0.65	$ 0.39	$ 0.53	$ (0.26)	$ 0.59	$ 0.54	$ 3.16	$ 1.24	$ 2.28
Debt extinguishment costs									$ 0	$ (16,887)	$ 0
Transaction costs						$ 25,100			$ 8,324	$ 33,890	$ 300

Schedule II - Valuation and Q94

Schedule II - Valuation and Qualifying Accounts (Details) - Allowance for Doubtful Accounts [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation Allowances and Reserves, Balance, Beginning Balance	$ 113,357	$ 27,862	$ 22,379
Charged to Cost and Expenses	287,427	139,274	21,983
Charge-off Against Allowances	(233,373)	(53,779)	(16,500)
Valuation Allowances and Reserves, Balance, Ending Balance	$ 167,411	$ 113,357	$ 27,862